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Acute myeloid leukemia (AML) is a highly aggressive form of blood cancer, characterized by 
an interruption in the differentiation process and by rapid proliferation of immature myeloid 
leukemia cells leading to bone marrow failure. On a molecular level, multiple genetic and 
epigenetic alterations are detected in hematopoietic progenitors that may contribute to disease 
progression, which results in the considerable inter- and intraindividual heterogeneity of AML 
clones. This heterogeneity also contributes to high plasticity in metabolic reprogramming, 
allowing cancer cells to maintain proliferation and cell growth under the high demands of 
expanding growth. Leukemia cells may employ different metabolic routes based on the 
molecular alterations of the disease, and this may in turn imply that certain AML patient subsets 
have common metabolic characteristics. These AML subsets may either have a more extensive 
adaptive capacity, or be more sensitive to therapies targeting metabolism. Thus, it may be 
possible to stratify patients according to metabolic phenotypes/capacities, which in turn may 
serve as a common therapeutic target.  
   In the four papers presented in this thesis, we investigated AML cell metabolism, either as a 
possible target for treatment (Papers I and II), or to examine if metabolic alterations in AML 
patients might have prognostic value (Papers III and IV). In the first two papers, we studied 
the in vitro antileukemic effects of eight different metabolic drugs (metformin, 2DG, 6AN, 
BPTES, ST1326, lonidamine, AZD3965 and chloroquine (CQ)), alone and in combination with 
chemotherapy (AraC), targeting different metabolic pathways and proteins involved in the 
regulation of cancer cell metabolism. In addition, we studied the metabolomic profiles of AML 
patients, (i) before and after treatment with disease-stabilizing therapy including all-trans 
retinoic acid (ATRA) and valproic acid, and (ii) in cases of chronic graft versus host disease 
(cGVHD) after allogenic hematopoietic stem cell transplantation (allo-HSCT). We aimed to 
see if alterations in systemic metabolite profiles can be used as a prognostic tool to help 
determine which patients might benefit from cGVHD treatment.  
   The results presented in this thesis confirm the heterogeneity of AML patients as regards 
susceptibility to metabolic targeting agents. A subset of patients with generally high sensitivity 
to multiple metabolic drugs was identified using an unsupervised hierarchical clustering 
analysis based on the antiproliferative effect of metabolic inhibitors. We saw that the clustering 
of this subset was largely driven by the patient cells´ sensitivity to metabolic drugs effecting 
the glycolytic pathway, supporting the idea that glycolysis is the main metabolic pathway for 
many types of cancer. We saw that the majority of our AML patient cells were sensitive to 
chloroquine, a known inhibitor of late-stage autophagy, also used to treat malaria. CQ proved 
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to have antileukemic effects, and interestingly there was also a smaller subset of patient cells 
that showed high in vitro susceptibility to CQ, but on whom standard chemotherapy (AraC) had 
little or no effect. We did not however identify any significant molecular similarities among the 
patients with similar response to metabolic inhibitors, nor did we find correlations to any of the 
known prognostic markers (i.e. secondary versus de novo, AML cell differentiation (FAB 
classification, CD34 expression), karyotype, FLT3-ITD or NPM1 mutations). 
   Our studies also showed that systemic metabolomic profiling can be used to examine effects 
of treatment with ATRA and valproic acid. We observed alterations in the amino acid and lipid 
profiles when studying ATRA and valproic acid as monotherapy, and changes were most 
apparent after valproic acid treatment. Even though, patients with rapidly progressive disease 
showed extensively altered lipid metabolism, pretreatment metabolite profiles could not be used 
to distinguish responders from non-responders to this AML-stabilizing treatment. Metabolic 
profiles were also altered in patients with cGVHD after allo-HSCT compared to patients 
without signs of cGVHD. We were able to identify a subset of 11-metabolites not effected by 
immunosuppressive treatment, that might have both diagnostic and prognostic value for 
cGVHD. 
   To conclude, AML patients are heterogeneous with regard to susceptibility to metabolic 
inhibitors, and further investigation has to be conducted to identify common therapeutic targets. 
Patients are heterogeneous also with regard to their metabolic profiles, making it challenging 
to analyze and identify significant changes of single metabolites. However, our studies show 
that changes in metabolomic profiles may influence both epigenetic regulation and bone 
marrow microenvironment. These changes may in turn modulate disease progression as well as 
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1 Introduction  
1.1 General background 
Acute myeloid leukemia (AML) is an aggressive form of blood cancer [1]. It is characterized 
by the abnormal proliferation and differentiation of clonal bone marrow myeloblasts, resulting 
in impaired normal hematopoiesis and thereby bone marrow failure. Even though AML is the 
most common acute leukemia in adults, its incidence is of only 2.5-3 per 100.000 [2]. The 
median age at the time of first diagnosis is 65-70 years, meaning there is a majority of elderly 
patients. Elderly patients tend to have poorer prognostics due to adverse cytogenetics, resulting 
in refractory disease. These patients should not receive the most intensive and potentially 
curative treatment due to an unacceptable risk of severe toxicity and treatment-related mortality 
[3]. AML is highly heterogeneous with regard to both cytogenetic abnormalities and differences 
in molecular genetics [3]. New genomic sequencing techniques have revealed a spectrum of 
frequent mutations and distinct mutational patterns [4, 5]. Based on molecular genetics, new 
targeted therapies have been suggested. However, the therapeutic approaches and the prognoses 
differ between patients subgroups [6]. More recent studies also suggest that metabolic 
reprogramming is important for chemosensitivity [7]; metabolic targeting is therefore emerging 
as a possible therapeutic strategy in the treatment of AML [8].  
 
Metabolic reprogramming plays a key role in cancer cells´ ability to escape the mechanisms of 
homeostatic control, and contributes to the aggressiveness of the disease. This also applies to 
AML. High metabolic plasticity helps cancer cells acquire and utilize necessary nutrients from 
an often nutrient-poor environment. This allows for continued fast proliferation, expansive 
growth and survival even under stressful conditions, as the cells rapidly outcompete normal 
hematopoietic cells [9].  As we learn more about AML cells´ ability to alter their metabolism, 
it is understood that the high heterogeneity of the disease also applies to their metabolic 
reprogramming. As a result of both direct and indirect oncogenic mutations, different subtypes 
prefer different nutrients, and utilize different metabolic pathways, making metabolic targeting 
challenging [9]. However, our knowledge to date of metabolic reprogramming is scarce. More 
studies are needed to see if researching AML cell metabolism may contribute to improve 





1.2 Diagnosis, subclassification and prognostic evaluation  
The only curative treatment for AML as of today comes with severe toxicity and high treatment-
related mortality [3]. Refractory disease and disease relapse are common. Finding the patients 
who will not only tolerate, but also benefit from this treatment is therefore crucial. As the 
molecular heterogeneity of AML is becoming increasingly apparent, new diagnostic 
procedures, as well as new subclassifications of the disease are emerging. The prognostic 
importance of this molecular heterogeneity is now generally accepted [10]. However, localizing 
new subsets that might benefit from new targeting approaches is proving to be challenging.  
1.2.1 Diagnosis and subclassification of human AML 
Acute promyelocytic leukemia (APL) is a separate subset of AML; the other AML subsets can 
be referred to as non-APL variants. All the studies in this thesis include only patients with non-
APL variants, and the term AML throughout the thesis refers to the non-APL variants of AML.  
According to the World Health Organization (WHO) classification, AML is generally 
characterized by the presence of at least 20% leukemic myeloblasts among nucleated bone 
marrow cells. There are some exceptions in  the groups labelled  “AML with recurrent genetic 
abnormalities” and “acute erythroid leukemia” as explained in detail in the WHO classification 
system [11]. A small subset of acute leukemia patients cannot be classified as myeloid or 
lymphoblastic; specific diagnostic criteria are then used for these patient groups with either 
mixed phenotype or unclassified acute leukemia [12]. Cytogenetic and molecular genetic 
analyses are mainly used for the prognostic evaluation of the patients [2].     
The previous French-American-British (FAB) classification was established several decades 
ago and was based merely on morphology and cytochemistry. It categorized the leukemic cells 
into subtypes M0 to M7 based on the degree of lineage differentiation and required at least 30% 
blast cells as the basis for an AML diagnosis [13]. However, the FAB classification does not 
reflect the genetic and clinical diversity of the disease that is important for the prognostic 
evaluation of patients. The first WHO classification for tumors of the hematopoietic and 
lymphoid tissues was published in 2001 [14], and the last update was published in 2016 [6]. 
The WHO classification divides AML into: AML with recurrent cytogenetic translocations, 
AML with myelodysplasia-related changes, therapy-related (secondary) AML, AML not 
otherwise categorized, Myeloid sarcoma, Myeloid proliferations associated with Down 




 A summary of the World Health Organization (WHO) 2016 classification of acute myeloid leukemia 
and related neoplasms [11]. 
Acute myeloid leukemia (AML) and related precursor neoplasms 
 AML with recurrent genetic abnormalities 
  
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARα 
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1);DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM (EVI1) 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.1);RBM15-MKL1 
AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
AML with mutated RUNX1 
 
 AML with myelodysplasia-related changes  
 Therapy-related myeloid neoplasms  
 AML, not otherwise specified (NOS)  
 
 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomocytic leukemia 
Acute monoblastic and monocytic leukemia 
Pure erythroid leukemia 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
 
Myeloid sarcoma 
Myeloid proliferations associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
 
 Acute leukemias of ambiguous lineage  
 
Acute undifferentiated leukemia 
Mixed-phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2);BCR-ABL1 
MPAL with t(v;11q23.3); KMT2A rearranged 
MPAL, B/myeloid, NOS 
MPAL, T/myeloid, NOS 
Acute leukemias of ambiguous lineage, NOS 
Genetic abbreviations are listed in the list of genetic abbreviations in the front of the thesis. 
1.2.2 The prognostic impact of cytogenetic abnormalities  
Cytogenetic abnormalities are detected in approximately 55% of all AML patients [15]. Several 
of these abnormalities are strong and independent predictors for prognosis, and karyotyping is 
therefore mandatory for the WHO classification. Eight translocations and inversions are 
included in the WHO category “AML with recurrent genetic abnormalities”. Based on 
cytogenetic alterations, patients can be stratified into three classes with prognostic value, (i) 
favorable t(8;21)(q22;q22.1) [RUNX1-RUNX1T1], inv(16)(p13.1q22) or t(16;16)(p13.1;q22) 
[CBFB-MYH11] and t(15;17)(q24;q21) [PML-RARα], (ii) intermediate t(9;11)(p22.3;q23.3) 
[MLLT3-KMT2A], and (iii) unfavorable/adverse t(6;9)(p23;q34.1) [DEK-NUP214], 
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inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) [GATA2,MECOM(EVI1)] and t(1;22)(p13.3;q13.1) 
[RBM15-MKL1][11] (Table 1). 
Core binding factor (CBF) is a group of heterodimeric transcription factors essential for normal 
hematopoiesis, and is composed of two subunits: a deoxyribonucleic acid (DNA) binding CBF-
alpha chain (runt-related transcription factor 1 (RUNX1)-RUNX2-RUNX3), and a non-DNA 
binding CBF-beta chain (CBFβ). Genetic rearrangements involving components of the CBF 
complex are present in about 5-13% of cases of AML, usually in younger patients,  and are 
associated with a favorable prognosis [11]. Patients with t(8;21)(q22;q22.1) AML have the 
fusion transcript  RUNX1-RUNXT1 which likely results in transcriptional repression of normal 
RUNX1,  through aberrant recruitment of nuclear transcriptional co-repressor complexes [11]. 
Inv(16)(p13.1q22) or t(16;16)(p13.1;q22) both result in the fusion of CBFβ and MYH11 that 
codes for smooth muscle myosin heavy chain [11]. Patients with CBF leukemias benefit from 
consolidation chemotherapy with high dose cytarabin (AraC). Monitoring of the fusion 
transcripts can also detect minimal residual disease (MRD) [15]. Patients with favorable 
cytogenetics also include PML with the translocation t(15;17) resulting in the oncogene PML-
RARα. This variant of AML requires a specific treatment different from the other AML variants 
and has a long-term leukemia-free survival of more than 90% [16]. Patients with 
t(9;11)(p21.3;q23.3) are categorized as intermediate cytogenetics. The lysine methyltransferase 
2A (KMT2A) gene (also known as MLL) [6] is a histone methyltransferase that assembles 
protein complexes that regulate gene transcription through chromatin remodeling. In 
translocations involving 11q23, the KMT2A results in a fusion gene, most common with 9p22 
giving the fusion transcript MLLT3-KMT2A. KMT2A (11q23.3) has an overall poor prognosis, 
but is modified by the fusion partner 9p21.3, giving t(9;11)(p21.3;q23.3) a better prognostic 
classification than the other 11q23 fusion genes [15]. 
The abnormalities t(6;9)(p23;q34.1), inv(3)(q21.3q26.2) and t(1;22)(p13.3;q13.1) are all 
associated with an unfavorable prognosis. The translocation t(6;9)(p23;q34.1) with the fusion 
gene DEK/NUP214 is associated with basophilia and multilineage dysplasia. This abnormality 
is uncommon in AML and more than 70% of the cases are accompanied by fms related tyrosine 
kinase 3 (FLT3) mutations [15, 17]. The inv(3)(q21.3q26.2) causes the distal GATA binding 
protein 2 (GATA2) enhancer to reposition itself, causing activation of ecotropic viral integration 
site 1 (EVI1) instead of GATA2[18]. The EVI1 gene encodes a transcript factor that is essential 
for self-renewal of HSC and it increases proliferation, prevents differentiation and is involved 
in epigenetic regulation of transcription. The AML cells may or may not carry signs of 
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differentiation [17]. Finally, t(1;22)(p13.3;q13.1) forms the RBM15-MKL1 fusion gene. This 
abnormality results in acute megakaryoblastic leukemia (AMKL) [19]. It occurs in less than 
1% of all AML cases, is uncommon in patients without Down syndrome and a majority of these 
patients are less than one year of age [11].    
1.2.3 The prognostic impact of molecular genetics 
Based on high-throughput sequencing techniques a large number of mutations with documented 
or potential prognostic impact have been identified. These include FLT3, nucleophosmin 
(NPM1), CCAAT/enhancer-binding protein alpha (CEBPA), RUNX1, additional sex combs 
like-1 (ASXL1), tumor protein 53 (TP53), KMT2A, isocitrate dehydrogenase (IDH), KIT proto-
oncogene receptor tyrosine kinase (KIT), Wilms tumor suppressor gene1(WT1), DNA 
(cytosine-5)-methyltransferase 3A (DNMT3A), Tet methylcytosine dioxygenase 2(TET2) and 
serine and arginine rich splicing factor 2 (SRSF2) (Table 3) [17]. The prognostic impact of 
FLT3, NPM1, CEBPA, RUNX1, ASXL1 and TP53 mutations is generally accepted (Table 2), 
and is especially important for the prognostic evaluation of the 40-45% of patients that have 
normal cytogenetics [4].  
NPM1 and CEBPA mutated AML were incorporated as separate entities in the WHO 2016 
classification (Table 1), while FLT3 was not regarded as a separate entity mainly because of its 
association with other entities, but its prognostic significance was emphasized [20]. 
Furthermore, the WHO classification added, as a provisional category, BCR-ABL1 mutated 
AML to identify de novo AML that benefits from treatment with tyrosine kinase inhibitors and 
AML with mutated RUNX1 (Table 1) [6]. The number of mutations in the AML genome is 
generally lower than for many other human malignancies [21, 22], but it should be emphasized 
that AML is usually a heterogeneous disease where individual patients have multiple 
somatically acquired driving mutations and coexisting competing clones [23].  
The Cancer Genome Atlas Research Network analyzed 200 adult patients with de novo AML 
by either whole-genome (n=50) or whole-exome (n=150) sequencing, ribonucleic acid (RNA) 
and microRNA expression and DNA methylation status. They observed an average of 13 
mutations per patient; 23 genes were recurrently mutated including NPM1, FLT3, CEBPA, 
DNMT3A, IDH1, IDH2, enhancer of zeste homolog 2 (EZH2), U2 small nuclear RNA auxiliary 
factor 1 (U2AF1), structural maintenance of chromosomes 1A (SMC1A) and structural 
maintenance of chromosomes protein 3 (SMC3)[21].  Nearly all samples had at least one 
potential driver mutation, and these mutations could be classified as either transcription-factor 
fusions (18%), NPM1 (27%), tumor-suppressor genes (16%), DNA-methylation-related genes 
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(44%), signaling genes (59%), chromatin-modifying genes (30%), myeloid transcription-factor 
genes (22%), cohesion-complex genes (13%), and spliceosome-complex genes (14%) [21]. 
Furthermore, more than half of the patients had at least one subclone in addition to the founding 
clone, and their observations also suggested that mutations in epigenetic regulators occur early 
in preleukemic progenitor cells, before leukemogenic events [23]. This last observation is also 
supported by other studies [24, 25].  
A more recent study included 1540 AML patients from three prospective clinical trials. They 
used karyotyping and targeting resequencing of 111 myeloid cancer genes and identified 5234 
driver mutations across 76 genes or genomic regions [22]. At least one driver mutation was 
identified in 96%, and two or more in 86% of the patients. The genetic patterns in this cohort 
identified three additional genomic subsets, i.e. AML with mutations in genes encoding 
chromatin and/or RNA-splicing regulators, AML with TP53 mutations and chromosomal 
aneuploidies; and AML with IDH2 mutations. Patients with chromatin-spliceosome and TP53-
aneuploidy had poor outcome. The study also showed that co-occurring driver mutations have 
a significant prognostic value. This was especially pronounced in AML with NPM1-mutations, 
where co-mutations identified groups with favorable or adverse prognosis [22].  
 The genetic risk stratification of AML based on the 2017 European Leukemia Net (ELN) 
recommendations [4].   
 
AML genetic risk stratification based on the 2017 ELN recommendations 
 
     Risk 
category 
Genetic abnormality 
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
Mutated NPM1 without FLT3-ITD or with FLT3-ITD low  
Biallelic mutated CEBPA  
Intermediate Mutated NPM1 and FLT3-ITD high  
Wild-type NPM1 without FLT3-ITD or with FLT3-ITD low (without adverse-risk 
genetic lesions)  
t(9;11)(p21.3;q23.3); MLLT3-KMT2A  
Cytogenetic abnormalities not classified as favorable or adverse  
Adverse t(6;9)(p23;q34.1); DEK-NUP214  
t(v;11q23.3); KMT2A rearranged  
t(9;22)(q34.1;q11.2); BCR-ABL1  
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)  
−5 or del(5q); −7; −17/abn(17p)  
Complex karyotype, monosomal karyotype  
Wild-type NPM1 and FLT3-ITD high  
Mutated RUNX1, ASXL1 and Mutated TP53  
Genetic abbreviations are listed in the list of genetic abbreviations in the front of the thesis. 
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1.2.4 Recurrent gene mutations with prognostic value for AML 
Based on the 2017 ELN recommendations, the diagnostic workup in AML should include 
screening for FLT3, NPM1, CEBPA, RUNX1, ASXL1 and TP53 mutations [4]. These mutations 
are described in detail; additional mutations are listed in Table 3.  
AML with FLT3 mutation 
The FLT3 gene encodes a tyrosine kinase receptor expressed by normal progenitors as well as 
AML blasts [11]. FLT3 mutations are detected in 20-40% of patients and are most common in 
AML with normal karyotype and AML with t(6;9)(p23;q34.1). The most common mutations 
are (75-80%) internal tandem duplications (ITD) between exons 14 and 15 in the 
juxtamembrane domain, but missense mutations in exon 20 in the second tyrosine kinase 
domain (TKD) are also detected. FLT3 mutations are associated with high blast counts, 
increased relapse risk and poor overall survival (OS) [26].  
AML with NPM1 mutation 
NPM1 mutations are one of the most common recurrent genetic lesion in AML, and occur in 
about one third of AML patients. They are relatively specific for AML [11]. NPM1 mutations 
usually involve exon 12 and exceptionally occur in exon 11, and about 40 variations of them 
have been identified. Mutation A accounts for 70-80% of NPM1 mutations in adults [27]. NPM1 
mutations are associated with normal karyotype. However, 5-15% of patients with NPM1 
mutations show chromosomal aberrations [27]. Secondary mutations are common in AML: 
approximately 50% of patients with DNMT3A mutations and 40% of patients with FLT3  
mutations also have NPM1 abnormalities [28] (Figure 3). NPM1 without FLT3 mutations have 
a favorable prognosis. In combination with FLT3-ITD the prognosis is worse although better 
than for patients with FLT3-ITD alone [29].  
AML with CEBPA mutation 
CEBPA encodes a transcription factor involved in the control of proliferation and differentiation 
of myeloid progenitors. Although mutations can occur throughout the gene sequence, they are 
mainly out-of-frame insertions or deletions in the N-terminal and in-frame insertions or 
deletions in the C-terminal [17]. CEBPA mutations occur in 6-15% of AML patients and 22-
33% of them have FLT3-ITD [11]. For patients with the normal karyotype AML the mutations 
are associated with a favorable prognosis, but whether or not FLT3-ITD has an impact in this 




RUNX1 is involved in translocations such as (t8;21)(p22;q22) and t(3;21)(q26.2;q22) (see 
section 2.2), but it can also be involved in recurrent intergenic mutations (10% of all AML 
patients) that lead to a preleukemic AML-predisposing state [30].  RUNX1 mutations are also 
associated with radiation exposure [31], inherited disorders such as Fanconi anemia [32], and a 
rare autosomal dominant familial platelet disorder predisposing to AML [33]. RUNX1 
mutations alone are associated with a favorable prognosis, but the combination of RUNX1 and 
cohesion complex mutations (RUNX1-ASXL1, RUNX1-SRSF2) is associated with an adverse 
prognosis[23]. 
Mutated ASXL1  
The ASXL1 gene encodes a chromatin binding protein of the polycomb group that seems 
important for epigenetic regulation of gene expression [34, 35]. It acts as a coactivator for the 
retinoic acid receptor, is involved in histone demethylation and may therefore have a role in 
leukemogenesis [36]. ASXL1 mutations occur in approximately 5-18% of all AML patients and 
are more common in secondary AML. Sequential studies have reported a change of mutation 
status during disease evolution, suggesting high mutation instability [36]. These mutations are 
associated with adverse prognosis [36], but may not be an independent prognostic factor [36].   
Mutated TP53 
TP53 is a tumor suppressor gene [37]. In contrast to many other malignancies, TP53 mutations 
are uncommon in AML [38], and they are associated with complex karyotypes involving 
chromosomes 3, 5 and 17 [37-39]. TP53 mutations are associated with poor outcome. The 
mechanisms behind this prognostic impact seem to involve gain of functions with altered 











 Other mutations that have, or may have clinical/prognostic significance according to the WHO 2016 
classifications and the ELN 2017 recommendations (adapted from [23, 41]) [3, 11, 21, 23, 42, 43]. 
Gene Characteristics Prognostic significance 
IDH1 Occurs in 6-10% of patients with AML. 
Associated with early leukemogenesis. 
Associated with NPM1 mutation. Associated 
with clonal hematopoiesis in healthy elderly 
patients. 
The mutation in itself is currently not 
prognostic, but IDH1 inhibitors are in 
clinical development. Associated with 
possible poor outcome in combination with 
NPM1.  
IDH2 Associated with NPM1 mutation.  The mutation in itself is currently not 
prognostic, but IDH2 inhibitors are in 
clinical development, and are associated 
with favorable prognostics.  
DNMT3A Frequency increases with age (< 60 5-10%, > 
60 20-30%). Gene involved in epigenetic 
regulation. Associated with early 
leukemogenesis. Associated with clonal 
hematopoiesis in healthy elderly patients. 
Associated with FLT3-ITD, NPM1, IDH 
mutations.   
Associated with recurrent disease and poor 
prognosis.  
KIT Occurs in less than 5% of patients. Highest 
prevalence in patients with core-binding 
factor (25-35%). Signaling gene, KIT, located 
at 4q11-12 is a member of type III tyrosine 
kinase family. Most common in exon 8 and 
17. 
In AML with CBF, in particular 
t(8;21)(p22;q22), KIT is associated with 
poor prognosis. KIT alone is not sufficient 
to assign patients to a different risk 
category. There are inhibitors against KIT 
in clinical development.  
KMT2A Occurs in approximately 5% of AML 
patients. Gene involved in epigenetic 
regulation and essential for chromatin-
spliceosome class of AML. Associated with 
RUNX1 mutations, trisomy 11 and CN-
AML.   
The mutation in itself is currently not 
prognostic, but KMT2A inhibitors are in 
clinical development. 
TET2 Frequency increases with age (<60: 7-25%, 
>60: years 20-30%). Gene involved in 
epigenetic regulation. Early event 
hematopoiesis. Associated with IDH1 and 
IDH2 mutations. Associated with clonal 
hematopoiesis in healthy elderly patients 
Mutation may lead to recurrent disease and 
poor prognosis. In the ELN 2010 
recommendation, it is classified as a 
favorable subgroup. 
NRAS Occurs in approximately 15% of all AML 
patients. Most common with normal 
karyotype, AML with inv(16)/t(16;16), and 
AML with inv(3)/t(3;3).  
Mutant RAS may be predictive for 





RNA splicing factors. Tightly correlated 
cluster of mutated genes. Prevalence 
uncertain. Associated with early 
hematopoiesis in healthy elderly people. 
Associated with antecedent hematological 
disorder and multilineage dysplasia. 
Few studies on prognostic value in AML, 





Cohesion complex genes. Prevalence 
uncertain. Associated with NPM1 mutation 
and t(8;21) 
Clinical significance uncertain.  
Abbreviations: ELN: European Leukemia Net, ITD: internal tandem duplication, CBF: core binding factor. 
Genetic abbreviations are listed in the list of genetic abbreviations in the front of the thesis. 
1.2.5 The prognostic impact of response to the first induction cycle 
The response to the first induction cycle is an independent prognostic factor for younger patients 
receiving intensive chemotherapy. The study by Wheatley et al. included 1711 patients below 
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55 years of age. The relapse risk for patients with complete remission based on morphological 
evaluation was of 46%. For patients with partial remission the risk increased to 48% and for 
patients with resistant disease, it reached  69% [44]. There is also a correlation between 
karyotype and response to first induction therapy [44]; this has also been reported by others 
[45]. Evaluation of MRD is now emerging as a new prognostic parameter especially for patients 
classified as having intermediate risk according to conventional criteria. For this reason patients 
can now be classified as complete remission  (CR) with or without MRD (CRMRD-), and this 
seems to be an independent prognostic factor at least for subsets of AML patients [4].                                           
1.2.6 The prognostic impact of leukemization 
High white blood cell (WBC) count at the time of diagnosis is associated with an adverse 
prognosis at least for certain subsets of AML patients [46, 47]. However, its prognostic impact 
seems to be relatively weak compared to cytogenetics and response to first induction cycle [44]. 
Some studies suggest that the use of WBC count as a continuous variable has a stronger 
prognostic impact than a cutoff of  100 x 109/l [48]. WBC counts exceeding 100 x 109/L have 
been associated with increased induction mortality in adult AML; this is mainly due to fatal 
hemorrhages [48]. Furthermore, FLT3-ITD has been associated with a high WBC count [49], 
and WBC counts exceeding 100 x 109/L seem to be associated with an inferior prognosis in 
patients with FLT3-ITD [47]. Alternatively, the bone marrow blast count may also be used for 
prognostication; patients with 20-29% bone marrow blasts at the time of diagnosis seem to have 
a better prognosis than patients with >30% blast [50]. 
1.2.7 Other prognostic parameters 
Increasing age seems to be an independent marker of adverse prognosis. This is not only due to 
poorer performance status, but rather due to an increased frequency of genetic abnormalities 
associated with chemoresistance [4], and secondary AML (secondary to myelodysplastic 
syndrome (MDS) [51], chronic myeloid leukemia (CML), myeloproliferative neoplasm [52], 
or prior cytotoxic therapy [4]). Therapy-related myeloid neoplasms (t-MN) are defined as a one 
of the main subsets in the WHO 2016 classification, and include treatment-related AML (t-
AML), t-MDS and t-MDS/myeloproliferative neoplasm [11]. t-MN have a particularly poor 
prognosis [11]. The prognosis depends on karyotype; balanced translocations have a generally 
better outcome except for (i) t(15;17)(q22;12) and (ii) inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22), and (iii) abnormalities involving chromosome 5 and/or 7 as well as (iv) 
complex karyotype [11]. Finally, TP53 mutations are relatively frequent in t-MN 
(approximately 33%) and contribute to the adverse prognosis [53]. The leukemia stem cells 
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(LSC) profile may also have prognostic value. LSCs govern the ability of self-renewal and 
multipotency as seen in normal stem cells (see section 3.1 “The hierarchical organization of 
normal hematopoiesis and the leukemic hematopoiesis in AML”), and they also show 
similarities in their global gene expression profiles [54, 55]. A previous study suggests that 
detection of a global stem cell-like gene expression profile of the primary AML cell population 
is associated with an adverse prognostic impact in patients with normal karyotype [55]. Finally, 
the detection of clonal heterogeneity by karyotyping of pretreatment primary AML cells is an 
independent marker of adverse prognosis [56].  
1.3 Epigenetics 
The word “epigenetic” means “in addition to changes in genetic sequence”, and is used to 
describe heritable processes that alter gene expression without changing the DNA sequence 
[57]. Global epigenetic abnormalities are common in human malignancies and are important 
both for leukemogenesis and chemosensitivity [5]. The best known epigenetic mechanism is 
DNA methylation. DNA methylation is the covalent binding of a methyl group to cytosine in 
CpG regions in the DNA; these regions are concentrated in so called “CpG islands”[5]. AML 
subsets have distinct DNA methylation profiles that may correlate with specific gene mutations, 
e.g. IDH and NPM1 mutations [21, 58, 59], and methylation signatures seem to have an 
independent prognostic impact [59].  
Other important epigenetic mechanisms are histone modifications, i.e. posttranslational 
alterations that are crucial for chromatin structure and gene expression. Modifications can either 
activate or repress gene expression and include acetylation, methylation, phosphorylation, 
ubiquitination or sumoylation. Histone modifications are regulated by various enzymes 
including histone acetyltransferases, histone deacetylases (HDACs), histone methyltransferases 
and histone demethylases [5]. Acetylation leads to opening of chromatin and promotes gene 
transcription. Histone deacetylation on the other hand, promotes chromatin condensation and 
represses gene transcription. HDACs are often overexpressed in cancer cells and are regarded 
as therapeutic targets [5, 60].  
1.4 The leukemic cell population 
1.4.1 The hierarchical organization of normal hematopoiesis and the leukemic 
hematopoiesis in AML 
Both normal and leukemic hematopoiesis have a hierarchical organization, and the cells then 
proceed through an organized developmental hierarchy that is initiated by the hematopoietic 
stem cells (HSCs) [61]. The HSCs give rise to the different hematopoietic lineages, the first 
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step being cellular development into committed progenitors and the last step being development 
into at least nine fully differentiated main effector cells (Figure 1) [62]. Most effector cells have 
a high turnover and a short life span, whereas the HSCs are characterized and defined by 
multipotency and long-term self-renewal [61].  
In the hematopoietic hierarchy model, the immediate progeny after the HSCs are also 
multipotent cells and they are therefore referred to as multipotent progenitors. These cells have 
a limited capacity for self-renewal and the HSCs are therefore the only hematopoietic cells to 
possess both these properties. There are several models for the differentiation of HSCs into the 
various lineages, but it is generally accepted that multipotent progenitor cells differentiate into 
either a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP), which 
determines their subsequent commitment to either a lymphatic or a myeloid pathway [63]. The 
CLPs give rise to the B-lymphocytes, T-lymphocytes, and natural killer cells, while the CMPs 
give rise to granulocyte/monocyte progenitors and megakaryocyte/erythrocyte progenitors [62].  
Figure 1. The hierarchical organization of normal hematopoiesis. Human hematopoiesis has a structural 
hierarchic organization, initiated by the multipotent, self-renewing hematopoietic stem cell (HSC). Downstream 
from the HSC are the multipotent progenitors, which in turn give rise to the lineage-committed common 
progenitors (CLP and CMP). The CLP and CMP will ultimately generate fully differentiated blood cells, including 
thrombocytes, erythrocytes, monocytes, granulocytes, dendritic cells, and the lymphocytes. The darkening of the 
background color illustrates the increased lineage-commitment in the hierarchic organization. Abbreviations are 
listed in the list of abbreviations in the front of the thesis.  
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Identifying stem and progenitor cells is challenging and depends on various tools and strategies, 
including cellular, molecular and functional assays, to distinguish stem cells from other cell 
population. To make it even more challenging, there are no clear molecular definitions of stem 
cells. Cluster of differentiation (CD) molecules are cell surface markers frequently used for 
identifying cell types/subsets. Multipotent cells do not express lineage-specific differentiation 
markers and are referred to as Lin-.   
The AML cell population is also hierarchically organized, initiated by the LSCs [64]. The 
heterogeneity within the hierarchical organization is reflected in morphological signs of AML 
cell differentiation, in the expression of molecular stem cell markers and in various cell surface 
or intracellular differentiation markers [65]. Genetic changes responsible for causing AML 
usually occur in cells that have self-renewal potential, i.e. the HSCs or the multipotent 
progenitors [66], and cells that continue to divide are most likely to accumulate chromosomal 
abnormalities or molecular mutations. However, the AML cell population may also show an 
additional heterogeneity that is not caused by the hierarchical organization alone, e.g. some 
patients show a clonal heterogeneity with cells that differ in their AML-associated genetic 
abnormalities [56, 67]. Clonal heterogeneity can also be reflected by differences in the 
activation of intracellular signaling pathways [68]. Both genetic and functional (i.e. constitutive 
intracellular signaling) evidence of clonal heterogeneity seem to be associated with an adverse 
prognosis [56, 68]. 
Only a small subset of cancer cells is capable of extensive growth [69-71], and the first to 
provide direct evidence of an LSC was Lapidot et al. [72] and Bonnet et al. [73] in the mid 
´90s. They showed that when transplanting primary AML cells into respectively SCID or 
NOD/SCID mice, only a small subset of the cells could initiate disease development in vivo 
[72, 73]. This population called SCID leukemia-initiating cells (SL-IC), possessed a high self-
renewal capacity and was able to differentiate; the cells were thus considered to be LSCs. The 
SL-ICs were usually (but not always) CD34+/CD38- cells regardless of the phenotype of the 
majority of the blasts within the AML cell population [55, 73]. Finally, the expression of certain 
molecular markers seems to differ between HSCs and LSCs. This includes Thy-1 (CD90) and 
c-kit (CD117) that are expressed on the surface of HSCs but not on LSCs [74-77], whereas 
interleukin (IL) -3 receptor α chain (CD123) seems to be expressed mainly by the LSCs together 
with CD13, CD96, CLEC12A [76, 78], CD25, CD47, IL 1 receptor accessory protein (IL1RAP) 
and C-type lectin-like receptor 1 (CCL-1) [76, 79-81]. However, the AML stem cells differ 
between patients and have been found in all four cell subsets defined by the two markers CD34 
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and CD38 [55], and it is therefore not currently possible to identify a specific AML stem cell 
phenotype that is similar for all patients.  
1.4.2 The stem cell niche 
Normal hematopoiesis supplies the human body with more than 100 billion mature blood cells 
every day [82]. These cells are derived from a small population of HSCs and in adults they are 
mainly found in a quiescent state in the bone marrow stem cell niches [83]. These niches were 
first described four decades ago [84], and they function as a specialized microenvironment that 
consists of various specialized cells that support hematopoiesis and regulate and balance the 
characteristics of the stem cells, i.e. quiescence (G0 state), self-renewal and differentiation [85]. 
The quiescent state ensures their life-long self-renewal [85].   
During embryogenesis the HSCs travel between different niches, starting in the yolk sac where 
immature precursors give rise to erythrocytes [86], and definitive HSCs are later found in the 
aorta-gonad-mesonephric region and the placenta [87, 88]. After development of vasculature, 
the HSCs migrate to the fetal liver [86] before they colonize the bone marrow [86]. This last 
step represents an active recruitment mediated by the release of stromal cell-derived factor 1 
(SDF-1) also known as C-X-C motif chemokine 12 ligand (CXCL12) by the bone marrow 
stromal cells. This chemokine then binds to the chemokine receptor CXCR4 expressed by the 
stem cells [89]. The CXCL12/CXCR4 interaction is also essential for the maintenance and 
quiescence of HSCs [90, 91]. In addition, CXC12 up-regulates the stem cell expression of 
Vascular Cell Adhesion Molecule-1 (VCAM-1) and Very Late Antigen (VLA-4) that are 
important for homing and retention of HSC in the niches [92]. 
Stromal cells comprise most of the non-hematopoietic cells in the bone marrow and include 
cells of endothelial, mesenchymal (adipocytes and osteoblasts) and neural origin. These cells 
form the stem cell niches and thereby support the homeostatic balance of the stem cells between 
self-renewal, differentiation and quiescent [93]. However, these cells also maintain the bone 
marrow framework through their contribution to local vascularization, bone remodeling and 
metabolic regulation of the hematopoietic cells [93]. Previous research suggests that most HSCs 
are located in endosteal niches [94], in association with chimeric antigen receptor  (CAR) cells 
or close to sinusoidal blood vessels in perisinusoidal niches [95, 96] (Figure 2).  
The bone marrow has a high density of vessels comprised of a single layer of bone marrow 
endothelial cells surrounded by perivascular cells and non-circulating hematopoietic cells. The 
endothelial cells can be divided into subtypes based on their phenotype, expression of adhesion 
molecules and production of hematopoietic growth factors [93]. The bone marrow vessels form 
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a microvascular tree that starts with arterial vessels surrounded by sympathic nerves, smooth 
muscle cells and matrix components. These vessels have low permeability. They branch into 
thinner arterioles that further branch into capillary vessels that are located at the interface 
between bone marrow and the bone surface where they are important for bone remodeling. The 
thin-walled venous vessels form sinusoids that are highly permeable and serve as a main site 
for cell trafficking [97]. The sinusoidal epithelial cells produce high levels of stem cell factor, 
CXCL12, and E-selectin; they express vascular endothelial growth factor receptor 2 (VEGFR2) 
and are thereby important for bone marrow regeneration after bone marrow damage [98].  
The mesenchymal compartments that surround the endothelial cells are also important for the 
regulation of hematopoiesis, and these cells also have a hierarchical organization with 
multipotent mesenchymal stromal cells (MSCs)  that can give rise to osteoblasts, adipocytes, 
chondrocytes and reticular stromal cells [93, 99].  MSCs express several regulators of 
hematopoiesis, including CXCL12, angiopoietin 1 (Ang-1) and stem cell factor. The CXCR12 
abundant reticular cells (CARs) are a subpopulation of mesenchymal progenitor cells with 
adipogenic and osteogenic potential in vitro [100]; they are a main source of CXCL12 and also 
express several adhesion molecules, e.g. VCAM-1 [93].  
The osteoblasts have a role in HSC regulation through their expression of the glycoprotein 
osteopontin that is important for adhesion, migration and proliferation of HSCs [101]. 
Osteoblasts also express other adhesion molecules including annexin II, n-cadherin, CD44, 
CD164, VCAM1 and ICAM1 [96], as well as several soluble regulators of hematopoiesis 
including G-CSF, GM-CSF, MCSF, IL-1, IL-6, IL-7, CXCL12 [94, 96], thrombopoietin [102], 
Ang-1 [103], Notch ligands [104] and Wnt ligands [105].  
The number of BM adipocytes increases with age and correlates inversely with hematopoietic 
activity. Naveiras et al. showed that mice with impaired adipogenesis had increased 
hematopoietic activity in the bone marrow at sites that would normally be rich in adipocytes. 
They also observed that the pharmacological inhibition of adipogenesis after bone marrow 
transplantation increased the hematopoietic progenitors in the recovering marrow [106]. These 
observations suggest that adipocytes play an inhibitory role in HCS maintenance.  
The stromal compartment of the bone marrow also includes neural cells, e.g. glial fibrillary 
acidic protein, non-myelinating Schwann cells and adrenergic neurons. The sympathic nervous 
system regulates the expression of CXC12 through circadian noradrenaline secretion [107]. 
Adrenergic signaling seems to be important for the circadian regulation of hematopoiesis [108]. 
The glial cells, especially non-myelinating Schwann cells, are also involved in the regulation 
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of hematopoiesis [109]. Loss of Schwann cells is associated with decreased TGF-β levels and 
loss of HSCs. Finally, an extracellular matrix, which is a three-dimensional extracellular 
macromolecule complex, is essential for stem cell niche homeostasis, maintenance and 
regeneration [110]. 
Figure 2. The stem cell niche. Hematopoietic stem cells (HSCs) are found in specialized well vasculated niches, 
where distinct cells contribute to the maintenance, migration and proliferation of HSCs. A complex group of 
stromal cells, including endothelial cells, mesenchymal stem cells (MSCs), osteoblasts, osteoclasts and CAR cells 
are implicated in HSCs maintenance. In addition, sympathic neurons indirectly regulate HSCs through MSCs, and 
direct regulation from Schwann cells. Finally, hematopoietic cells such as macrophages, megakaryocyte and 
monocyte also influence the HSCs migration and proliferation. Abbreviations are listed in the list of abbreviations 
in the front of the thesis.  
1.4.3 The cytokine network 
Cytokines are small proteins that mainly mediate signaling between cells by binding to specific 
cell surface receptors. They are important for the regulation of cell viability, proliferation, 
differentiation and migration. Cytokines are thereby important regulators of many processes, 
including inflammation, angiogenesis and normal as well as leukemic hematopoiesis [111]. 
Cytokines can act on the cells that release them (autocrine), on other cells close by (paracrine) 
or on distant cells (endocrine). One cytokine may act on different types of cells (pleiotropy) or 
different cell types may secrete the same cytokine. Cytokines may also be redundant in their 
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activity. Thus, effects of cytokine networks can be complex. Cytokines have shown to be 
important for the communication between AML cells and their neighboring leukemia-
supporting stromal cells [111]. Receptor ligation initiates downstream signaling through 
intracellular pathways. Abnormalities of cytokine and growth factor signaling pathways are 
common in AML, and these patients also have abnormal systemic cytokine levels that 
normalize in CR, e.g. increased CXCL8 levels that at least partly reflect the leukemia cell 
burden [112]. The cytokines that commonly show constitutive release by primary AML cells 
can be divided into interleukins (IL), chemokines (CCL or CXCL), immune-regulators, 
hematopoietic growth factors and others (more detailed in Table 4.) [113]. Chemokines are a 
subgroup of cytokines with low molecular weight that are known to induce chemotaxis, though 
some also possess other functions. The chemokine system has been investigated in detail in 
human AML [114], and these studies have shown that patients can be divided into specific 
subsets based on their chemokine release subset [114-116]. However, primary AML cells 
release a wide range of soluble mediators [116, 117], and the overall cytokine profile is even 
associated with prognosis [118]. Finally, the cytokines are not the only soluble mediators that 
are important, soluble cytokine receptors and soluble adhesion molecules may also contribute 




 General and simplified classification of cytokines. Cytokines can be divided into six cytokine families 
based on their biological effects. Table modified from [113]. 
Cytokine family Subgroup Main physiologic effect 












Regulate migration of granulocytes, lymphocytes 
and monocytes 
Promote angiogenesis and inflammation 
Enable medullar homing 
Differentiation induction (CCL17 and CCL22) 
Interferons Type I: INFα/ β/ώ 









Pro-inflammatory and pyrogenic 
Activates non-specific immunity 
Adhesive molecule expression on endothelial 
surface 
May induce apoptosis 
Overproduction causes SIRS 







Mobilization of HSC from BM to PB 
Stimulate proliferation and maturation of myeloid 
precursors 
TGF-β  Stimulates growth of fibroblasts and extracellular 
matrix production 
MMP inhibition 
Abbreviations are listed in the list of abbreviations in the front of the thesis.  
 
1.5 Treatment   
1.5.1 Potentially curative treatment  
The therapeutic strategy for patients with AML has not changed significantly during the last 30 
years [3], and the only curable treatment is intensive chemotherapy possibly including 
autologous or allogenic stem-cell transplantation (allo-HSCT) [4].  
Induction therapy 
The initial intensive induction chemotherapy will often be a continuous infusion of AraC for 
seven days combined with three days of anthracycline treatment; this is referred to as the “7+3 
regime” [4]. The goal of this therapy is to achieve disease control with normalization of 
peripheral blood cell counts and no morphological signs of leukemia in the bone marrow; this 
is often referred to as CR. This is achieved for 60-80% of adults below 60 years of age, whereas 
for elderly patients above 60 years of age the CR rate is of only 40-60% [4]. The reasons for 
this reduced rate include increased frequency of both high-risk genetic abnormalities and 




Patients in CR after induction therapy continue with consolidation therapy. This treatment aims 
to reduce and eradicate MRD. Standard post-remission treatment strategies include 
conventional intensive chemotherapy and possibly autologous or allo-HSCT [3]. The decision 
whether to continue with conventional chemotherapy or HSCT is based on the prognostic 
evaluation of the patients, i.e. the risk of relapse without intensified treatment versus the risk of 
severe morbidity or mortality if the treatment is intensified with autologous and especially allo-
HSCT [4]. For patients with low-risk AML, conventional chemotherapy will often be preferred, 
possibly combined with autologous HSCT. Allo-HSCT is considered for younger patients 
(below 70-75 years of age) without severe comorbidity and intermediate or high-risk disease. 
Allo-HSCT is the most effective antileukemic treatment due to the intensive pre- 
transplant conditioning treatment (with high-dose chemotherapy and/or possibly radiation 
therapy) and due to the post-transplant immune-mediated graft-versus-leukemia (GVL) 
reactivity [121]. Due to the increased use of mismatch or unrelated donors as well as cord blood 
sources, a suitable donor can be found for most patients [4]. Because of this, as well as non-
myeloablative or reduced-intensity conditioning (RIC) regimens, more patients can nowadays 
be allotransplanted. However, because many patients are elderly or unfit, only a minority of 
AML patients undergo transplantation [122]. 
If CR is not achieved after the first induction cycle, then a second induction cycle is tried. If 
CR is still not achieved after a second attempt, the patients are considered to have refractory 
disease. A second induction is also tried in younger and fit relapse patients. There is no standard 
salvage regime for primary refractory or relapse AML [4]. However, allo-HSCT is the only 
curable alternative for both relapsed and refractory disease [123]. To achieve this there are three 
possible strategies: (i) additional intensive induction cycles to try to achieve CR before allo-
HSCT, (ii) intensive chemotherapy cycle to reduce the leukemia burden immediately followed 
by allo-HSCT [4], or (iii) allo-HSCT without prior CR, though this has significantly lower OS 
[124].  
1.5.2 Complications to AML therapy  
The early 4-weeks induction treatment mortality rate is usually of 5-10% of AML patients; this 
risk depends on age and comorbidity and the most common causes of death are organ 
failure/toxicity, infections and hemorrhages. The mortality during conventional intensive 




The mortality of allo-HSCT is usually higher and depends on several factors, but age and 
comorbidity are important also in these patients [125]. Hemorrhages are frequent during the 
early post-transplant period, but during intensive conditioning therapy and allo-HSCT shortly 
afterwards, the risks of severe infections and occlusive disease are the predominant 
complications [126]. Infections are also common during the early post-transplant cytopenia 
(bacterial and fungal infections) and also later after hematopoietic reconstitution (especially 
viral reactivation). In the long term, immune-mediated complications with organ damage turn 
out to be the main challenge   (i.e. acute and chronic graft versus host disease, GVHD) [127]. 
These immune-mediated complications are the major long term causes of non-relapse mortality 
[128] and affect a wide range of organs. Acute GVHD mainly affects the skin, liver and 
gastrointestinal tract whereas chronic GVHD (cGVHD) may affect many additional organs and 
the pulmonary form of cGVHD is especially severe [129]. The pathogenesis of GVHD involves 
several subsets of immunocompetent cells, including donor CD4+ and CD8+ T cells causing 
immune-mediated tissue damage, but B cells as well as other antigen-presenting cells are also 
important [130]. Thus, the pathophysiology - especially of cGVHD is not fully understood, but 
the main contributions seems to be (i) central T cell tolerance failure, (ii) B cell abnormalities, 
and (iii) formation of prefibrotic and fibrotic lesions [131] as described in detail in a recent 
review [131].  
1.5.3 AML stabilizing treatment 
Many elderly and unfit patients will only receive disease-stabilizing treatment due to an 
unacceptable risk of severe toxicity and/or treatment-related mortality if intensive therapy is 
tried. This treatment can be low-dose AraC or demethylation agents; low-dose AraC induces 
CR in 15-25% of patients, but the median survival is of only 5-6 months [132]. Some of the 
alternative therapies will be briefly described below.  
Demethylating agents 
DNA methylation can result in gene silencing, which in turn can lead to inactivation of tumor 
suppressor genes. Demethylating agents induce DNA hypomethylation and thereby re-
expression of silenced genes, e.g. tumor suppressor genes [133]. The two drugs 5-azacitidine 
and 5-aza-2´-deoxycitidine are currently approved for treatment of AML. Both drugs inhibit 
methyltransferase and thereby have direct cytotoxic or proapoptotic effects. In a randomized 
trial, decitabine showed a slightly increased survival (7.7 months versus 5.0 months) compared 
to other treatments (usually low-dose AraC) without any major differences in toxicity [134]. 
Another randomized trial showed that azacitidine increased median survival (10.4 months 
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versus 6.5 months) compared with conventional treatment [135]. Both these drugs are 
recommended by the ELN guidelines [4]. 
Valproic acid plus all-trans retinoic acid  
Valproic acid is an anti-epileptic drug; it is generally well tolerated but has a teratogenic 
potential and distinct anti-neoplastic properties [136]. Valproic acid is a short-chain fatty acid 
that functions as a histone deacetylase (HDAC) inhibitor [137]. To form chromatin, DNA is 
wrapped around histones in the cell nucleus. Acetylation is one of the main histone modificators 
that lead to opening of the chromatin, promoting gene transcription. HDACs will therefore 
promote chromatin condensation and repress gene transcription, and are shown to be 
overexpressed in malignant tissue. HDAC inhibition results in re-expression of gene 
transcription and has antiproliferative and proapoptotic effects also in AML cells [138-141]. 
When used as monotherapy in AML, valproic acid has low response rates (3-5%) [142, 143], 
but the combination of valproic acid and all-trans retinoic acid (ATRA) has a response rate of 
approximately 30% [133, 144]. 
ATRA is a vitamin A metabolite used in the treatment of APL where the absence of ATRA 
induces chromatin condensation and transcriptional repression [16]. ATRA binds to the RARα, 
which leads to decomposition of the PML/RARα gene complex in APL and thereby results in 
growth suppression and induction of myeloid differentiation [145]. Antileukemic effects of 
ATRA have also been reported in non-APL variants of AML [146-148], and ATRA seems to 
increase the ability of HDAC-inhibitors to induce differentiation and inhibit proliferation [149, 
150]. Even though the combination of ATRA and valproic acid has clinically relevant 
antileukemic activity, complete remission is very uncommon despite the fact that 30-40% of 
the patients respond with increased peripheral blood cell counts, lasting for up to 1-2 years in 
exceptional patients [133]. Thus, the combination of ATRA and valproic acid possibly together 
with low-toxicity chemotherapy has an acceptable toxicity and a stabilizing potential for a 
subset of AML patients. 
Low-dose cytarabine 
This therapeutic strategy has been used for several decades for elderly and unfit AML patients 
and various doses have been tried [146]. The previous MRC study showed that this treatment 
has a limited effect especially for patients with low-risk disease characteristics, whereas 
survival was not improved for patients with high-risk disease [146]. A recent study also 
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suggested that low-dose cytarabine may be combined with the hedgehog pathway inhibitor 
glasdegib [151]. 
Low-dose melphalan 
Low dose melphalan as a strategy for elderly and unfit patients has been investigated in patients 
with AML or MDS. The studies are few, relatively small and for some of only a minority of 
patients had AML [152-156]. This therapeutic strategy can be considered, but the 
documentation should be regarded as weak.  
1.5.4 Other therapeutic targets in AML   
The biological characterization of primary AML cells has identified several possible therapeutic 
targets [3], and a number of ongoing clinical trials are looking into new areas, including 
targeting of tyrosine kinases such as FLT3, AXL and KIT inhibitors [157-159], epigenetic 
regulation (DNA methylation or histone acetylation), as well as promising second-generation 
hypomethylation agents [160]. BET bromodomain inhibition is also being studied [161], as well 
as various immunological approaches based on checkpoint inhibition or antibody therapy 
including both monoclonal antibodies and bispecific antibodies targeting CD33 and CD3 
(NCT03971799). Furthermore, strategies to target metabolic regulating enzymes  (e.g. mutant 
metabolic IDH1 and IDH2 enzymes) [162] are being vastly investigated, and FDA has now 
approved the use of IDH inhibitors for treatment of AML [163].  
Finally, an exciting new strategy to target AML is BCL-2 inhibition [164]. BCL-2 is an anti-
apoptotic molecule that is found to be overexpressed in LSCs [165]. Moreover LSCs are shown 
to be uniquely dependent on oxidative phosphorylation (OXPHOS), and BCL-2 inhibition 
targets OXPHOS, selectively eradicating LSCs [166]. Venetoclax, a BCL-2 inhibitor was 
recently approved by the FDA in combination with azacitidine or decitabine or low-dose 
cytarabine for treatment of newly diagnosed AML patients ≥ 75 years, or patients unable to 
receive intensive chemotherapy due to comorbidities. Recent studies of venetoclax in 
combination with azacitidine or low-dose cytarabine has given very promising results [167-
169], but again the treatment seems most effective for patients with favorable disease 






 Metabolic definitions and characteristics used in this thesis.  
 Definition Characteristics 
Metabolism The chemical 
transformations within 
the cells that allow the 
organism to perform  
energy-consuming 
operations 
Metabolism is commonly divided into catabolism 
(which breaks down organic substances that produce 
energy, intermediates and NADPH) and anabolism, 
(which uses energy, intermediates and NADPH to 
construct cellular components) 
Metabolites All small molecules 
(<1-1.5 kDa) within an 
organism. 
Metabolites function as intermediates and products of 
metabolism. Examples include carbohydrates, amino 
acids, lipids, nucleotides, vitamins and so on.  
Metabolon The total composition 
of the metabolites in 
an organism is the 
metabolon 
The composition is determined by the transcription 
and translation of the genome, molecular protein –
protein interaction and enzymatic activity, as well as 
external factors. 
Metabolic profiles The entire metabolite 
composition of an 
organism 
The metabolic profile can give us information on the 
organism´s function, or response to genetic, epigenetic 
or environmental changes 
Metabolomics The systematic study 
of the metabolon is 
metabolomics 
During the last decade metabolomics have been 
increasingly used to identify potential biomarkers in 
diseases, as well as to improve our understanding of 
the metabolon and the associated pathways 
Abbreviations are listed in the list of abbreviations in the front of the thesis. 
1.6.1 Cancer cell metabolism 
Since the discovery of cancer cells´ altered metabolism, cancer cell metabolism has emerged as 
a target for cancer therapy. While normal cells, in the presence of oxygen, mainly prefer 
OXPHOS, cancer cells are more dependent on alternative metabolic pathways, mainly 
glycolysis. The conversion of glucose into lactate even in the presence of oxygen is termed 
“aerobic glycolysis”, and was first postulated by Otto Warburg and colleagues in the 1920s, 
hence the term the Warburg effect [7, 171]. Why cancer cells prefer other, less energy efficient 
metabolic pathways to OXPHOS is still not fully understood. However, cancer cells are 
dependent on ATP production for survival only in certain conditions. Under normal 
circumstances, the cytosolic level of nicotinamide adenine dinucleotide phosphate (NADPH) 
is the limiting factor for fast proliferation. NADPH has two main functions in mammalian cells: 
(i) it provides redox to counteract oxidative stress, which is crucial for cancer cells to be able 
to survive under conditions with high metabolic stress, (ii) it acts as a co-enzyme for anabolic 
enzymes vital for generating new building blocks to sustain growth and proliferation [172]. 
Cancer cells´ ability to alter their energetics in order to meet the metabolic demands of rapid 
proliferation and survive stressful conditions is crucial for cancer development, and is today 
recognized as one of the hallmarks of cancer [8]. The main metabolic pathways used by cancer 
24 
 
cells to gain energy and NADPH besides OXPHOS and glycolysis, are glutaminolysis, fatty 
acid β-oxidation and the pentose phosphate pathway (Figure 3).  
 
Figure 3. Metabolic pathways in cancer cells. The main metabolic pathways in cancer cells besides 
from OXPHOS are glycolysis, glutaminolysis, fatty acid β-oxidation, lactate transport and the pentose 
phosphate pathway. In addition, the figure illustrates the AMPK pathway, and autophagy. Abbreviations 
are listed in the list of abbreviations in the front of the thesis.  
 
1.6.2 Metabolic pathways 
Glycolysis  
The majority of cancer cells prefer aerobic glycolysis as their main metabolic pathway. This is 
compounded by the fact  that cancer cells take up an enormous amount of glucose compared 
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with cells from surrounding tissue [7]. Glycolysis is the first step in the catabolism of glucose, 
where glucose molecules are converted into pyruvate in the cytosol to be further processed to 
generate ATP. This is a far less energy efficient metabolic pathway compared to OXPHOS, 
where one glucose molecule can generate up to 36 ATP, while glycolysis only generates 2 ATP 
[8, 173]. However, glycolysis also produces more intermediates, as well as NADPHs, and 
building blocks for amino acids and nucleosides that are required in large quantities when 
synthesizing new cells [9]. Glycolysis is also a faster pathway than OXPHOS, so even though 
the energetic yield is much lower for each glucose molecule, one can produce ATP at a higher 
quantity by glycolysis given sufficient excess of glucose [173, 174].  
So what causes tumor cells to initiate the high consumption of glucose? Normal cells´ glucose 
uptake is strictly regulated by growth factor signaling, as well as interactions with the 
extracellular matrix [175, 176]. In contrast, cancer cells are shown to be significantly less 
dependent on external requirements, and more dependent on genetic alterations in internal 
signaling pathways [8, 177].  Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) 
signaling is the main regulator for glucose uptake. PI3K/Akt signaling causes upregulation of 
glycolysis by promoting increased expression of glucose transporter GLUT1 mRNA [178] and 
translocation of GLUT1 from endomembranes to cell surface. In addition it potentiates the 
activity of hexokinases (HKs), the rate limiting enzymes of the glycolysis, and 
phosphofructokinase (PFK), the enzyme that catalyzes the key irreversible step of glycolysis 
[179]. Studies have shown that Akt-hyperactivation promotes aerobic activation without 
affecting the rate of OXPHOS, thus promoting aerobic activation through the Warburg effect 
[180]. The PI3K-Akt pathway is upregulated in a subset of AML cells, potentially contributing 
to metabolic reprogramming [181]. The PI3K-Akt signaling is not the only signaling pathway 
that plays a role in glucose metabolism. There are multiple other signaling nods facilitating 
uptake of glucose that are upregulated in cancer cells - notably, RAS, another oncogenic 
signaling protein, that has also been shown to upregulate GLUT1 mRNA expression, increasing 
intracellular glucose consumption [182]. Cancer cells´ increased glycolytic activities have been 
shown in various cancers, and have also been linked to treatment resistance in AML [183, 184]. 
Growing evidence suggests that oncogenes and tumor suppressors may play a role in promoting 
the switch to glycolysis. This dependency on glycolysis may be seen upon as a weakness that 
can be exploited therapeutically. A potential target for inhibiting the glycolytic pathway is HKs. 
HKs are, as mentioned, the rate limiting enzyme for glycolysis, converting glucose to Glucose-
6-phosphate (G6P). HKs influence the magnitude of glucose within the cell by facilitating the 
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entry of glucose. They also determine the direction of flux by converting glucose to G6P, which 
has a feedback inhibition on HK.  There are four major HK isoforms in mammals (KK1-4), all 
encoded by separate genes. HK1 and HK2 are the two high affinity HKs. HK1 is expressed in 
most mammalian tissues, while HK2 is expressed in a high level only in a limited number of 
cells in adult tissues [185]. However, high levels of HK2 are observed in cancers cells [186, 
187], meaning that HK2 has a selective overexpression in cancer. This is manifested by the use 
of positron emission tomography (PET), where the glucose analog  [18F] fluoro-2-deoxyglucose 
is phosphorylated by hexokinase to form fluoro-2-deoxyglucose-phosphate, which can be 
detected by PET [187]. In addition, HK2 conditional knockout mice have shown that HK2 is 
required for tumor initiation and maintenance in a study using mouse models of lung and breast 
cancer [187]. Drug induced inhibition of HK2 with HK2 inhibitors such as 2-deoxy-D-glucose 
(2DG) and Lonidamine has also been known  to decrease proliferation and/or increase apoptosis 
in both leukemic cell lines and primary cells [188-190].  
Amino acid metabolism in cancer cells 
Metabolic reprogramming goes far beyond cancer cells´ increased glucose assumption and the 
Warburg effect. Other metabolic pathways are required for the production of nutrients, and 
three major classes of macromolecules (proteins, lipids and nucleic acids) are essential for cell 
growth and proliferation [191]. Amino acids play a dual role as they are used as both building 
blocks for the protein synthesis and as metabolites for biosynthetic reactions [192]. Studies have 
shown that cancer cells (including AML) have altered amino acid metabolism compared to 
healthy cells [192-194]. This is supported by our own findings in Paper III [195]. Amino acid, 
particularly glutamine, also provides a carbone source, which allows malignant cells to rely on 
high glycolytic rates [191]. Through glutaminolysis, the amino acid glutamine is converted to 
lactate, providing reduced NADPH that is needed in the lipid synthesis, and a carbon source for 
the TCA cycle intermediates to maintain mitochondrial function under aerobic glycolysis [196, 
197]. Glutamine also contributes to reduced nitrogen that is used in the de novo synthesis of 
nitrogen-containing compounds such as purine, pyrimidine, G6P and non-essential amino acids 
[9]. Proliferating tumor cells have a high demand for glutamine. This was first described by the 
American physiologist Harry Eagle in the 1950s [198], and has later been confirmed in various 
studies [9]. The main signaling pathways that regulate glutaminolysis are still not fully 
understood, but key oncogenes such as c-myc and RAS, which are upregulated in AML, have 
been demonstrated to stimulate glutamine metabolism [199, 200]. 
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The main glutaminolytic enzymes are the glutamine-utilizing enzymes glutaminase (GLS), the 
gatekeeper enzyme which catalyzes the hydrolysis of glutamine to glutamate in mitochondria, 
and glutamate dehydrogenase (GDH) which produces α-ketoglutarat (αKG) from glutamate to 
fuel the TCA cycle. In mammalian cells, the GLS family has two isoforms, known as GLS1 
and GLS2. GLS2 is a known p53 target gene [201]. Several studies have shown that drugs 
targeting these enzymes, such as bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 
3 (BPTES), a selective GLS1 inhibitor, exert an antitumor effect in different types of tumors 
[202-206], including AML [207]. As certain cancer cells have been shown to be addicted to 
glutamine, drugs targeting glutaminolysis are emerging as a potential novel therapeutic strategy 
to “starve” the cancer cells of energy for growth, and trigger apoptosis [207].  
Fatty acid synthesis and oxidation  
In addition to glucose and glutamine, fatty acids are an important energy source for proliferating 
cells. De novo synthesis of fatty acids is required for synthesis of membranes, and therefore 
crucial for cell growth and proliferation [208]. Fatty acid synthesis is an anabolic process that 
converts acetyl CoA to malonyl CoA through acetyl CoA carboxylase. Fatty acids are 
catabolized through fatty acids oxidation (FAO), also known as β-oxidation [208]. FAO 
generates one molecule of acetyl CoA in each oxidation cycle, and two in the last cycle (Figure 
3), which in turn can be used to produce cytosolic NADPH.  The production of FAO-derived 
cytosolic NADPH has been reported to be crucial to counteract oxidative stress in human 
glioblastoma cells, where inhibition of FAO has led to a decrease in NADPH levels and an 
increase in reactive oxygen species (ROS) -dependent cell death [209]. Furthermore, a high-
throughput screening study of primary AML cells, found that Avocatin B, a lipid derived from 
avocado, reduced human primary AML cells´ viability by inhibiting FAO, decreasing NADPH, 
resulting in ROS-dependent leukemia cell death [210].  Human AML cell lines are also reported 
to be dependent on FAO for survival. Sanudio et al. showed that etoxomir, a carnitine palmitoyl 
transferase 1 (CPT1a) inhibitor, decreased leukemia progenitor cells in approximately 50% of 
primary AML samples [211]. Targeting FAO by inhibiting CPT1a, one of the enzymes that 
transports fatty acids into the mitochondria, has shown promising results. CPT1 is considered 
the rate limiting enzyme in FAO, and inhibition of CPT1a prevents production of ATP from 
fatty acids [208]. Etoxomir induces apoptosis in several studies with AML [211], but has 
exhibited toxic effects (hepatotoxicity) in clinical trials [212]. Other studies using the CPT1 
inhibitor ST1326 to inhibit FAO have reported impaired cancer cell survival and decreased 
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proliferation in AML cell lines and primary AML cells [213], as well as in vivo Burkitt’s 
lymphoma cells [214]. 
Pyruvate to lactate, the preferred fate for pyruvate in cancer cells  
Pyruvate is a central metabolite in a number of metabolic processes. In the last step of the 
glycolytic breakdown of glucose, pyruvate is synthesized by pyruvate kinase (PK). From here, 
pyruvate can convert to lactate in a reversible process by lactate dehydrogenase, which 
facilitates the rapid recycling of NAD+ necessary to maintain a high glycolytic rate. 
Alternatively, it can enter the oxidative route, where pyruvate is imported into the mitochondrial 
matrix where it can fuel the TCA cycle. Pyruvate may also be converted into alanine or malate 
through alanine aminotransferase or malic enzyme [215]. In healthy cells most of the pyruvate 
converts to Acetyl-CoA to fuel the TCA cycle. In tumor cells however, pyruvate converting to 
lactate is the preferred reaction, due to the upregulation of lactate dehydrogenase in tumor cells 
[216]. This benefits the cancer cells as it facilitates regeneration of NADPH. The serum 
concentration of lactate is directly related to tumor differentiation, treatment resistance and 
metastasis. It can also be a diagnostic indicator of disease progression [8]. Interestingly, some 
tumors are found to contain two subpopulations of cancer cells that differ in their energy 
generating pathways. One subpopulation consists of glucose-dependent (the Warburg effect) 
cells that secrete lactate, whereas cells from the second population preferentially import and 
utilize the lactate produced by their neighbors as the main energy source, employing part of the 
citrate cycle to do so. These two subpopulations function symbiotically [217]. This symbiotic 
relationship is an efficient way for cancer cells to maintain a sufficient metabolism under 
nutrient-poor conditions. Furthermore, converting pyruvate to lactate reduces ROS, thereby 
promoting tumor survival [216].Transportation of lactate occurs primarily through the 
monocarboxylate transporters (MCT) 1-4, which function as an important modulator for this 
metabolic symbiosis [217]. MCTs have also emerged as promising therapeutic targets for 
cancer treatment, since inhibiting MCT1 leads to accumulation of intracellular lactate, which 
disables cell growth and eventually leads to cell death [218]. AZD3965 is a selective MCT1 
inhibitor that has shown to decrease proliferation in human gastric and small cell lung cancer 
tumor xenografts in vivo [219, 220], and is now in a clinical trial for adult solid tumors (clinical 
trial information: NCT01791595). 
Pentose phosphate pathway  
Pentose phosphate pathway (PPP) is a parallel metabolic pathway to glycolysis, and a major 
pathway for glucose catabolism. The PPP consists of two distinct phases: one oxidative branch 
29 
 
and one non-oxidative branch. In the oxidative branch, G6P is converted into ribulose-5-
phosphate which generates NADPH [216],  NADPH is further used for both intracellular ROS 
detoxification and catabolic metabolism. The non-oxidative branch synthesizes pentose, which 
is required for the synthesis of ribonucleotides [221]. Therefore, the PPP is frequently referred 
to as one of the main antioxidant cellular defense systems, and important for the production of 
nucleotides [222]. Furthermore, studies have shown that the PPP has distinct carcinogenic 
impact, and that PPP is important for cancer cell proliferation, apoptosis, invasion, drug 
resistance and metastasis [222]. In addition, Parkhitko et al. have discovered that some cancer 
cells have distinct autophagy-dependent PPP alterations, revealing that PPP may be an 
autophagy dependent compensatory metabolic mechanism [223].  
The history of drugs inhibiting PPP started  as early as 1926, when the anti-malaria drug, 
plasmochin, led to the first drug-induced hemolytic anemia, affecting G6PD, which is one of 
the key enzymes of PPP [224].  G6PD has later shown to have strong anti-tumor effects. The  
inhibition of G6PD decreases proliferation in both in vitro in cell lines and in vivo xenograft 
mice models [225]. Inhibition of 6-phosphogluconate dehydrogenase (6PGH), the third enzyme 
in the PPP, can decrease proliferation and tumor-growth in xenograft mice models [226]. 6-
aminonicotinamide (6AN) is a combined G6PD and 6PGH inhibitor that has shown promising 
anti-cancer results. In a study done on a PML cell line, 6AN suppressed growth, migration and 
invasion of the cancer cells [227].  
AMPK and inhibition of OXPHOS induce a metabolic shift to catabolic state 
Metformin is a well-known drug used to treat diabetes mellitus type II. However, after several 
epidemiological studies linking metformin to a reduced risk of developing various cancer types 
[228-230], metformin’s potential as an anti-cancer drug has received increased attention. The 
two major effects of metformin are (i) activation of AMPK, the key energy sensor in the cells 
that acts as a metabolic switch which alters the cells from an anabolic to a catabolic state in 
response to stress [231, 232], and (ii) decrease of electron transport chain complex I (ETCI) 
activity [233-235]. Targeting ETCI will induce ROS, leading to a metabolic shift to a catabolic 
state. This means that metformin decreases energy-consuming processes such as protein 
synthesis, and increases energy-producing processes like glycolysis for ATP and lactate 
production, PPP for purine biosynthesis, fatty acid metabolism, as well as anaplerosis and 
mitochondrial gene expression [233]. Notably, leukemic cells with high basal AKT 
phosphorylation are more resistant towards metformin-induced apoptosis; the same applies to 
leukemic cells that relay mainly on glycolysis [232]. Consequently, glucose starvation, 
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treatment with glycolytic inhibitors such as 2DG, or AKT inhibitors will increase these cells´ 
sensitivity to metformin [232]. Some studies have shown that LSCs, which generally have low 
ROS, are more dependent on OXPHOS than other leukemic cells, and that these cells cannot 
compensate OXPHOS by increasing glycolysis [232]. This might render LSCs more vulnerable 
towards metformin.  
1.6.3 AML cell metabolism  
Metabolic alterations play a central role in AML cells´ leukemogenesis and disease progression. 
As previously mentioned, there is a large heterogeneity among the different AML cells, this 
also applies to their metabolic preferences. Studies have shown that different leukemic cells 
seem to differ in their dependency on glycolysis or oxidative phosphorylation. A study of AML 
cells derived from a small amount of patients (n=23) reported that highly glycolytic primary 
AML cells were more resistant to apoptosis induced by antileukemic therapy in vitro, indicating 
resistance to induction chemotherapy similar to that observed in solid tumors [183]. However, 
the same study also found that a higher level of glycolytic metabolism in leukemic cells at the 
time of diagnosis was associated with a significantly improved duration of CR and OS after 
induction chemotherapy. These results, though seemingly contradictory, suggest that glycolytic 
metabolism plays a significant role in leukemic survival and chemoresistance. Metabolic 
alterations linked to AML cells´ disease progression have been found in several of the major 
metabolic pathways, but there is a clear need for more knowledge regarding AML cells´ 
metabolic reprogramming. Optimally, characterization of metabolic pathways in leukemia cells 
may identify proteins/pathways correlated with drug responsiveness or disease aggressiveness 
as shown by Jain et al. for the role of glycine in breast cancer using metabolic profiling [236]. 
However, due to the heterogeneity of the disease, identifying common therapeutic targets has 
been challenging. The pharmaceutical development and testing of metabolic inhibitors are at 
an early stage, and even though a lot of research has been done on AML cells both in vitro and 
in vivo, there are to our knowledge just a few clinical trials with metabolic targeting drugs on 
AML patients (Table 8).  
1.6.4 The systemic metabolic profiles in patients with AML 
Metabolomic profiling of patients with AML has revealed a panel of altered metabolites with 
potential risk stratification [237]. A large metabolomic study compared the pretreatment serum 
samples of 400 AML patients to 446 health controls. This showed alterations in 45 metabolic 
pathways, demonstrating increase in the pyruvate production and downregulation of free fatty 
acids, indicating increased FAO. In addition, the study revealed a distinct glucose metabolism 
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in the AML patients, with significant alterations in six out of 10 identified serum metabolites 
in this pathway having prognostic value. The result also showed that enhanced glycolysis 
contributed to increased resistance to chemotherapy, and inhibition of glycolysis decreased 
proliferation, and increased sensitivity towards chemotherapeutic cytotoxicity [237]. Metabolic 
profiling has also shown prognostic value for predicting the outcome of GVHD after allo-
HSCT. In a large retrospective study, serum asymmetric dimethylarginine (ADMA) levels of 
938 patients with GVHD after receiving allo-HSCT were investigated. This showed that high 
levels of pre-transplant serum ADMA were associated with a higher risk of non-relapse 
mortality. ADMA is an endogenous metabolite that inhibits nitric oxide synthase, and is closely 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.7.1 Definition and regulation 
The word autophagy is derived from the Greek words auto, meaning "self" and phagein, "to 
eat", and can be seen as the body's own “cleansing process”. This catabolic process starts with 
the formation of a phagophore from a membrane, which engulfs intracellular waste and 
subsequently forms double membraned vesicles (Figure 4). These vesicles, called 
autophagosomes, are transported to lysosomes where their contents are digested by lysosomal 
acid proteases and “recycled”. Products from this degradation process, such as amino acids, can 
then be re-used in metabolic pathways or for building macromolecules. This way autophagy 
provides an endogenous source of nutrients, which may be exploited as a survival strategy 
during stressful conditions [223, 247].  
 
In mammalian cells autophagy is controlled by several protein complexes composed of 
autophagy-related genes (ATG). To date, about 40 ATG proteins have been identified [248], 
and these can be classified into three main functional groups according to the  stage of 
autophagy they control (Table 4) [249]: (i) initiation-step proteins, (ii) phagophore nucleation  
proteins and (iii) proteins involved in autophagosome completion. The main regulator of 
induction of autophagy is the mammalian target of rapamycin  complex (mTORC) 1[250]. 
Under conditions with sufficient nutrients, mTORC1 inhibits autophagy, whereas nutrient 
deprivations lead to inhibition of mTORC1, activating autophagy [251]. Through mTORC1 
inhibition, different extracellular stress factors activate proteins such as unc-51 like autophagy 
activating kinase 1(ULK1)/ATG1, PI3K, mATG13, FIP200 and ATG101 [249, 250]. The key 
players involved in phagophore nucleation are BECLIN-1/ATG6, ATG14, VPS34, VPS15, 
UVRAG and BIF-1. Finally, the vesicle completion consists of two conjugation systems: the 
ATG12-ATG5-ATG16 system and the ATG8 family. These two systems are essential for the 
elongation and the closure of the autophagosomes [249]  (Figure 4). Autophagy can be 
presented as both a non-selective and a selective process [250]. An example of selective 
autophagy is mitophagy, which is selective degradation of damaged mitochondria [252]. To be 
able to distinguish cargoes ready for degradation from their functional counterparts, selective 
autophagy depends on autophagy receptors and adaptor proteins like p62, neighbor of BRCA1 
gene 1 protein (NBR1) and autophagy-linked FYVE protein (ALFY) [253, 254]. The autophagy 
receptors that recognize the cargo have specific ligand-binding domains (e.g. an ubiquitin-
binding domain) that interact with the ATG8/LC3 family proteins (Figure 4). Non-selective 
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autophagy seems to share the same core machinery as selective autophagy; however, the 
autophagy receptors and adaptors do not seem to be required for non-selective autophagy [253]. 
 
Figure 4. The main machinery and regulation of the autophagic network.  Autophagy is controlled by several 
protein complexes composed of autophagy-related (ATG) genes. The machinery can be divided into three main 
steps, (i) autophagy induction mTORC1 ULK1/ATG1, PI3K, mATG13, FIP200 and ATG101, (ii) phagophore 
nucleation; BECLIN-1/ATG6, ATG14, VPS34, VPS15, UVRAG and BIF-1, and (iii) vesicle completion; the two 
conjugation systems ATG12-ATG5 and the ATG8 family. Selective autophagy depends on autophagy receptors 
and adaptor proteins such as p62, NBR1 and ALFY. The autophagy receptors that recognize the cargo have specific 
ligand-binding domains (e.g. an ubiquitin-binding domain). They also interact with the ATG8/LC3 family 
proteins, like p62, which can attach to either ubiquitin or kelch-like ECH-associated protein 1 (KEAP1) on the 
autophagosomes, leading to their selective degradation. Abbreviations are listed in the list of abbreviations in the 
front of the thesis. 
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1.7.2 The role of autophagy in cancer cells  
In healthy tissue, the autophagic process can be tumor suppressive by eliminating damaged 
organelles, proteins or oncogenic substrates [255]. Autophagy may also play a role in cancer 
development, as cancer cells may use autophagy to maintain their metabolism and unlimited 
proliferation under stressful and hypoxic conditions, by digesting their own cell-organelles to 
provide energy (ATP). Indeed, autophagy is often reported to be upregulated in cancer cells, 
promoting cancer cell survival and drug resistance [255]. The effect of autophagy on cancer 
development and growth seems to correlate with the autophagic level, which in turn is affected 
by intracellular and extracellular stressors, such as ROS accumulation [250]. Autophagy in 
healthy cells is an important tumor suppressive mechanism, which contributes to the 
degradation of damaged organelles and proteins that may have oncogenic potential. This 
property has also been exploited in AML treatment. Interestingly, in a study on APL, autophagy 
facilitated therapy-induced degradation of the PML-RARα oncogene, thereby facilitating 
leukemia treatment [256]. Watson et al. also found that loss of autophagy in an MLL-ENL 
model of AML led to increased proliferation in vitro, a glycolytic shift and more aggressive 
leukemias in vivo [257]. On the other hand, AML cells can use autophagy as a prosurvival 
response to treatment, providing substrates for metabolism under stressful conditions, making 
them more treatment resistant [255]. Autophagy is upregulated in human AML cell lines 
exposed to hypoxia, enabling them to overcome an initial growth restriction [245]. 
Pharmacological inhibition of hypoxic AML cells has also been shown to increase cell death, 
and to enhance sensitivity to chemotherapy [245]. Folkerts et al. showed that AML CD34+ 
cells were more sensitive to the autophagic inhibitor hydrochloroquine (HCQ) than normal 
bone marrow CD34+ cells. The fraction of AML CD34+ cells with low ROS levels had higher 
basal autophagy, with reduced survival after HCQ treatment compared to the CD34+ fraction 
with high ROS, indicating that autophagy inhibition affects the immature sub-fraction of AML 
[246]. Recent studies examined the autophagic interactions between the cancer cells and the 
surrounding stromal cancer cells [258, 259], postulating that cancer cells induce oxidative 
stress, increasing ROS production which activates transcriptional factors such as HIF-1α and 
NF-κB. This induces autophagy and mitophagy in the microenvironment surrounding the 
cancer cells, making the surrounding stromal cells secrete high energy nutrients such as ketones 
and lactate that the cancer cells can then feed on. This enables them to maintain proliferation 
under nutrient scarce conditions [258]. This hypothesis, also called the reverse Warburg effect, 
states that cancer cells are fed by nutrients from increased autophagy of adjacent stromal cells, 
while mainly relying on OXPHOS, not glycolysis, for energy production [259].  
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2 Main hypothesis and aim 
AML is a heterogeneous disease, as regards to morphology, growth characteristics, cytogenetics 
and epigenetics. In addition, recent data suggests that leukemia cells have abnormal cellular 
metabolism and that the cells may employ different metabolic routes to control their growth 
and survival. 
Our main hypothesis is that systemic regulation of metabolism and cellular metabolism play 
important roles in the development of AML. We propose that AML cells derived from certain 
AML patient subsets have common metabolic characteristics. These AML subsets may either 
(i) have a more extensive adaptive capacity (in which case this metabolic adaptation may render 
cells more resistant to drug induced cytotoxicity), or (ii) be more sensitive toward metabolic-
targeting drugs. Thus, it may be possible to stratify patients according to metabolic 
phenotypes/capacities, which may then serve as a common therapeutic or prognostic target.   
Based on our hypothesis, the primary objective of this Ph.D. project is to investigate systemic 
metabolic profiles of AML patients, and characterize the metabolic phenotype of AML cell 
populations, in particular how they respond to inhibitors of metabolic pathways. We aim to 
study the heterogeneity of AML cell metabolism to reveal potential new therapeutic targets, 





3 Summary of papers  
Paper I: Targeting cellular metabolism in acute myeloid leukemia and the role of patient 
heterogeneity 
Authors: Ida Sofie Grønningsæter, Håkon Reikvam, Elise Aasebø, Sushma Bartaula-Brevik, 
Tor Henrik Tvedt, Øystein Bruserud and Kimberley Joanne Hatfield. 
We examined the antileukemic effect of metabolic drugs targeting (i) glycolysis (lonidamine 
and 2DG), (ii) pentose phosphate pathway (6AN), (iii) the glutaminolysis pathway (BPTES), 
(iv) the AMPK pathway (metformin), (v) fatty acid oxidation (ST1326) and (vi) the pyruvate 
pathway (AZD3965). Primary AML cells taken from 81 unselected patients were treated with 
drugs either alone or in combination with standard chemotherapy (AraC). Cell proliferation was 
determined using the [3H]-thymidine incorporation assay, and viability/apoptosis/necrosis 
frequencies were analyzed by flow cytometry. Metformin, 2DG, 6AN, BPTES and ST1326 
result in significant antiproliferative and/or pro-apoptotic effects on patients` leukemia cells, 
while lonidamine and AZD1326 generally did not show the same cytotoxicity. As expected due 
to the heterogeneity of AML patients, we observed a wide variation among patient samples 
regarding sensitivity to the different metabolic inhibitors, although no correlations were found 
between sensitivity and characteristics of AML patients, i.e. FAB classification, cytogenetics 
or gene mutations of FLT3 and NPM1 were found. Additive inhibitory effects on AML cell 
growth were seen when the inhibitors metformin, 2DG, 6AN and ST1326 were used in 
combination with AraC. Moreover, we identified a subset of 29 patients with generally strong 
antiproliferative effects after drug treatment. Gene expression and proteomic studies revealed 
different metabolic and transcriptional regulations in this subset. Furthermore, antiproliferative 
effects of 2DG on AML cells were still observed after coculture of AML cells with growth-
inducing mesenchymal stem cells (MSCs). Our findings suggest that inhibitors of metabolic 
pathways represent a novel targeted approach for treatment of AML that should be investigated 
further. 
Paper II: Effects of the autophagy-inhibiting agent chloroquine in acute myeloid leukemia  
Authors: Ida Sofie Grønningsæter, Håkon Reikvam, Karen Marie Hagen, Sushma Bartaula-
Brevik, Tor Henrik Tvedt, Øystein Bruserud and Kimberley Hatfield  
We evaluated the effects of CQ, an inhibitor of autophagy, on cell viability and proliferation in 
81 AML patient samples. Cell viability after 48-hour drug treatment was measured using flow 
cytometry, and cell proliferation was analyzed after 7-day drug treatment using the [3H]-
thymidine incorporation assay. A subgroup of AML patients was more sensitive to treatment 
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with CQ, showing a greater antiproliferative effect and decreased viability after drug treatment. 
We also identified a small subset of patients that were sensitive to CQ, but on which AraC had 
little or no antiproliferative effect. We then compared gene expression profiles based on the 
strong/low antiproliferative effects of CQ, and identified 99 genes upregulated in the patient 
subset with high susceptibility to CQ. Among these genes were several linked to AML 
leukemogenesis. In addition, we examined at the constitutive mediator release after CQ 
treatment. A subset of 18 patients showed generally increased mediator levels after CQ 
treatment, and this subset showed increased upregulation of genes, of which several are 
associated with metabolic processes.  
Furthermore, we investigated the expression of ROS, autophagic flux, cells cycle phases, and 
viability, apoptosis and necrosis in HL60 and MOLM-13 cell lines treated with CQ alone or in 
combination with the metabolic drugs metformin and 2DG. We found that CQ leads to 
accumulation of lysosomes, thus inhibiting autophagy in both cell lines, though different 
responses were seen for the different cell lines. Both metformin and 2DG seemed to decrease 
autophagy when used in combination with CQ.  CQ also decreased viability and increased 
apoptosis in both cell lines, though no effects were seen on ROS levels or cell cycle distribution 
after CQ treatment. To conclude, CQ has antileukemic effects on AML and should be explored 
further for its antileukemic activity, alone or in combination with other drugs. 
Paper III: Systemic metabolomic profiling of acute myeloid leukemia patients before and 
during disease-stabilizing treatment based on all-trans retinoic acid, valproic acid, and 
low-dose chemotherapy 
Authors: Ida Sofie Grønningsæter, Hanne Kristin Fredly, Bjørn Tore Gjertsen, Kimberley 
Joanne Hatfield and Øystein Bruserud  
This study is based on results from two previously published clinical studies conducted at 
Haukeland University Hospital [144, 260]. Older and unfit AML patients were included to 
investigate the combination of the drugs ATRA, valproic acid and low-dose therapy with 
hydroxyurea, 5-mercaptopurine, and/or AraC, as disease-stabilizing treatment. Before and 
during treatment, serum samples were collected from all patients included in the clinical studies. 
In the current study, we compared the metabolic profiles of 44 patients stratified as either 
responders (n=18) or non-responders (n=26, six of them showing rapidly progressive disease) 
to treatment. Furthermore, we investigated the metabolomic changes during ATRA and 
valproic acid monotherapy, which were compared to the corresponding untreated controls 
(n=20). Metabolomic analysis was performed by Metabolon®, and the global metabolite 
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profiling measured a total of 886 biochemicals. Analysis revealed that ATRA and valproic acid 
induced changes in fatty acid and lipid metabolism. In addition, the lipid metabolism of patients 
with rapidly progressive disease was extensively altered. As monotherapy, only valproic acid 
caused significant alterations; twenty-three metabolites were significantly altered by seven-day 
valproic acid treatment (p < 0.05, q < 0.05). The majority of altered metabolites belonged to 
lipid (especially fatty acid) and amino acid pathways, including several carnitines. These 
metabolomic effects, and especially the effects on lipid metabolism, may be important for the 
antileukemic and epigenetic effects of this treatment. 
Paper IV: Patients with treatment-requiring chronic graft versus host disease after 
allogeneic stem cell transplantation have altered metabolic profiles due to the disease and 
immunosuppressive therapy: potential implication for biomarkers 
Authors: Håkon Reikvam, Ida Sofie Grønningsæter, Knut Anders Mosevoll, Roald Lindås, 
Kimberley Joanne Hatfield and Øystein Bruserud.  
cGVHD is the most common and severe long-term complication of allo-HSCT. New 
biomarkers are needed both for the diagnosis and for the evaluation of treatment in allo-HSCT 
patients with cGVHD. We analyzed the serum metabolomic profiles of patients with and 
without cGVHD one year after transplantation, revealing potential associations between the 
serum metabolomic profiles and the development of cGVHD. Furthermore, we explored the 
effects of immunosuppressive therapies on the metabolomic serum profiles of 51 hematology 
patients who underwent allo-HSCT from 2006-2014 at Haukeland University Hospital. Of 
these patients, 31 had signs of cGVHD, while 20 had no sign of cGVHD one-year post-
transplant, and all but two patients with cGVHD received immunosuppressive treatment (i.e. 
cyclosporine, steroids). Metabolomics analysis was performed by Metabolon®, and a total of 
755 metabolites were identified in all samples. A random forest analysis of serum profiles 
revealed 30 top-ranked metabolites to be highly discriminative for cGVHD, whereof 18 were 
related to fatty acid metabolism, most of them belonging to the annotation’s sphingolipids, 
plasminogens, lysolipids and phospholipids. We also compared the systemic metabolomic 
profiles of patients receiving or not receiving immunosuppressive treatment and found 
differences in amino acid and lipid metabolites between these groups. The overall effect on 
metabolomic alterations is most likely due to both the cGVHD, and immunosuppressive 
treatment. However, we did identify a subset of 11 metabolites that seem to mainly reflect the 




4 Material and methodological considerations  
4.1 Patient selection  
All the studies in this thesis are based on samples from patients treated for hematological 
diseases at Haukeland University Hospital during a 20–year period. This is the primary/referral 
hospital for patients in the largest part of the western region of Norway, which has a population 
of approximately 580 000 inhabitants, accounting for around 11% of the country´s population 
[261]. In Papers I, II and III we analyzed samples from patients with AML. The AML cancer 
incidence and rate in western Norway is similar to that of the rest of the country. Thus our 
material is considered to reflect a population based on an unselected patient group of Norwegian 
AML cancer. Furthermore, previous studies have shown that our patient cohorts are 
representative of AML in general with regard to cytogenetic analysis and the most important 
genetic abnormalities related to prognostics and chemosensitivity, i.e. FLT3 mutations [262]. 
In Papers I and II, we investigated primary AML cells taken from 81 unselected patients. AML 
blasts were taken from peripheral blood, and all patients had high, relative or absolute levels of 
circulating AML cells in peripheral blood. We obtained highly enriched AML cells by 
performing gradient separation alone, thereby avoiding the induction of functional alterations 
in the leukemic cells – a potential problem during cell isolation that has been discussed in detail 
previously [263, 264]. Peripheral blood cells have also proved to be representative of the 
corresponding bone marrow cells, and although quantitative differences may be seen, the major 
characteristics of the leukemic cells are maintained [181, 265]. In Paper III,  we analyzed 
serum samples from AML patients, which were collected during the course of two clinical 
studies conducted at Haukeland University Hospital between 2004 and 2007 [266], and 2008 
and 2012 [144]. Both clinical studies were based on a combined treatment of ATRA and 
valproic acid in addition to low-toxicity conventional therapy with hydroxyurea, 5-
mercaptopurin or low-dose AraC. This is considered a low-toxicity or disease stabilizing 
treatment and was offered to patients that were found unfit for intensive treatment during these 
time periods. Our present study included an unselected subset of samples which were taken 
from 44 patients included in these two studies. 18 patients were classified as responders and 26 
did not respond to this treatment. As there is no general agreement with regard to the response 
criteria for low-toxicity or disease stabilizing treatment [144], our patients were evaluated on 
the basis of both the conventional criteria for patients receiving intensive AML chemotherapy 
[267] and the MDS criteria [268]. In Paper IV we analyzed serum samples from 51 patients 
with hematological diseases who were allotransplanted between 2006-2014 at Haukeland 
University Hospital, all with HLA-matched family donors. Ninety-five patients were 
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transplanted at our institution during this period; 25 of them died from treatment-related causes, 
6 patients relapsed, and 13 were lost to follow-up. The decision to perform an allo-HSCT was 
taken by the Norwegian Advisory Board for Stem Cell Transplantation and based on national 
guidelines.  
Taken together, all our studies are considered as population-based and include an unselected 
and consecutive group of well-characterized patients that reflect the general AML and allo-
HSCT patient population. Written informed consent was obtained from all patients included in 
this thesis.  
4.2 AML patient cell preparation and cryopreservation 
The methods for inclusion of patients [262], preparation, cryopreservation and thawing are 
highly standardized [269, 270], and the same methods are used for all samples in our biobank. 
Density gradient centrifugation was used to isolate AML cells, resulting in a highly enriched 
AML cell population >90%. This method offers a minimal risk of inducing functional 
alterations, and just a small degree of contamination that mainly consists of small lymphocytes 
that release cytokines only after activation [271]. In our experience, normal peripheral blood 
mononuclear cells, cultured in medium alone without specific activation, do not show 
detectable proliferation or detectable cytokine release. Thus, though we cannot rule it out, they 
are unlikely to have any major impact on our results.   
The use of cryopreserved patient derived cells instead of freshly prepared cells gives the 
opportunity to analyze and compare a larger subset of patients simultaneously. This does not 
only make it possible to analyze different patient characteristics in parallel, it also reduces the 
risk of variation between analyses, which is unavoidable when multiple analyses are done over 
time. In addition, using cryopreserved samples makes it possible to reproduce the results. The 
disadvantage of using DMSO in cryopreservation includes a decline of viability of the AML 
cell population through the freezing and thawing processes.  DMSO can have other effects on 
cells, e.g. affecting cell differentiation and chromosome stability [272]. Still, cryopreserved 
cells are the preferred cells for analysis as long as there are no known effects on attributes to be 
studied. 
4.3 The relevance of investigating the overall AML cell population 
Chemoresistant relapse is still a main cause of death in AML [4], and relapse is thought to be 
derived from remaining LSCs [67]. However, the results from several previous studies suggest 
that biological characteristics of the total AML cell population are important markers for in vivo 
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chemosensitivity and thereby probably reflect important common biological characteristics for 
the majority of the hierarchically organized AML cell population. Firstly, the response to the 
first chemotherapy cycle with induction of complete hematological remission after only one 
chemotherapy cycle is an important prognostic parameter. CR can be regarded as a 
characteristic of the total AML cell population [4], because the clinical experience has shown 
that additional cycles are needed to eradicate remaining AML (stem) cells [4, 273, 274]. 
Secondly, several biological characteristics of the overall AML cell population are associated 
with prognosis, including global as well as selected gene expression profiles [55, 275], 
epigenetic regulation [276], single molecular markers detected at the mRNA or protein level 
[277, 278] and functional characteristics (e.g. constitutive mediator release) [116, 279]. Finally, 
the use of bone marrow examination 17 days after induction treatment (i.e. morphological 
evaluation of blast percentage) to guide the later chemotherapy should also be regarded as 
evaluation of the overall AML population [4]. The same may be true for the evaluation of MRD 
based on the membrane molecule profile detected at the time of diagnosis [280]. Thus, studies 
of the total AML cell population seem to reflect biological characteristics that are relevant for 
in vivo chemosensitivity.  
4.4 Cell lines  
Two human leukemia cell lines were used in this thesis, HL60 and MOLM-13. These cell lines 
were chosen for their different genotypic properties representing two different AML 
populations. HL60 is p53-null, representing FAB M2 [281], and MOLM-13 is a M5 cell line 
expressing FLT3-internal tandem duplication (ITD) [282]. They are both well-established cell 
lines and widely used for experiments within the field of AML. The cell line models were used 
in Paper II, and cell lines were chosen to avoid the influence of spontaneous stress induced 
apoptosis that occurs during in vitro culture of primary human AML cells [283].  However, it 
is important to remember that immortalized cell lines are not “normal” anymore; many cell 
lines have been passaged for decades which makes the cells prone to genotypic and phenotypic 
changes,  thus altering cell characteristics; in addition fast growing subclones with biological 
advantages may arise and can effect results during experimental studies [284]. 
To ensure the authentication of our cell lines, an authentication test using short tandem repeat 
(STR) profiling was performed on the two cell lines used in this thesis. Both were an exact 
match for HL60 and MOLM13 profiles. Furthermore, cell lines were kept in culture for only 3-
4 weeks before a new batch of cells (same passage) were thawed and used in studies, thus 
reducing the chance of introducing changes and/or contamination cells. To sum up, cell lines 
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are helpful to use for standardization and confirmation of experiments where a large number of 
cells are needed. Cell lines have less variability than primary cells and are easier to culture, and 
more viable. Ideally several cell lines of the disease should be examined in experimental studies, 
and patient cells should be used for further validation of results to confirm biological relevance 
and reveal potential variability between patient subsets. 
4.5 Drug selection 
The doses used in this thesis were chosen based on reported in vitro studies, as well as on in 
vivo serum levels and tolerable concentrations for drugs that have been tested in the clinic 
(Table 7). AraC (1-b-arabinofuranosylcytosine), CQ, metformin, 2DG, and lonidamine have all 
been used in vivo, and their clinical tolerance has been well documented (Table 8). 6AN, 
BPTES, ST1326 and AZD3965 have not yet been established in the clinic and our doses were 
chosen based on in vitro and in vivo preclinical studies (Table 7). There is, however, one study 
from 1961 investigating the clinical toxicity and tumor-inhibitory effects of 6AN on 30 patients 
with advanced solid tumors [285]. For AZD3965 there is an ongoing trial where AZD3965 is 
given to patients with B cell lymphoma and Burkitt’s lymphoma (NCT01791595); this is to our 
knowledge the first time this type of drug is given to patients [286]. BPTES has been shown to 
have poor aqueous solubility and an unfavorable pharmacokinetic profile that has limited its 
clinical development. As far as we know there are no clinical trials with BPTES, but preclinical 
studies are investigating BPTES delivered in nanoparticles to improve drug solubility and 
efficacy [287]. A clinical trial with another glutaminase inhibitor (CB-839) for treatment of 
advanced or metastatic renal cell carcinoma (NCT03428217) is currently taken place.  
Inhibitors of CPT-1, are not new to the field either: etomoxir, an irreversible inhibitor of CPT-
1 has already been through phase II clinical development for treatment of type II diabetes and 
heart failure, but due to adverse side effects, the phase II trial with etomoxir was ended [212]. 
Based on our information, the clinical development of etomoxir as an anti-carcinogenic agent  
has also been terminated due to the severe hepatotoxicity associated with the  treatment [288]. 
For this reason, we chose to study the less characterized CPT-1 inhibitor ST1326. An in vitro 
study of CLL cells showed no cytotoxic effect of ST1326 on normal CD34+ cells, thus ST1326 
might be a good alternative to etoxomir for further treatment based on CPT-1 inhibition [289].  
However, in this study we found the solubility of the drug to be challenging, which explains 
why we did not pursue the use of this drug in all our experimental assays. A summary of the 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.6 Measurement of cell proliferation and viability/apoptosis 
In Papers  I and II we evaluated the AML cell proliferation after seven days of in vitro culture 
using a [3H]-thymidine assay as described in detail [311]. The cells were cultured in the 
presence of metabolic drugs or in medium alone (or added vehicle control) for six days before 
[3H]-thymidine isotope was added, and the following day [3H]-thymidine incorporation was 
estimated. During the first six days an increased spontaneous or stress induced apoptosis can 
be observed [283]. Thus, this proliferation assay reflects the characteristics of a minor subset 
of cells that are able to survive and still proliferate after seven days of in vitro culture. This 
subpopulation seems to reflect the enrichment of more primitive colony-forming progenitor-
like cells [312], allowing for the analysis of less-differentiated AML cells. It is suggested that 
progenitor cells are one of the major causes of disease relapse, which is the main cause of death 
in AML. [3H]-thymidine assays therefore provide a beneficial way of evaluating the effect of 
metabolic drugs on the progenitor population.  
In the same articles, we determined by flow cytometry the amount of cell viability, apoptosis 
and late apoptosis/necrosis in cells exposed to drug treatment [283]. Previous studies indicate 
that in vitro cultured AML cells undergo spontaneous in vitro apoptosis, and the percentage of 
viable cells decreases during the first days of the culture until it reaches a low level [283]. We 
estimated the cell viability after 48 hours (24 and 48 hours for cell lines in Paper II). This assay 
may thus reflect the characteristics of the major subsets of mature cells in the hierarchically 
organized AML cell population. There is an array of preventive measures to avoid spontaneous 
apoptosis in cells. In our proliferation assay and our viability/apoptosis assay we cultured cells 
in medium enriched with growth factors. However, there will always be some level of 
spontaneous apoptosis when cells are removed from their microenvironment and subjected to 
in vitro treatment.  
4.7 Measurement of cytokine release  
There are various methods for analyzing mediators such as cytokines. In this thesis we have 
used Luminex® assays, purchased from R&D Systems™ (Minnesota, MN, US), which involve 
fluorescent bead-based multiplex technology. This capture/detection sandwich type 
immunoassay allows the measurement of up to 100 different analyses in a single 50 µL sample 
[313]. Because multiplex  assays only require a small sample volume and are time-saving, they 
have become an attractive method to investigate immune responses [313]. However, analytical 
differences have been reported between different manufacturers, product lots and storage time 
[314], but kits purchased from R&D Systems™ have been described as some of the most 
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accurate kits for the measurement of cytokine concentrations in supernatants, with good 
recovery ranges and reproducibility for most cytokines [313]. As with most lab techniques, 
Luminex® is highly operator-dependent, and this will always be a possible source of error. Intra-
plate variability may occur, which can be reduced by running more than one assay plate, and a 
standardized inter-assay control is preferable. All samples analysed with Luminex® assays in 
this thesis were cell culture supernatant samples. This is considered to be more robust than 
serum or plasma samples since it contains lower levels of interfering substances (i.e. proteins, 
metabolites, hetrophilic antibodies) [315]. All samples had similar storage time and the 
Luminex® kits had the same lot number. In Luminex® assays, the same dilution of a sample is 
used when analyzing all mediators in a sample. For some cytokines, there can be a considerable 
number of cytokines whose levels are below or above the detection range. Optimally, samples 
below or exceeding the lowest or highest point of the standard range should be re-analyzed at 
a different dilution, but due to the cost of Luminex® assays, this was not done. In order to 
perform statistical analysis, values below (or above) detection range were set lower than the 
detection limit (or higher in a few cases). This should not affect the results, as rank sum testing 
was used to evaluate cytokine data. It could however impact the logistic regression and 
hierarchical clustering, and has to be taken into consideration when using these types of 
analyses. Furthermore, the mediator concentrations measured in supernatants can be affected 
by AML cell autocrine and paracrine loops, as well as the degradation by proteases, but the 
levels in supernatants are still relevant as they reflects the levels that are available for 
communication between cells in the cell culture.  
 
4.8 Liquid Chromatography-Tandem Mass Spectrometry methods  
In this thesis, mass spectrometry methods have been used to perform metabolomics in Papers 
III and IV and proteomics in Paper I. The mass spectrometer measures the intensity of ionized 
biochemicals (in this thesis metabolites or peptides,) differing in their mass to charge ratio (m/z). 
The relative abundance of the individual m/z detected in the mass spectrometer generates a mass 
spectrum. To separate the biochemicals, a high-performance liquid chromatograph (HPLC) is 
directly coupled to the mass spectrometer. The untargeted metabolomic profile analyses in this 
thesis were performed in collaboration with Metabolon, Inc. (Durham, NC, US), and the 
preparation and analysis of serum samples are described in more detail in Paper III. 
Metabolon® uses ultra-high-performance liquid chromatography/tandem accurate mass 
spectrometry (UHPLC/MS/MS) to analyze samples. All systems are operated in a rigorously 
controlled environment to remove as much noise from the process as possible. Compounds 
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were identified by comparison to Metabolon®´s library entries of purified standards or recurrent 
unknown entities. Metabolon, Inc. maintains a library based on authenticated standards that 
contains retention time/index (RI), mass to m/z and chromatographic data (including MS/MS 
spectral data on all molecules present in the library).  
As for mediators, human plasma and serum are widely used matrices for investigating 
metabolites. Here too, different collecting procedures will influence the concentration since 
both the collecting procedures and the coagulation cascade influence concentration of proteins 
and metabolites in these matrices [316]. Serum has been obtained from coagulated blood. Blood 
cells, fibrin and coagulation factors are then separated from serum by centrifugation. During 
the centrifugation process, platelets may release metabolites, and there is therefore a higher 
metabolite concentration in serum than in plasma where heparin or EDTA is added before the 
removal of blood cells [316].  Several studies have examined differences between plasma and 
serum for metabolomics [317-319]. They report good reproducibility rates for both plasma and 
serum, while revealing a clear difference between the metabolic profiles in the two matrices 
[316, 319]. As expected, the metabolite concentration is generally higher in serum samples, 
suggesting that serum samples are more sensitive for detection of biomarkers [316]. In addition, 
plasma was shown to be more affected by incubation time than serum [319]. Serum samples 
have therefore been recommended as the sample of choice in metabolomic studies [319].  
4.9 Statistical methods and terminology 
For our studies, two types of statistical analysis have been used; significance tests, and 
classification analyses. In Papers I and II, all significance tests were done using SPSS® (IBM 
Statistical Package for the Social Sciences v. 23.0; IBM SPSS statistics Inc., Chicago, IL, USA) 
and GraphPad® (Graph Pad Software, San Diego, CA, USA) software. The data obtained from 
experimental studies of AML patient cells could not be considered as having a normal 
distribution, and therefore non-parametric tests (Mann-Whitney U, Wilcoxon signed rank test 
and Kruskal-Wallis H-test with Dunn´s Post Hoc test) were used for statistical comparisons. In 
Papers III and IV, standard significance tests were performed in ArrayStudio 
(https://arraystudios.com/), R (http://cran.r-project.org/) and the data analysis software program 
JMP® (JMP®, Statistical DiscoveryTM from ©SAS Institute Inc. Lane Cove, NSW 2066, 
Australia) by Metabolon, Inc. (Durham, NC, USA) on log transformed data. Welch´s two 
sample t-test was used to identify metabolites that differed significantly between groups. The 
paired t-test was used for comparison of paired samples, and ANOVA contrasts were used to 
analyze pharmacological effects for responders and non-responders separately. Since statistics 
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provides the basis for our research, as for most medical research, it is imperative that the right 
test is used. We have based our choice of methods on the type of research question being asked 
and the type of data to be analyzed (e.g. is the data normally distributed, do multiple 
comparisons have to be taken into account, are the groups being tested paired or unpaired, etc.).  
In this thesis, the statistical significance of data was set to p-values < 0.05. The lower the p-
value, the more evidence we have that the null hypothesis (that two populations are equal) is 
not true. A statistical significance set to 0.05, means that 5 % of the time we incorrectly 
conclude that the populations were different, when they were in fact the same. The p-value of 
0.05 is the false positive rate when there is only one test. However, for a large number of tests, 
as in Papers III and IV, we need to account for false positives. There are different methods to 
correct for multiple testing. The oldest methods are family-wise error rate adjustments 
(Bonferroni, Tukey etc.), but these tend to be extremely conservative for a very large number 
of tests. For large scale analysis involving microarrays, proteomics and metabolomics, using 
the q-value to calculate the False Discovery Rate (FDR), is therefore more common, in contrast 
to the family-wise error rate adjustments which allow for zero false discoveries. FDR allows 
for a small number of false discoveries; this needs to be taken into account when evaluating the 
results. Optionally, one can use z-statistics which focus on fold change. This makes it possible 
to correct false positives while capturing the biochemicals with the fold change that could be 
most biologically interesting. The American Statistical Association (ASA) stated that  “No 
single index should substitute for scientific reasoning”; thus in addition to statistical analysis, 
other validation methods should preferably be performed and findings should be reviewed 
critically [320]. 
Classification analyses that have been used in this thesis are first and foremost hierarchical 
clustering analyses (Papers I, II and IV). Hierarchical clustering is an unsupervised method 
for clustering data and can show large scale differences. With these analyses we aim to build a 
hierarchy of clusters where objects (in this case AML patients) that have similar features cluster 
together, and more dissimilar objects are dispersed further apart. This makes it possible to 
identify subgroups within the patient cohort. However, hierarchical clustering analysis should 
be interpreted with care. Hierarchical clustering mainly shows large scale differences and 
should not be used for specific analysis at patient level. There are many types of hierarchical 
clustering and many distance metrics that can be used. In our papers, we have used the program 
J-express 2012 software for all our clustering analysis (MolMine AS, Bergen, Norway).  
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In Papers III and IV, random forest analysis was used to provide an unbiased method to predict 
which variables (in this case metabolites) make the largest contribution to the classification. To 
determine the “variable importance”, a random forest analysis uses a supervised classification 
technique based on an ensemble of decision trees [321]. To do this, Mean Decrease Accuracy 
(MDA) was used as the metric. MDA is determined by randomly permuting a variable, running 
the observed values through the trees, and then reassessing the prediction accuracy. This allows 
a random forest analysis to provide an “impotency” rank ordering of the variables. When the 
full forest is grown, the class predictions are compared to the true classes, generating the “out-
of-bag error rate” as a measure of prediction accuracy. Thus, the prediction accuracy is an 
unbiased estimation of how well one can predict sample class in a new data set. A random forest 
analysis has several advantages: it makes no parametric assumption, variable selection is not 
needed, it does not overfit, it is invariant to transformation and it is fairly easy to interpret.  
Metabolite pathway enrichment analysis was used for biological interpretation of metabolite 
data at a system level using the MetaboLync analysis tool (MetaboLync® Portal, supplied by 
Metabolon, Inc.). This analysis is based on the same concept as gene set enrichment analysis 
(GSEA) [322]. A metabolite pathway enrichment analysis tests whether the metabolites 
involved in a predefined pathway occur towards the top or the bottom of a ranked query 
compound list. Instead of focusing on single metabolites in a sample group, it helps to discover 
metabolic pathways or networks that are altered in the experiment, and it is designed to handle 
many-to-many relationships that may occur between the compounds and the metabolite 
annotations [323]. The advantage with this type of analysis is that it helps overcome analytical 
challenges that are typical for single–metabolite analysis with large scale data, such as a low 
number of significant alterations after correcting for multiple hypothesis testing, because the 
relevant biological differences are modest relative to the noise inherent to the technology. 
Interpretation is dependent on the researcher’s area of expertise which may miss important 
effects on pathways, especially since a small increase in a set of metabolites within the same 
metabolic pathway may have a much higher biological effect than a 20-fold increase of one 





5.1 Targeted therapy  
Over the past decades, tremendous progress in understanding the molecular mechanisms of 
cancer has been made, and specific genes and pathways crucial for cancer progression have 
been identified, laying the foundation for target-specific treatment. Some major discoveries 
have been done for a subset of cancer patients, exemplified by the differentiation agent ATRA 
for treatment of PML patients, imatinib (also known as Glivec®) for CML and ALL patients 
(targeting the BCR-ABL fusion gene), and gefitinib in epidermal growth factor receptor mutated 
cancers. However, the more we reveal about the underlying mechanisms of cancer 
development, the more complex and heterogenic the disease is proving to be. Even within a 
specific cancer type such as AML, the malignant population is not only heterogenic, it is in 
constant change, both because of genetic instability and epigenetic alterations. In addition, the 
malignant cells can change their metabolic pathway preference based on their 
microenvironment, which may be in constant change (e.g. altered nutrient availability, pH, 
oxygen levels). It is therefore difficult to target a single specific gene or pathway, and 
combination treatment or multiple target agents may be required to combat cancer. 
5.2 Targeting metabolic reprogramming in AML 
One of the most prominent abilities of cancer cells is the way they can alter their metabolic 
preferences, making them more resilient. A promising target for new cancer treatment has 
therefore been to target metabolic alterations, making cancer cells more vulnerable. Cancer 
cells generally have higher metabolic plasticity which allows the cells to use different sources 
of nutrients, including glucose, glutamine and fatty acid, to fuel the TCA cycle. This makes 
them able to survive under stressful metabolic conditions, outcompeting normal hematopoietic 
cells [324]. This highly diverse and flexible metabolism contributes to both the aggressiveness 
of the disease and the high percentage of refractory disease. It has also made metabolic targeting 
challenging since blocking one metabolic pathway does not necessary kill cancer cells. It can 
simply make the cells shift to utilize another pathway for cell growth and survival [191]. 
Simultaneously targeting more than one metabolic pathway may therefore be an approach to 
eliminate the cancer cells´ ability to survive under stressful conditions and render them 
vulnerable to chemotherapy. In Paper I we used a hierarchical cluster analysis to identify a 
subset of patients with high sensitivity to several metabolic inhibitors.  The thought behind this 
was to identify a subset that might benefit from a treatment combining multiple metabolic 
targets. This analysis identified a subset of 29 patients, sensitive to several metabolic inhibitors. 
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We were not able to identify common molecular or biological similarities for the patient subsets 
that had either high or low sensitivity to metabolic drugs. Nor did the known prognostic markers 
for chemotherapeutic sensibility (i.e. secondary AML, karyotype, FLT3-ITD, NPM1 mutations, 
CD34 expression) show any significant correlations with metabolic vulnerability. Thus, the 
susceptibility to the antiproliferative effects of metabolic inhibitors seems to depend at least 
partly on other cellular/molecular mechanisms than the susceptibility to conventional 
chemotherapy. 
In 2009, recurrent mutations in two key metabolic enzymes were identified, namely the 
cytosolic and mitochondrial isocitrate dehydrogenases (IDH1 and IDH2, respectively). IDH 
mutations are found in 15-20% of all AML patients [325]. The mutation in itself is currently 
not prognostic, but as IDH inhibitors are in clinical development, the mutation is associated 
with a favorable outcome [4]. The IDH enzymes are required to provide NADPH for lipid 
biogenesis, protect against oxidative damage, and facilitate α-KG-dependent dioxygenases. As 
IDH is a key enzyme in the TCA cycle, mutated IDH leads to the production of the 
oncometabolite 2-hydroxyglutarat (2-HG). 2-HG promotes DNA and histone 
hypermethylation, which in turn blocks cellular differentiation, promoting leukemic 
transformation and disease initiation. Mutant IDH inhibitors (enasidenib and ivosidenib) have 
shown promising results and have recently obtained FDA approval for IDH mutated AML 
patients. Interestingly, IDH mutated AML cells have shown to be especially sensitive to 
inhibition with the glutaminase inhibitor BPTES [241, 326]. There are however, to our 
knowledge no clinical trials with BPTES in IDH mutated AML patients (Table 7). In our patient 
cohort (Paper I), there were only five patients (out of 81) with IDH mutations. This was not 
enough to make any statistically significant assumptions, but all five patients were significantly 
inhibited by BPTES in this study (Wilcoxon Signed Rank-test), compared to their respective 
untreated controls. Glutaminase inhibitors are showing promise: CB-389 has been FDA-
approved for renal cell carcinoma and is in clinical trials for several other malignancies 
(including hematological cancers, though not for AML, see Table 7) [327].  
FLT3 inhibitors have failed to achieve long-term remission as monotherapy [328], even though 
experimental studies suggest that they can impair glutamine metabolism and thereby have 
proapoptotic activity [329]. A combination of glutamine and FLT3 inhibitors has therefore been 
suggested as a possible therapeutic strategy, and CB-389 combined with AC220 induces 
increased apoptosis and cell death in FLT3 mutated AML cells [330].  However, we did not 
find any significant association between the effects of BPTES and FLT3 mutations (Paper I).  
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FLT3 mutations lead to abnormal activation of the PI3K-Akt-mTOR pathway [331].  Metabolic 
reprogramming is mainly driven by the nutrient-sensors AMPK, mTOR and PI3K/Akt; 
dysregulation of these sensors is seen in more than 60 % of AML patients and is associated 
with cancer cell survival and proliferation [332-334]. These observations suggest there is a 
crosstalk between various metabolic pathways, the regulators of these pathways and driver 
mutations (including IDH, FLT3, p53 and NPM1) in AML. AML cells with different mutations 
may therefore depend on the same metabolic pathways.  
5.3 Signaling mechanisms, glycolytic metabolism and autophagy 
The nutrient sensors AMPK, mTOR and P13K/Akt are important for metabolic regulation [332-
334]. Both mTOR1 and AKT support glycolysis in AML cells, and starvation or glucose 
deprivation leads to AMPK activation that indirectly inhibits mTOR and induces apoptosis in 
AML, as suggested by our observations described in Paper I.  AMPK activation will also lead 
to direct and indirect (through mTOR inhibition) activation of ULK1, the major autophagy 
initiation protein [249, 250]. Furthermore, there seems to be a close connection between PPP 
and autophagy and certain cancer cells show distinct autophagy-dependent PPP modulations 
[223]. In Paper II we studied antiproliferative and proapoptotic effects on AML cells (i.e. 
patient cells, the AML cell lines HL60 and MOLM-13) of the autophagy inhibitor CQ alone or 
in combination with AraC or the metabolic drugs metformin and 2DG. Metformin is an AMPK 
activating drug, but it also seems to inhibit autophagy through suppression of UPR [292]. This 
too was suggested by our own results in Paper II.  Similarly, 2DG showed an additional 
inhibitory effect when combined with CQ both in the present and previous studies [294]. CQ 
as monotherapy showed a generally lower autophagic flux for HL60 than for MOLM 13; this 
is consistent with previous studies showing that HL60 cells display a glycolytic profile that is 
associated with Akt/mTOR1 activation and low autophagy flux [246, 335]. Furthermore, 
previous studies have also shown that autophagy limits glycolysis in AML and this is associated 
with reduced autophagy flux [246, 335]. This may explain the weak effect of CQ monotherapy 
on the viability of HL60 cells (which mainly depend on glycolysis) but the additive effect when 
combined with metformin (Paper II).  Taken together these observations suggest that combined 
treatment with different autophagy inhibitors should be considered.  
5.4 Cancer cell culture media 
The availability of different nutrients influences the plasticity of the AML cells [336]. 
Commercial media have been designed to supply cancer cells with nutrients essential for 
continuous proliferations [337] and do not therefore recreate physiological conditions. They 
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often lack metabolites normally present in human fluids, while others metabolites important for 
growth and proliferation (e.g. glucose, glutamine, pyruvate) are usually present in very high 
concentrations [338]. The culture medium may influence cell metabolism and thereby 
susceptibility to metabolic targeting [339]. Such effects may contribute to the generally lower 
susceptibility to CQ, metformin and 2DG for AML cell lines (Paper II) compared to patient 
cells (Papers I and II). All our studies of patient cells were performed with serum-free 
StemSpan SFEMTM medium supplemented with growth factors, whereas cell lines were 
cultured in RPMI-1640 supplemented with 10 % inactivated fetal calf serum. RPMI-1640 
contains both glucose and amino acids (e.g. glutamine, arginine, proline) in addition to the 
supplemented serum that contains high levels of growth factors. StemSpan SFEMTM does not 
contain serum. Thus, in vitro AML studies require the use of carefully characterized 
experimental models that are described in detail in the scientific reports.  
5.5 Toxicity of metabolic drugs and their potential as combination therapy 
Combination therapies have provided some of the most effective results with regard to AML 
treatment. The most common chemotherapy regime to treat AML today is a combination of 
three days with an anthracycline, and seven days with standard-dose AraC, hence the name 
“3+7” (see section 1.4.1, Potentially curative treatment). Combination therapy is also used as 
a consolidation therapy, as in Paper III of this thesis, with ATRA and valproic acid [144, 266]. 
As the role of epigenetic alterations in cancer development has become more apparent, clinical 
trials with a combination of epigenetic modifiers are becoming more frequent. Both ATRA and 
valproic acid have been used in various combination regimes for AML treatment. HDAC 
inhibitors in particular have emerged as important agents in clinical trials, as HDAC 
dysregulation is associated with many forms of cancer. Valproic acid, which is a well-known 
epileptic drug, has generally low toxicity and is well tolerated. However, results for valproic 
acid as monotherapy in the clinic have been somewhat disappointing. Nonetheless, used in 
combination therapy it has shown promising results, and has therefore been included in several 
clinical trials also for AML [133]. 
To combine two or more different agents against metabolic signaling pathways allows for the 
simultaneous targeting of multiple pathways, which can minimize treatment resistance since 
the cancer cells have to adapt to different toxic effects simultaneously. In addition, the 
resistance of AML cells towards treatment often depends on certain dysregulated cellular 
signaling pathways, so targeting these dysregulations might sensitize the cancer cells to other 
agents. This might make cells that were initially refractory to standard treatment receptive to 
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this treatment, or it may result in the need of much lower doses of chemotherapy or radiation 
to have clinical effects. Lower doses of treatment will reduce unwanted toxicity, which in turn 
means that more patients could tolerate the treatment.  
However, combination treatments also have disadvantages. The combination of multiple agents 
can have an additive effect on unwanted side effects in patients. When using multiple agents, it 
could be difficult to assess which agent is poorly tolerated, and adjusting doses could be 
challenging. The best doses and order of the drug would have to be carefully selected, to 
optimize the use and minimize the side effects. Especially if the drugs have similar side effect 
profiles, toxic substances may accumulate. Furthermore, the metabolizing capacity of drugs 
differs from one patient to another. The pharmacokinetics of a particular drug can be influenced 
by genetic variations or alterations in drug-metabolizing enzymes. Patient reactions can also be 
influenced by simultaneous treatment with other drugs, especially drugs that modulate 
metabolism. Therefore, drug interactions and side effect profiles have to be thoroughly 
investigated when creating new combination treatment regimes. Nevertheless, simultaneously 
targeting one or more pathways might be exactly what it takes to outmaneuver the cancer cells´ 
plastic metabolism. The challenge is to find the right balance.  
Side effects of the metabolic drugs described in this thesis have been reported after use in 
clinical studies, and are summarized in Table 7. The most common ones are gastrointestinal 
side effects (including diarrhea, anorexia and nausea), fatigue, and dizziness. More severe side 
effects such as electrocardiographic changes (2DG and CQ) auditory changes due to toxic effect 
on the eighth cranial nerve (6AN) and retinopathies (CQ) have also been reported. However, 
severe hematological and gastrointestinal toxicity seems to be relatively uncommon, suggesting 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.6 Metabolic inhibition is not specific to AML cells 
The ability to preferentially kill cancer cells without increasing toxic effect to normal cells, so-
called targeted therapy, is the most important aim when trying to find new cancer therapy. To 
achieve this, we need to understand the biological differences between normal cells and cancer 
cells. In this Ph.D. project we have mainly focused on leukemic cells` response to metabolic 
treatment (Papers I and II), and systemic metabolic alterations in AML patients reacting to 
disease-stabilizing treatment, and treatment-requiring GVHD after allo-HSCT (Papers II and 
IV).  
Toxic effects on normal cells have not been a main focus of this study. However, it is important 
to test and compare effects on normal cells too. It is nonetheless difficult to determine which 
cell-type can be used as an appropriate control. We chose to use human MSCs and UCB cells 
as healthy controls (Papers I and II), but they were derived from few subjects (only five UCB 
donors and one MSC donor). In Paper I, the metabolic inhibitors had similar antiproliferative 
effects on the UCB and the AML cells. However, metformin had an overall stronger effect on 
the proliferation of AML cells compared to UCB cells. In the viability assay, the UCB cells 
were generally less sensitive towards all metabolic drugs (except AZD3965). In our coculture 
assay with MSCs, 2DG had an antiproliferative effect for the majority of AML patients, even 
in the presence of MSCs, and the AML cells were significantly more sensitive to 2DG than the 
MSC cells. In Paper II, CQ had a similar inhibitory effect on the proliferation of UBC and 
AML cells, and in addition, the MSCs were less inhibited in MSC-AML cocultures, compared 
to the AML cells. As all MSCs originated from the same donor, it is difficult to conclude on 
the overall MSCs sensitivity towards CQ compared to AML cells in our assays. However, this 
shows that the AML cells do not protect the MSCs from CQ-induced toxicity.  
In our studies we have primarily investigated the effect of metabolic inhibitors on AML cells, 
and the healthy control cells were merely included to give a brief guidance as to how these 
drugs might affect the surrounding environment. As we used UCB and not isolated CD34+ stem 
cells, there are no guarantees that the proliferating cells do not contain T-cells. However, T-
cells would normally require a specific antigen signal, as well as a co-stimulatory protein to be 
fully activated and proliferate [346], neither of which are found in the serum-free StemSpan 
SFEMTM medium used in these assays. The growth factors G-CSF, SCF and FLT3-L, which 
were added to the medium, should not affect T-cell proliferation. However, certain drugs, such 
as streptokinase, can initiate antigen-stimulated T-cell activation, without antigen present. 
Response peaks after 6-7 days of culture [347]. Therefore, a possible T-cell activation cannot 
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be ruled out, although it is unlikely, as all of our drugs showed a dose-dependent inhibition of 
proliferation. Thus, the proliferating cells in our UCB controls are most likely CD34+ cells. It 
would of course have been optimal to use isolated bone marrow CD34+ cells as controls in our 
assays. However, these commercially available cells are expensive, and since LSCs were not 
the main focus in these studies, isolating CD34+ cells was not prioritized.  
5.7 T-cell metabolism 
In Paper IV we looked at the metabolic alterations of allo-HSCT recipients, identifying 
metabolic characteristics of patients with treatment requiring cGVHD. Allo-HSCT is 
commonly used to treat severe hematological malignancies, including AML. Allo-HSCT relies 
on the ability of engrafted immune systems, mainly the T-cells, to remove residual leukemic 
cells, known as the GVL effect [348, 349]. However, the greater the GVL effect, the greater the 
risk of developing GVHD. We examined the metabolic profiles of allo-HSCT patients one-year 
post-transplantation, to see if the metabolic profiles could be used to diagnose and determine 
the severity of cGVHD requiring systemic immunosuppression, and to study the effect of 
immunosuppression on the metabolic profiles of cGVHD patients. As patients were examined 
at a defined time point, the metabolic profiles of the patients were likely to be influenced both 
by the pathology and the duration of cGVHD, and differences in the immunosuppressive 
treatment. The pathology of cGVHD is still not fully understood, but it is generally accepted 
that it involves inflammatory mechanisms related to T-cells [349]. Emerging evidence has 
revealed that metabolic alterations impact the activation and differentiation of T-cells. Whereas 
naïve, regulatory and memory T-cells rely mainly on OXPHOS for energy production, the 
metabolism of activated T-cells is in many ways  similar to cancer cells [350]. Like tumor cells, 
activated T cells mainly rely on aerobic glycolysis instead of OXPHOS [350]. Activated T cells 
can undergo metabolic reprogramming, upregulating other metabolic pathways like 
glutaminolysis and FAO, if they need to secure  different energy sources for cell growth, 
proliferation, differentiation and cytokine production [351]. Furthermore, recent studies support 
the hypothesis that metabolic pathways are important for shaping the T-cell responses and are 
recognized as key players in T-cell activation and differentiation. They play an important role 
in modulating the T-helper cell lineages, and do not only function as passive support and as 
nutrient sources [352]. This supports our findings in Paper IV, that systemic metabolic profiles 
may be used as a prognostic indicator and help identify patients with treatment-requiring 
cGVHD. However, this metabolic reprogramming is strongly influenced by signals from the 
cells´ microenvironment and intracellular energy status, where, among other factors, AMPK, 
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mTORC1 and HIF are important signaling pathways. This is supported by studies showing that 
immunosuppressive molecules, such as rapamycin which inhibits mTORC1, also have an 
impact on T-cell metabolism [351]. 51 patients were included in our study (Paper IV), 31 with 
cGVHD. All except two patients with active cGVHD received immunosuppressive treatment 
(i.e. cyclosporine, steroids). One could therefore speculate about the possibility that the 
metabolic alterations we detected in these patients are, at least in part, related to drug-induced 
modifications of T-cell metabolism.  
5.8 The antileukemic effect of valproic acid; epigenetics and the emerging role of lipid 
metabolism in AML 
In Paper III the aim of the study was to compare the pretreatment metabolomic profiles found 
in non-responders and responders to AML-stabilizing treatment with ATRA and valproic acid 
(to see if responders/non-responders could be identified). We aimed to characterize how these 
profiles altered during the early period of this treatment (two-day or seven-day monotherapy 
with either ATRA or valproic acid, respectively). Valproic acid is an epigenetic targeting drug 
that functions as an HDAC inhibitor (see section 1.1.8 Epigenetics). We found a highly 
significant change in the lipid metabolite profiles after treatment with valproic acid; especially 
levels of fatty acid metabolites were altered. In coherence with our findings in Paper III, lipid 
dysregulation has been established as an important phenotype in cancer cells, and 
reprogrammed FAO has been reported for various cancers, also for AML [353, 354]. In recent 
years, the literature has increasingly focused on altered lipid metabolism both intracellular in 
AML cells, and signaling to adipocytes in the cells´ microenvironment (mainly the bone 
marrow) [353-358]. In addition, there seem to be several links between epigenetic regulation 
and fatty acid metabolism in AML [359]. 
Firstly, epigenetic regulation is important for general fatty acid metabolism. Acetyl-CoA is the 
precursor of fatty acid synthesis and is produced in the mitochondria from fatty acid oxidation. 
Acetyl-CoA is converted to citrate in the TCA cycle, and transported into the cytoplasm by the 
citrate transporter, where it can be used to regenerate Acetyl-CoA that can be used in the fatty 
acid synthesis. This process is catalyzed by the two Acetyl-CoA-carboxylase (ACC) isoforms 
ACC1 and ACC2, and the fatty acid synthase (FAS) complex [359]. This is reflected in our 
findings in Paper III, where we, in addition to an increase in fatty acid metabolites, also see an 
increase in TCA- metabolites between non-responders with rapidly progressive AML and non-
responders with less aggressive disease. This suggests an increase in the transition of fatty acids 
to the energy metabolism in patients with rapidly progressive disease. Expression of ACC2 is 
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also a key driver of fatty acid β-oxidation in AML cells [360].  Repression of this gene by 
histone deacetylation allows for simultaneous β-oxidation and fatty acid synthesis to take place 
[360]. Secondly, changes in the expression of genes encoding fatty acid synthesis enzymes have 
been seen in response to dietary changes. A carbohydrate-rich diet increases ACC1 and FAS, 
promoting fatty acid synthesis. On the other hand, fasting has been shown to decrease fatty acid 
synthesis and inhibit ACC1 and FAS expression. Obesity has been shown to favor AML growth 
[361]. The mechanisms behind this include the expression of both fatty acid binding protein 4 
(FABP4) and DNA methyltransferase 1. High-fat diet-induced obese mice, with increased 
FABP4, have a much higher leukemia burden. This diet accelerates AML cell growth [362]. 
These findings are supported by a recent study showing that genetic disruption of FABP4 in 
AML cells or mice blocked cell proliferation in vitro and induced leukemia regression in vivo 
[362]. Finally, valproic acid has been shown to alter lipid metabolism and fatty acid oxidation 
[363, 364]. Our results in Paper III thereby support the hypothesis that valproic acid alters 
epigenetic regulation in AML both through direct effects on histone acetylation and indirectly 
through modulation of fatty acid metabolism. 
5.9 Metabolic preferences of LSCs may influence the treatment strategy 
While conventional chemotherapy eliminates most of the proliferating bulk of AML cells, some 
of the disease-initiating LSC population is spared, leading to disease progression and relapse 
[66, 365-367]. This may indicate that LSCs display some different molecular or metabolic 
advantages, making them more resistant to conventional therapy and increasing risk of relapse. 
One could therefore argue that also targeting LSCs is likely to result in better outcomes for 
AML patients. Recently, striking characteristics of LSCs have been discovered: firstly, LSCs 
depend mainly on OXPHOS fueled by amino acids to drive the TCA cycle. Secondly, LSCs 
have low ROS levels, while mature blasts generally exhibit higher ROS levels. Thirdly, LSCs 
have been shown to have an overexpression of the anti-apoptotic molecule BCL-2 [165]. Not 
only does targeting BCL-2 increase apoptosis, it also targets LSCs selectively, partly by 
mechanisms impairing OXPHOS [165, 166, 368]. An ongoing multicenter clinical trial 
(NCT02203773) investigating Venetoclax, a BCL-2 inhibitor, in combination with the 
hypomethylating agents azacitidine or decitabine is showing promising preliminary results, 
demonstrating CR/CRi rates reported from 61-85% [166]. Furthermore, metabolomic analyses 
of circulating blasts from the patients before and after venetoclax/azacitidine treatment, 
revealed alterations of metabolites in the TCA cycle, reduction of the central antioxidant 
glutathione and reduction of amino acids in the LSCs, which were not found for the majority 
62 
 
of blast cells after treatment [166]. Further studies have shown that metabolic plasticity is 
important for resistance of venetoclax [368]. To conclude, these studies suggest that 
combination treatment targeting cancer cell metabolism has potential in AML, and gives rise 




6 Concluding remarks 
All four articles included in this thesis support the evidence that the heterogeneity of AML also 
applies to AML cell metabolism. The plasticity of AML cells enables them to adapt to 
environmental conditions, and optimize the consumption of what is available in terms of 
nutrients (i.e. glucose, amino acid and fatty acids). This allows the AML cells to maintain fast 
proliferation and cell growth, thus rapidly outgrowing normal hematopoietic cells.  However, 
the results from Papers I and II demonstrate that this heterogeneity also renders sub-
populations more sensitive to metabolic targeted therapy. These subpopulations do not seem to 
have any associations to the well-established risk factors for chemoresistance after conventional 
intensive chemotherapy (i.e. secondary AML, karyotype, FLT3-ITD, NPM1 mutations, CD34 
expression) or long-term AML-free survival. Thus, the mechanisms behind metabolic 
vulnerability seem to depend, at least partly, on other cellular and molecular mechanisms than 
conventional chemotherapy. The literature suggests that metabolic rewiring is highly dependent 
on both cellular and environmental contexts. This, including the heterogeneity among the AML 
cells, as well as the limitations of experimental models, has made it difficult to find specific 
metabolic targets. Future preclinical and clinical studies have to be performed in order to 
identify subsets with common characteristics suitable as metabolic targets, or combinations of 
targets, better suited to harm AML cells, while simultaneously sparing healthy cells. 
Our results show that different subsets are more sensitive to the inhibition of different metabolic 
pathways, and rely not only on glycolysis and OXPHOS, but also on amino acid and lipid 
metabolism. Lipid metabolism is emerging as a potential therapeutic target, given the 
alterations found in AML cells, as is supported by our own findings in Paper III. Even so, 
targeting lipid metabolism has proven to be challenging, and successful results from clinical 
trials are still lacking. Our studies presented in Papers III and IV, suggest nonetheless that the 
alterations seen in AML cells´ lipid and amino acid metabolism might have prognostic value, 
predicting both disease progression and treatment responses. In this context, it is tempting to 
suggest patient metabolic profiles as a potential prognostic tool for AML treatment and 
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Abstract:  
Acute myeloid leukemia (AML) is an aggressive blood cancer resulting in accumulation of 
dysfunctional white blood cells in the bone marrow. Changes in cell metabolism are features 
of many cancers, including AML, and this may be exploited as a therapeutic target. In this 
study, we investigated the in vitro antileukemic effects of drugs inhibiting different metabolic 
pathways. Drug-efficacy on AML cells from 81 patients was evaluated using proliferation 
and viability assays; we also compared global gene expression and proteomic profiles for 
various patient subsets. The drugs metformin, 2DG, 6AN, BPTES and ST1326 had strong 
antiproliferative and proapoptotic effects for most patients, whereas lonidamine and 
AZD3965 had an effect only for a minority. Antiproliferative effects on AML cells were 
additive when combined with the chemotherapeutic agent AraC. Drug-effects showed no 
associations with clinical or biological characteristics of patients. Using hierarchical 
clustering, we identified a subset of 29 patients with a strong antiproliferative effect towards 
metabolic drugs. Gene expression and proteomic studies suggested that this subset was 
characterized by altered metabolic and transcriptional regulation. Antiproliferative effects of 
drugs were maintained in the presence of mesenchymal stem cells (MSCs), and the metabolic 
inhibitors also had anti-proliferative effects on MSCs and umbilical cord blood cells. 
Therapeutic targeting of cell metabolism may have potential in AML, but the optimal strategy 
will probably differ between patients.  
 





Acute myeloid leukemia (AML) is the most common leukemia in adults. It is an aggressive 
hematologic malignancy characterized by accumulation and enhanced cell proliferation of 
immature myeloid precursors in the bone marrow, leading to marrow failure [1]. AML is a 
heterogeneous disease with regard to phenotypic, molecular and clinical features, with 
variations in differentiation, karyotype, molecular genetics and epigenetics of the leukemic 
cells. There is also heterogeneity with respect to the susceptibility of chemotherapeutic 
treatment [2]. Current treatment is based on high-intensity induction chemotherapy; however, 
not all patients are eligible for this potentially curative treatment, and a large amount of AML 
patients relapse, which is associated with impaired survival. The 5-year overall survival rate 
after intensive therapy is below 50% and even lower for patients older than 70 years [3], and 
new treatment options for AML are therefore warranted. 
   Changes in cell metabolism have been described as hallmarks of cancer and metabolic 
targeting is considered as a possible therapeutic strategy in various cancers, including AML 
[4]. Cancer cells are often more dependent on glycolysis and have increased energy 
requirements in comparison to normal cells that mainly employ oxidative phosphorylation 
(OXPHOS) to gain energy in the presence of oxygen [5, 6]. The ability of malignant cells to 
alter their energy metabolism to meet their increasing bioenergetic demands is crucial for 
cancer development [7]. Complex metabolic capacities may contribute to the aggressiveness 
of cancer, including AML, allowing cells to survive under higher metabolic demands. 
However, AML patients are heterogeneous with regard to metabolic regulation [8-11], and 
in this study we wanted to further investigate if patients are heterogeneous also with regard 
to the antileukemic effects of metabolic targeting.  
   Several metabolic pathways can be utilized by cancer cells to gain energy and building 
blocks for growth and survival, including OXPHOS, glycolysis, glutaminolysis, fatty acid β-
oxidation, the pentose phosphate pathway (PPP) and the lactate synthesis pathway [12]. 
Hematological malignancies have been shown to rely on different metabolic routes 
depending on their genetic abnormalities [13-18], an observation suggesting that AML 
patients can be subclassified based on their metabolic phenotype and may vary in their 
susceptibility to metabolic targeting. To further study patient heterogeneity, we investigated 
the in vitro effects of seven drugs that affect various metabolic pathways (see Table 1) 
including metformin, 2-deoxy-D-Glucose (2DG), lonidamine, bis-2-(5-phenylacetamido-
1,3,4-thiadiazol-2-yl) ethyl sulfide (BPTES), 6-aminonicotinamide (6AN), AZD3965 and 




Materials and Methods 
2.1 Primary human cells. 
   Primary human AML cells. This study was approved by the Regional Ethics Committee 
(REK III 060.02, (100602), REK Vest 2013-634 (190313), REK Vest 2015/1410 (190615), 
2017/305 (070417) and samples were collected after written informed consent. The main 
characteristics of the 81 consecutive patients are presented in Table 1; acute promyelocytic 
leukemia (APL) patients were excluded. Peripheral blood mononuclear cells were isolated 
from patients with at least 80% AML cells among blood leukocytes and generally >15 x 
106/L blood leukocytes. Enriched AML cell populations could then be prepared by density 
gradient separation alone (density of 1.077, Ficoll-Hypaque; Nycomed, Oslo, Norway) and 
included >90% AML cells; contaminating cells consisted mainly of small lymphocytes [19-
21]. Primary AML cells were cryopreserved in RPMI 1640 medium (Sigma-Aldrich, St. 
Louis, Missouri, USA) with 10% dimethyl sulfoxide and 20% heat-inactivated fetal bovine 
serum (FBS) and stored in liquid nitrogen until thawed and used in experiments. 
 
Table 1. Biological and clinical features of the 81 AML patients in this study. 
 
 
Abbreviations: CMML, Chronic myelomonocytic leukemia; FAB, French-American-British; INS, 
insertion; ITD, internal tandem duplication MDS, Myelodysplastic syndrome; nd, not determined; 






   Primary umbilical cord blood (UCB) cells. Cells were obtained from five donors after 
written informed consent, REK Vest 2015/1759 (051115), 2017/305 (070417). Mononuclear 
cells were enriched in a similar manner to AML cell populations, by using density gradient 
separation, and stored in liquid nitrogen until used in experiments.  
 
2.2 Reagents 
Culture medium used in all experiments, except the coculture studies, was serum-free Stem 
Span SFEMTM medium (Stem Cell Technologies, Vancouver, BC, Canada) supplemented with 
granulocyte-colony stimulation factor (G-CSF), stem cell factor (SCF) and fms-related tyrosine 
kinase 3 ligand (FLT3L). All cytokines were purchased from Peprotech (Rocky Hill, NJ, USA) 
and used at a final concentration of 20 ng/ml. The seven metabolic inhibitors tested on AML 
cells are described in more detail in Table 2. Metformin hydrochloride (PHR1084), 2-Deoxy-
D-Glucose (abbreviated 2DG; 154-17-6), lonidamine (L4900) and BPTES (SML0601) were all 
obtained from Sigma-Aldrich (St. Louis, MO, USA), while 6AN (100-093-15) and AZD3965 
(199-12) were purchased from Cayman Chemical (Ann Arbor, MI, USA), and ST1326 
(870853; also known as Teglicar) from Avanti Polar Lipids (Alabaster, AL, USA). AraC 
(Cytosine Arabinoside) was provided by Pfizer (New York, NY, USA). The same lot numbers 
of drugs were used in all experiments. Stock solutions were prepared according to the 
distributors’ datasheets. Metformin and 2DG were passed through a 0.22 µm filter after being 
dissolved, and all drugs were aliquoted and stored at -20°C. Aliquots were thawed only once 
and diluted with their respective solvents (DMSO or PBS). 
 





2.3 Analysis of cell proliferation, viability and constitutive cytokine release AML cell 
proliferation.  
Proliferation was analyzed using a [3H]-thymidine incorporation assay [22]. AML cells were 
seeded (5 x 104 cells/well, 200 μL medium/well) in flat-bottomed 96-well microtiter plates 
(Nuncleon™; Nunc, Roskilde, Denmark). Cell cultures were added drugs at various 
concentrations, medium controls and solvent/vehicle controls. After 6 days of incubation at 
37ºC in a humidified atmosphere of 5% CO2, [3H]-thymidine (37 kBq in 20 μL saline per well; 
TRA 310; Amersham International, Amersham, UK) was added and cultures incubated for 
additional 22 hours before nuclear incorporation was determined by liquid scintillation 
counting. For each treated culture, proliferation (uptake of thymidine) was calculated by 
subtracting values obtained for untreated controls (medium alone) from drug-treated cultures, 
and detectable proliferation was defined as at least 1000 counts per minute (cpm). The median 
of triplicate cultures was used in all calculations.    
  Cocultures of MSCs and AML cells. Normal human mesenchymal stem cells (MSC) (Lonza, 
Cambrex BioScience, Walkersville, MD, USA) derived from a healthy donor (MSC24539) 
were expanded in complete mesenchymal stem cell growth medium (MSCGM™; Lonza) with 
10% heat-inactivated FBS and 4 mM L-glutamine. The MSCs were trypsinized and used in 
cocultures in passage four. AML-MSC cocultures were prepared in MSC medium, and the cells 
were then separated by a semipermeable membrane (0.4 µm pore size) using transwell plates 
(Costar 3401 plates; Costar, Cambridge, MA, USA), allowing only cytokine-mediated crosstalk 
with no direct MSC-AML cell contact. Cell proliferation of both the AML cells and MSCs were 
also analysed using the [3H]-thymidine incorporation assay after three days of coculture as 
described in detail previously[23].  
   Viability. The percentages of viable, apoptotic and necrotic AML cells were determined by 
flow cytometry using the ApoptestTM–FITC kit according to the manufacturer`s protocol 
(NeXins Research, Kattendijke, the Netherlands) [24]. Briefly, primary cells were cultured for 
48 hours in Stem Span SFEM™ medium supplemented with cytokines (1 x 106 cells/ml in 1 
ml/well) in 24-well culture plates with or without drugs. Cells were double-stained with 
AnnexinV fluorescein isothiocyanate (FITC) and propidium iodide (PI) according to the 
distributors staining protocol. Acquisition of data was done using a FACSVerse™ flow 
cytometer (BD Biosciences, San Jose, CA, USA), with a minimum of 10,000 events collected 
for each sample. The flow cytometry data was analyzed using FlowJo v10.3 software (Tree 




   Soluble mediator release. AML cells (1x 106/ml, 1 ml/well) were cultured for 48 hours in 
Stem Span SFEM™ medium supplemented with G-CSF, SCF and FLT3L (1 x 106 cells/ml and 
1 ml per well) in 24-well culture plates (Nucleon™; Nunc, Roskilde, Denmark). Culture 
supernatants were harvested and stored at -80° until analyzed using human magnetic Luminex 
multiplex assays (LXSAHM-17, R&D Systems; Minnesota, MN, US). Supernatants from 
cocultures of MSCs and AML cells were also harvested and analysed with the Luminex 
multiplex assays. Nineteen analytes were measured: (i) the chemokines CXCL1, CXCL10, 
CXCL5, CXCL8/IL-8, CCL2, CCL3, CCL4, CCL5, (ii) the interleukins IL-1β, IL-1RA, IL-6, 
(iii) the matrix metalloproteinases MMP-1, MMP-2, MMP-9, (iv) tumor necrosis factor-α 
(TNF-alpha), (v) the growth factors GM-CSF and HGF, and (vi) the proteinase inhibitors 
Cystatin C and Serpin E1/PAI-1.   
2.4 Mutational profiling, global gene expression profiling and proteomic analysis  
Mutational profiling.  
The TruSight Myeloid Sequencing Panel (Illumina, San Diego, CA, USA) was used to assess 
54 genes frequently mutated in myeloid leukemias as described previously [25], and data from 
this analysis was available for 35 of our AML patients. 
   Global gene expression profiling. Analysis of global mRNA profiles were performed on 21 
patients using the Illumina iScan Reader based on fluorescence detection of biotin-labeled 
cRNA as described previously [25]. For each sample, 300 ng of total RNA was reversely 
transcribed, amplified and biotin-16-UTP-labeled (Illumina TotalPrep RNA Amplification Kit; 
Applied Biosystems/Ambion, USA). The quantity and quality of the biotin-labeled cRNA was 
assessed using the NanoDrop spectrophotometer and Agilent 2100 Bioanalyzer, respectively. 
Biotin-labeled cRNA (750 ng) was hybridized to the HumanHT-12 V4 Expression BeadChip 
that targets 47,231 probes mainly derived from genes in the NCBI RefSeq database (Release 
38). Data from the array scanning were investigated in GenomeStudio and J-Express 2012 [26]. 
All arrays within each experiment were quantile normalized before being compiled into an 
expression profile data matrix. The PANTHER version 14.1 was used for functional 
classification of genes [27, 28]. 
   Proteomic analyses. Proteomics preparation and analysis was performed on 14 patients, as 
described previously [29, 30]. Briefly, filter-aided sample preparation (FASP) procedure [29] 
was used to prepare samples, which were further analyzed on the Q Exactive HF Orbitrap mass 
spectrometer (MS) (Thermo Fisher Scientific; Waltham, MA, USA) coupled to an Ultimate 




MS raw files were searched against a Swiss-Prot Homo sapiens FASTA file (downloaded 
28.08.18) and the label-free quantitation (LFQ) count was set to 1 in MaxQuant version 1.6.1.0 
[31]. 
2.8 Statistical analyses 
Mann-Whitney U-test, Kruskal-Wallis H-test with Dunn´s test for multiple comparisons, 
Wilcoxon signed rank test, Welch’s t-test and Kendall’s test were used for statistical analyses. 
Differences were regarded as statistically significant when p < 0.05. SPSS (IBM Statistical 
Package for the Social Sciences v. 23.0; IBM SPSS statistics Inc., Chicago, IL, USA) and 
GraphPad prism v. 5.02 (Graph Pad Software, San Diego, CA, USA). J-Express 2012 was used 
to perform all cluster-analysis; all cluster-analysis were made using complete linkage. The 
statistical analyses used for proteomics analysis have been described elsewhere [30]. 
Significantly different proteins were analyzed in the STRING database (version 11.0) [32] 
using experiments and databases as interaction sources at a confidence cut-off score of 0.7, and 
visualized in Cytoscape (version 3.3.0) [33]. Since data was collected over multiple days, a data 
normalization step was performed to correct inter-day and plate variation. Essentially, this was 
done by registering the medians to equal one (1.00) and normalizing each data proportionally, 
termed “block correction”.  
 
3. Results 
3.1. Drug screening study; effects on proliferation of AML and UCB cells after exposure to 
metabolic drugs 
A proliferation assay ([3H]-thymidine incorporation assay) was used for the initial testing of 
several metabolic drug concentrations on AML cells, i.e. we evaluated the ability of AML cells 
to survive after seven days of culture and still be able to proliferate after drug treatment. Six 
concentrations of each drug were initially tested (Figure S1). Metformin (1.25-40 mM), 2-DG 
(0.625-20 mM) and 6AN (50-500 μM) showed strong antiproliferative effects for all 17 patients 
investigated. The other four drugs had divergent effects, and especially lonidamine (25-300 
μM) and AZD3965 (6.25-200 nM) showed no or minor antiproliferative effects. Based on these 
initial results, the following drug concentrations were chosen for further experiments: 
metformin 1.25 and 2.5 mM, 2DG 0.3 and 0.6 mM, 6AN 50 and 100 µM and BPTES 10 and 
20 µM. Lonidamine and AZD3965 were further tested at their highest screening concentration 
of 300 µM and 200 nM, respectively, which were the maximum achievable concentrations in 




screening concentration of 50 µM; higher concentrations were not tested due to issues with poor 
solubility. Ara-C (0.0125-0.3 µM) had significant antiproliferative effects at all concentrations 
tested, with responses differing among patients (data not shown). Both DMSO and PBS alone 
showed no effect on AML cell proliferation or viability at the concentrations used in this study 
(data not shown).  
   The effects of metabolic inhibitors on the proliferation of human UCB-derived mononuclear 
cells were also tested in our [3H]-thymidine incorporation assay. Five samples where tested 
while four UCB samples showed detectable proliferation (> 1000 cpm) in untreated control 
cultures. Treatment with metabolic inhibitors had similar antiproliferative effects on UCB cells 
as seen on primary AML cells (Figure S1), however, metformin 5 mM inhibited proliferation 
of AML cells stronger than UCB cells at the same doses (p = 0.030, Mann-Whitney U-test). 
3.2. Several metabolic inhibitors have antiproliferative effects on primary AML cells, with no 
association with secondary AML, AML cell differentiation, karyotype, FLT3-ITD, NPM1 
mutation or patient survival  
We investigated the effects of drugs on cytokine-dependent AML cell proliferation for all 81 
patients. Detectable proliferation, defined as [3H]-thymidine incorporation >1000 cpm, was 
observed in the control cultures for 69 of the 81 patients (85% of patients). For these patients 
with detectable proliferation, drug treatment resulted in a highly significant antiproliferative 
effect compared to untreated controls (p ≤ 0.0001, Kruskal Wallis test, Dunn´s post-hoc test), 
for all drugs except lonidamine and AZD3965. The latter two drugs did not show any significant 
inhibitory effects on proliferation, though proliferation was decreased after drug treatment for 
certain patients (Figure 1). When comparing the effect of drugs on proliferation for individual 
patients, we observed that the antiproliferative effect varied considerably between patients. For 
certain patients, cell proliferation was inhibited completely by drug treatment while other 
patients had no effect with the same drug concentration. The strongest overall antiproliferative 
effect was seen after treatment with 2DG (Figure 1). Furthermore, we defined the 
antiproliferative effect as >20 % inhibition compared to untreated controls and investigated 
whether these antiproliferative effects showed any associations with AML cell differentiation 
(FAB classification, CD34 expression), cytogenetics, FLT3 or NPM1 mutations or occurrence 
of previous disease (versus de novo AML). A few associations of borderline significance were 
detected (p < 0.05, Table S1). Due to the large number of comparisons, and small sample 





   Our patient cohort included 40 younger patients who completed intensive induction and 
consolidation therapy; 15 of them remained in remission for a median of 105 months (range 39-
164) whereas the others died from resistant/relapsed AML. The antiproliferative effects 
observed with the metabolic inhibitors did not differ between patients when comparing long-











































Figure 1. Effects of treatment with metabolic inhibitors or AraC on AML cell proliferation. AML 
cells were cultured alone or treated with metabolic inhibitors or AraC for 7 days in suspension cultures, 
before proliferation was measured using the [3H]-thymidine incorporation assay. Detectable 
proliferation defined as >1000 cpm was found for 69 out of the 81 control cultures; except ST1326 
which included 54 patients with detectable proliferation among 62 patients tested. The figure illustrates 
the results only for patients with detectable proliferation. The median proliferation (% of untreated 
controls) for all patients are presented (25/75 percentiles, 5/95 percentile whiskers). The drug-free 
(untreated) controls were set to 100% (stippled line). Statistically significant effects are shown (ns, not 
significant, * p-value < 0.05, *** p-value < 0.0001). The Kruskal Wallis, with Dunn´s post-hoc test was 
used for statistical analyses.  
 
 
3.3. Metabolic inhibitors have additive antiproliferative effects when combined with AraC  
   The antiproliferative effects of metabolic inhibitors were also tested alone or in combination 
with AraC 0.0125 µM (81 patients examined, 69 showing detectable proliferation). The 
following concentrations of drugs were then used, metformin 1.25 mM and 2.5 mM, 2DG 0.3 
and 0.6 mM, 6AN 50 and 100 µM, BPTES 10 and 20 µM, ST1326 50µM, lonidamine 300 µM 
and AZD3965 200 nM. Significant additive effects (i.e. combined effects, being greater than 
their separate effects) were found after treatment with metformin 2.5 mM, 2DG 0.6 mM, 6AN 
50 and 100 µM and ST1326 50 µM in combination with AraC compared to AraC alone (Figure 
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Figure 2. The combined treatment of metabolic inhibitors with AraC on AML cell proliferation, 
using the [3H]-thymidine incorporation assay. The metabolic inhibitors were tested at the following 
concentrations: metformin 1.25 and 2.5 mM, 2-DG 0.3 and 0.6 mM, 6AN 50 and 100 µM, BPTES 10 
and 20 µM, ST1326 50 µM, lonidamine 300 µM and AZD3965 200 nM alone and in combination with 
AraC 0.0125 µM. All 69 patients with detectable proliferation in untreated control cultures were 
included in this analysis, except ST1326 which included 54 patients with detectable proliferation among 
62 patients tested. The results are presented as the median percentage of proliferation in cell cultures 
treated with metabolic inhibitors or in combination with AraC compared to the corresponding control 
cultures (column), ±SD (whiskers). The Kruskal-Wallis test with Dunn`s multiple comparison test was 
used for statistical comparisons between monotherapy and combination therapy compared to untreated 
controls (significance shown above each column), and between combination therapy with metabolic 
drugs and AraC, and AraC alone (illustrated above brackets at the top of the figure). ns = not significant, 
* p-value < 0.05 and, ** p-value 0.001 and ***, p-value < 0.0001; LON, Lonidamine; AZD, AZD3965. 
 
 
3.4. The antiproliferative effect of metabolic inhibitors differs between patients and a subset of 
patients show increased susceptibility to several inhibitors  
One of the most prominent alterations in cancer cell metabolism is the increased consumption 
of glucose. We therefore did an unsupervised hierarchical cluster analysis based on the effects 
of the metabolic inhibitors that can affect glucose metabolism, which include metformin, 2DG 
and 6AN (lonidamine was not included due to lack of significant effects on cell proliferation, 
Figure 1). This analysis was based on the percent inhibition of AML cell proliferation after drug 
treatment, i.e. the proliferation in treated cultures relative to the corresponding untreated control 
cultures. This clustering identified a subset of 22 patients with overall high sensitivity to these 




regard to cause of AML (secondary versus de novo), AML cell differentiation (FAB 
classification, CD34 expression), karyotype, FLT3-ITD, NPM1 mutations, age, gender or 
survival of the younger patients receiving intensive therapy. 
   We thereafter did an unsupervised hierarchical cluster analysis based on the five drugs with 
significant antiproliferative effects when analyzing the overall results (shown in Figure 1) 
which included metformin, 2DG, 6AN, BPTES and ST1326 (Figure 3B). We now identified a 
subset of 29 patients (the 29 upper patients) characterized by a strong antiproliferative effect by 
all or most of the five inhibitors. These 29 patients did not differ significantly from the other 
patients with regard to cause of AML (secondary versus de novo), AML cell differentiation 
(FAB classification, CD34 expression), karyotype, FLT3-ITD, NPM1 mutations or survival of 
the younger patients receiving intensive therapy (Table S2). Furthermore, the 29 upper patients 
in Figure 3B did not differ from the other patients with regard to degree of cytokine-dependent 
proliferation in control cultures.   
   We also performed a hierarchical cluster analysis based on the effects of cell proliferation 
after drug treatment relative to the corresponding untreated control cultures when all metabolic 
inhibitors and drug concentrations were included (Figure S2). Based on this analysis, the 
patients could be divided into three subsets (Figure S2).  
   The two hierarchical cluster analyses that were based on the antiproliferative effects of (i) 
drugs that can affect glucose metabolism (metformin, 2DG and 6AN) (Figure 3A) and (ii) the 
five metabolic drugs that have overall significant effects on cell proliferation (metformin, 2DG, 
6AN, BPTES and ST1326) (Figure 3B), did not differ much with regard to patient distribution 
in the different subclusters. This shows that the results obtained with the three drugs metformin, 












Figure 3. Unsupervised hierarchical cluster analysis based on the effects of metabolic inhibitors 
on proliferation of primary human AML cells. Primary AML cells were grown in suspension cultures 
in medium supplemented with exogenous growth factors, and treated with metformin 2.5 mM, 2DG 0.6 
mM, 6AN 100 µM, BPTES 20 µM, ST1326 50 µM or added medium (untreated controls) for 7 days 
before cell proliferation was analysed using the [3H]-thymidine incorporation assay. The percent 
inhibition (i.e. proliferation in treated cultures relative to untreated controls) was estimated for each 
patient/drug combination A) Clustering of patient samples based on effects of metabolic inhibitors 
that can influence glucose metabolism. The cluster analysis was based on the effect of metformin, 
2DG and 6AN on AML cell proliferation, and identified a subset of 22 patients with overall higher 
sensitivity towards these drugs (illustrated in dark red in the first column to the right of the cluster). The 
next columns to the right indicate biological and clinical characteristics for each individual patient (FAB, 
cytogenetics, secondary versus de novo, CD34 expression, FLT3-ITD and NPM1 mutations). B) 
Clustering based on significant antiproliferative effects of metabolic inhibitors on AML cells. The 
cluster is based on the results for all five inhibitors that showed significant antiproliferative effects on 
AML cells when analyzing the overa ll results (see Figure 1), and two main patient subsets were then 
identified. The upper cluster included 29 patients, shown as dark red in the first column to the right of 
the cluster (with stronger antiproliferative effects of drugs), and the lower cluster included 40 patients. 
Columns are also shown for patient subsets identified from clustering based upon inhibitors influencing 
glucose metabolism (from Figure 3A), and clustering based upon cytokine dependent proliferation after 
treatment with all metabolic inhibitors (data from Figure S2) and overall survival. 





3.5. A proteomic comparison of patient samples showing either generally strong or weak 
antiproliferative effects after treatment with metabolic inhibitors  
We did a proteomic analysis of AML cells derived from six patients with a generally strong 
antiproliferative effect after treatment with five metabolic inhibitors (Figure 3B, six patients in 
the upper cluster of 29 patients), versus eight patients that showed either no or little effect of 
treatment (Figure 3B, lower cluster). Forty-nine proteins showed a significant difference 
between the two groups (Welch’s t-test, p < 0.05) and thirty-one of these also had a significant 
fold change (p < 0.05) (Table S3 and S4). Among these, the largest group of proteins belonged 
to the classification Metabolism (19 proteins, including 4 mitochondrial proteins) and/or were 
involved in transcriptional regulation (9 proteins). We also did a functional network analysis 
(STRING database v. 11.0) based on the 49 proteins that showed a significant difference only 
based on the Welch’s t-test (Table S5). We then identified 17 proteins that interacted with other 
significant proteins, where the majority of proteins were involved in the formation of a network 
of 12 proteins that are important for regulation of autophagy/metabolism and/or transcription 
(Figure S6). Although this proteomic data and analyses should be interpreted with great care 
because few patients were included, they support that antiproliferative effects of metabolic 
inhibitors is influenced especially by the metabolic context (i.e. different expression of proteins 
involved in cellular metabolism) of the AML cells and in addition also by their transcriptional 
regulation.  
3.6. A comparison of global gene expression profiles for AML samples that differ in their 
general susceptibility toward metabolic inhibitors  
Our proteomic analysis suggested that differences in the susceptibility to the metabolic 
inhibitors are associated with differences in metabolism and transcriptional regulation. We 
therefore compared the global gene expression profiles for 21 consecutive patients, eight 
patients with strong antiproliferative effects after drug treatment (Figure 3B; upper subcluster 
of 29 patients) and 13 with intermediate/low antiproliferative effects (Figure 3B; lower 
subcluster of 40 patients). We performed a feature subset selection (FSS) analysis and by 
selecting genes with an R-score > ±3.5, we identified 265 differentially expressed genes, 133 
upregulated in the intermediate/low antiproliferative subset and 132 upregulated in the high 
antiproliferative subset. We then performed a hierarchical cluster analysis that clearly separated 
the two patient subsets (Figure S3). We thereafter performed gene ontology (GO) mapping 
using the PANTHER analytic tool based on the 265 upregulated genes. Among the categories 




two patient subsets. Genes belonging to transcription factors and involved in metabolic 
processes seem to be upregulated in the intermediate/low antiproliferative subset (cluster BI, 
Figure S3), while genes belonging to different enzyme systems (hydrolase, oxido reductase and 
transferase) and nucleic acid binding as well as cellular processes were upregulated in the subset 
with strong antiproliferative effects after drug treatment (cluster AII, Figure S3). 
   In addition, an extended molecular genetic analysis was available for 35 unselected patients 
(Figure S4). Most mutations had expected low frequencies [34], and for most mutations, there 
were too few patients to do any significant comparisons. For those mutations detected in more 
than five patients (i.e. FLT3, NPM1, TET2 and DNMT3A) we found no significant associations 
with the five metabolic inhibitors that showed significant overall effects on AML cell 
proliferation (i.e. percent inhibition after drug treatment compared with controls), nor did we 
see any significant associations with mutational class or the number of mutations per patient. 
3.8. Metabolic inhibitors decrease AML cell viability through proapoptotic effects  
For 78 of the 81 patients, AML cell viability was analyzed after 48 hours of culture with or 
without treatment with metabolic inhibitors. The highest concentrations of drugs, which were 
also tested in the proliferation assay, were tested in the apoptosis flow cytometric assay, i.e. 
metformin 2.5 mM, 2DG 0.6 mM, 6AN 100 µM, BPTES 20 µM, ST1326 50 µM, lonidamine 
300 µM and AZD3965 200 nM (Figure 4 A and B). The gating strategy to define viable, early 
apoptotic and late apoptotic/necrotic cells is illustrated for a representative sample in Figure S5. 
Of the 78 patients analyzed, six of the patients showed less than 5% viable cells in medium 
(untreated) controls and were excluded from the statistical analyses. The leukemic cell viability 
after 48 hours of culture showed a wide variation between patients, the median viability for 
untreated controls was 58% (range 14.6-89.1%), and the median viability ranged from 39.4% 
after treatment with 2DG to 58.6% after treatment with AZD3965. All drugs except AZD3965 
decreased AML cell viability compared to untreated controls for a significant majority of 
patients (Wilcoxon signed rank test, p-value < 0.05) (Figure 4A). The percentage of apoptotic 
cells was generally relatively low after 48 hours of drug treatment; still, apoptosis was 
significantly increased by all drugs compared to untreated controls except for lonidamine and 
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Figure 4. Effects of metabolic drugs on AML cell viability and apoptosis. AML cells derived from 
78 consecutive patients were cultured for 2 days in suspension cultures in medium supplemented with 
cytokines with or without metabolic inhibitors, before the percentage of viable and apoptotic cells were 
determined by flow cytometry using the AnnexinV/PI apoptosis assay. 72 patients had more than 5 % 
viable cells in untreated controls and were used in the statistical analysis. The percentage of A) viable 
and B) early apoptotic cells (median percentage, 25/75 percentiles, 5/95 percentile whiskers) is shown 
for all 72 patients. Significant effects of drug treatment compared to untreated controls are shown. 
(Wilcoxon signed rank test, * p-value < 0.05, *** p-value < 0.0001; ns, not significant).  
 
 
   Effects of metabolic inhibitors on the viability of UCB-derived mononuclear cells were also 
analyzed by flow cytometry after 48 hours of treatment with metformin 2.5 mM, 2DG 0.6 mM, 
ST1326 50 µM, BPTES 20 µM, AZD3965 200 nM and lonidamine 300 µM. The UCB cells 
from five donors were generally less sensitive towards all the metabolic drugs, with at least 





3.9. Identification of patient subsets based on AML cell viability after treatment with metabolic 
inhibitors  
To further study the patient heterogeneity, we did a hierarchical cluster analysis based on AML 
cell viability after treatment with or without drugs normalized to the corresponding median 
level (Figure 5A). We could then identify three patient subsets; an upper patient subset with a 
low cell viability (i.e. less than the median) both for untreated and treated cultures, patients in 
the lower cluster showed higher viability (i.e. higher than the median) after treatment with most 
drugs, while the middle cluster showed variable effects. Thus, the variation between patients 
with regard to spontaneous in vitro apoptosis is largely maintained in the presence of drugs 
targeting metabolic pathways. 
   We next did an unsupervised hierarchical cluster analysis based on the relative effect of the 
metabolic inhibitors on viability, i.e. percent cell viability in cultures treated with metabolic 
drugs, compared to control cultures (cells in medium alone) and the clustering analysis then 
identified two clusters (Figure 5B). The upper 24 patients in this analysis formed a separate 
cluster characterized by decreased viability (more apoptotic cells) after treatment with 
metabolic inhibitors and also a relatively strong spontaneous in vitro apoptosis in control 
cultures. When comparing the viability after drug treatment for the two patient clusters, less 
viable cells were seen after treatment with 2DG (p = 0.0005) and 6AN (p = 0.015) for the upper 
cluster of 24 patients (Table S6). Furthermore, the cluster with the strongest proapoptotic effect 
after drug treatment did not differ with respect to cause of AML (secondary versus de novo), 
AML cell differentiation, karyotype, FLT3-ITD or NPM1 mutations. Finally, we could not 
detect any correlations between the antiproliferative and proapoptotic effects of individual 






Figure 5. Unsupervised hierarchical cluster analysis based on the effects of metabolic inhibitors 
on AML cell viability. Primary AML cells were grown in suspension cultures in medium supplemented 
with exogenous growth factors. The cells were treated with metformin 2.5 mM, 2DG 0.6 mM, 6AN 100 
µM, BPTES 20 µM, ST1326 50 µM, lonidamine 300 µM and AZD3965 200 nM or untreated controls 
(medium alone) before effects on cell viability were determined using the AnnexinV/PI flow cytometric 
assay. A) Cluster analysis based on the viability of primary AML cells after treatment with 
metabolic inhibitors. The analysis is based on the percentage of viable cells in cultures after 48 hours 
with or without drug treatment. The data obtained from the 72 patient samples were normalized to the 
corresponding median level (median set as 1.0). Patients could then be divided into three main subsets; 
one upper subset showing low viability, one subset with intermediate viability, and one subset with 
generally high viability after drug treatment. These subsets are shown in the column to the right of the 
figure, also with a column showing the degree of AML cytokine-dependent cell proliferation (based on 
Figure S2) and the effect of metabolic inhibitors on cell proliferation (based on Figure 3B), as well as 
biological and clinical characteristics for the individual patients (i.e. FAB-classification, karyotype, 
etiology, CD34 expression, FLT3-ITD and NPM1 mutations). B) Cluster analysis based on the 
relative viability of AML cells after treatment with metabolic inhibitors for 48 hours. The analysis 
is based on the relative effect of metabolic inhibitors on AML cell viability after 48 hours treatment, i.e. 
the cell viability in cultures treated with drugs relative to the viability in control cultures (untreated 
cultures, set to 100%). The 72 patients could be divided into two main subsets; one upper patient subset 
showing reduced viability (shown in dark red) and one with intermediate/low effects on viability (light 
red) after drug treatment. The subsets are indicated in the column to the right of the figure, along with a 
column showing drug effects on AML cell viability normalized to median levels (based on Figure 5A), 
and the classification of younger patients receiving intensive chemotherapy as survivors or nonsurvivors 




3.10. Effects of metabolic inhibitors on the constitutive release of soluble mediators by 
primary AML cells 
We analyzed the concentration of 19 soluble mediators in culture supernatants collected after 
48 hours in vitro culture of AML cells derived from 72 patients. The release profiles varied 
considerably between patients, however based on these profiles, patients could be clustered into 
three main subsets using hierarchical cluster analysis (Figure S8). Still, no significant 
associations were found between the release of mediators and the effect of drugs on 
proliferation (Figure 3B) or viability (Figure 5B). Furthermore, the metabolic inhibitors had 
divergent effects on the release of soluble mediators (Figure 6A) that were relatively small 
compared with the large variations between individual patients that were maintained in the 




Figure 6. The effects of metabolic inhibitors on the constitutive release of soluble mediators by 
primary human AML cells. Primary AML cells from 72 patients were cultured for 48 hours with and 
without drug treatment before the concentrations of 19 soluble mediators were determined in 
supernatants using multiplex analysis. Concentration of drugs were: metformin 2.5 mM, 2DG 0.6 mM, 
6AN 100 µM, BPTES 20 µM, ST1326 50 µM, lonidamine 300 µM and AZD3965 200 nM. A) Overall 
effects of metabolic inhibitors on the release of soluble mediators by AML cells. Mediator levels 
measured in drug-treated cultures were compared to concentrations in untreated control cultures. 
Increased levels after drug treatment are shown in red, while decreased levels are shown in blue. 
Significant changes are indicated by the colors (p < 0.05 light color, p < 0.001 dark color, Wilcoxon 
signed rank test). B) Changes in the constitutive release of soluble mediators by metformin, 2DG 
and 6AN. Mediator concentrations measured in cultures after 48-hour drug treatment (white boxes) and 
untreated control cultures (grey boxes) are presented, with the median levels, 25/75 percentiles (boxes), 








3.11. 2DG has an antiproliferative effect on AML cells even in the presence of AML-supporting 
MSCs 
2DG was the metabolic inhibitor with the strongest antiproliferative or proapoptotic effect when 
analyzing the overall results (Figure 1 and Figure 4). Using the [3H]-thymidine incorporation 
assay, we therefore investigated whether 2DG (0.6 mM) also inhibited AML cell proliferation 
in the presence of normal MSCs when the different cell types were separated by a 
semipermeable membrane with no direct contact. Primary AML cells derived from 18 
unselected patients were tested, while only 14 patients showed detectable AML cell 
proliferation in the medium controls. Proliferation decreased after treatment with 2DG for the 
majority of patients even in the presence of MSCs (Figure 7A). Furthermore, MSC proliferation 
was also decreased after 2DG treatment of cocultures (Figure 7A), though 2DG had a stronger 
antiproliferative effect on AML cells than on MSCs (Mann-Whitney U-test, p = 0.0016). The 
constitutive release of soluble mediators was also measured in cocultures with and without 
treatment with 2DG. Only minor changes in the concentrations of soluble mediators were found 
in drug-treated cocultures compared to untreated cocultures , and overall the mediator release 
profile seemed to remain similar in the absence and presence of the glycolytic inhibitor 2DG 







Figure 7. Cell proliferation and mediator release after in vitro coculture of primary human AML 
cells and normal MSCs after treatment with the glycolytic inhibitor 2DG. Primary AML cells 
derived from 14 patients were cultured together with normal MSCs in transwell cocultures for 3 days, 
before proliferation was assayed using the [3H]-thymidine incorporation assay, and cytokine release was 
determined after 48 hours in supernatants using multiplex analysis. A) Effect of 2DG on cell 
proliferation in MSC-AML cocultures. Proliferation of MSCs and AML cells in 2DG-treated 
cocultures relative to the drug-free control cocultures (shown as stippled line at 100%) was calculated, 
and an antiproliferative effect by 2DG was then observed both for the MSCs (derived from one donor) 
and the AML cells (derived from 14 patients) during coculture. The median proliferation of the MSCs 
and the AML patient cells after treatment is indicated in the figure ( ‒ ). B) The constitutive soluble 
mediator release in cocultures with and without 48-hour treatment with 2DG. The results are 
presented as the median levels, 25/75 percentiles (boxes), 5/95 percentiles (whiskers) and outliers. The 
mediator concentrations (pg/mL) are given on the X-axis as log-values. Grey boxes illustrate mediator 
release measured in untreated cocultures, and white boxes are after treatment with 2DG.  
  
4. Discussion 
Metabolic pathways are dysregulated in different types of cancer, including AML, to meet the 
energetic and biosynthetic demands of cancer cells. A recent study described a prognostic 




number of metabolites, suggesting that a glucose signature had prognostic value [35]. 
Furthermore, glycolytic metabolism at diagnosis was associated with favorable clinical 
outcome in another study [36]. It seems that AML patients are heterogeneous with regard to 
metabolic regulation and its prognostic impact, and targeting of metabolism may be a promising 
therapeutic strategy in AML [4]. In this study, we have investigated the direct in vitro effects 
of metabolic inhibitors targeting main metabolic pathways on the survival and proliferation of 
primary human AML cells, and our results show that patients are heterogeneous with regard to 
direct effects of metabolic inhibitors.  
   We examined primary AML cells from patients with relative and/or absolute high levels of 
circulating AML cells, resulting in highly enriched AML cell populations (>90%) after density 
gradient separation, and our results are thus maybe only representative for this patient subset 
[37, 38]. [39]. However, our patients are representative for AML in general with regard to 
karyotypic abnormalities and molecular genetics [20, 25, 30]. Our methods for cryopreservation 
and thawing are highly standardized, but the cells have decreased viability after thawing, and 
will undergo spontaneous or stress-induced in vitro apoptosis during further culture [24]. 
However, most patient samples will have a viability of approximately 60-70% after thawing 
and may show reduced expression of certain cell surface molecules [40]. Our model to analyze 
effects of metabolic inhibitors on AML cell viability is thus based on a combined effect of 
stress-induced and inhibitor-induced apoptosis. Patient samples with low stress-induced 
apoptosis (i.e. high viability after thawing in control cultures) also had a weak proapoptotic 
effect induced by metabolic inhibitors. Finally, there was no significant association between 
the proapoptotic and antiproliferative effects, though the assays likely evaluate effects of 
metabolic inhibitors on different AML cell populations.  
   We used the [3H]-thymidine incorporation assay for our dose-response studies. [3H]-
thymidine is added after six days and nuclear incorporation is assayed one day later, i.e. we 
investigated the AML cell subset that is able to survive and still proliferate after six/seven days 
of culture. We selected the concentrations to be used based on (i) dose-response curves, (ii) no 
effect of DMSO concentrations (≤ 0.2%) used for dissolving drugs; (iii) previous experimental 
studies and (iv) clinical tolerated doses for those drugs that have so far been used in the clinic 
(Table 1). Metformin, 2DG, 6AN, BPTES and ST1326 all showed significant antiproliferative 
and proapoptotic effects, while lonidamine and AZD3965 only showed effects for a minority 
of patients (Figure 1 and Figure 4).  
   Patients with cytogenetically normal AML have been reported to have a distinct glucose 




having an impact on the clinical prognosis [36]. Glycolytic activity has been reported to be 
involved in the progression of several cancer types, and has also been shown to contribute to 
chemoresistance in patients with AML [41, 42]. Metformin, 2DG and 6AN are drugs that have 
effects on glucose metabolism. 2DG and 6AN directly inhibit glucose metabolism through 
inhibition of glycolysis and PPP, while the main effect of metformin on glucose metabolism is 
through its activation of AMPK, (which switches the cells from an anabolic to a catabolic state, 
inhibiting gluconeogenesis and hepatic glucose output) and through inhibition of OXPHOS. In 
addition, metformin decreases OXPHOS in cancer cells, which can be compensated for by 
increasing their glycolysis [43]. Some studies have shown that leukemic stem cells (LSCs) are 
more dependent on OXPHOS than more mature leukemic cells, and that these cells cannot use 
the glycolytic pathway to compensate for reduced OXPHOS [44]. It has recently been 
demonstrated that Venetoclax, a Bcl2 inhibitor, selectively targets LSCs by inhibiting 
OXPHOS [45]. Thus, LSCs might also be more vulnerable towards metformin. However, 
metformin has also been shown to have a direct inhibitory effect on hexokinase II, thereby 
inhibiting glycolysis [46], and another study showed that the proapoptotic effect of metformin 
is dependent on the glucose levels [47]. Thus, it seems that the antileukemic effects of 
metformin as well as 2DG and 6AN is affected by both extracellular and intracellular glucose 
levels, and will be most efficient on glucose dependent (glycolysis-driven) leukemia cells [47, 
48]. We therefore did an unsupervised hierarchical cluster analysis based on the effect of 
metformin, 2DG and 6AN (Figure 3A) (we left out lonidamine since we saw no significant 
effect of this drug in our patient cohort). This identified a subset of 22 patients with strong 
antiproliferative effects of all three drugs. However, we found no association between this 
subpopulation and any of the well-established risk factors for chemoresistance after 
conventional intensive chemotherapy (i.e. secondary AML, karyotype, FLT3-ITD, NPM1 
mutations, CD34 expression) or long-term AML-free survival. 
   The high metabolic plasticity of AML cells may allow fluctuation between the sources of 
nutrients needed to fuel the TCA cycle. This highly diverse and flexible metabolism of AML 
cells, not only contributes to the aggressiveness of the disease and the high percentage of 
refractory disease, but it can also make metabolic targeting challenging since blocking one 
metabolic pathway can simply make the cells shift to use another pathway instead of inhibiting 
their ability to proliferate. Simultaneously targeting multiple metabolic pathways may therefore 
be an approach to remove their ability to survive under stressful conditions and render them 
vulnerable to therapy. Venetoclax with azacitidine is currently enrolled in an ongoing 




with a CR reported between 61-85% [49]. However, LSCs from relapsed AML patients does 
not seem to have the same dependence on amino acids, as LSCs in these patients seems to be 
able to compensate through increased fatty acid metabolism [50]. Thus, adding the fatty acid 
inhibitor sulfo-N-succinimidyl oleate (SSO) seemed to resensitize the cells to 
venetoclax/azacitidine treatment [50]. These findings highlight the potential in targeting 
multiple metabolic vulnerabilities, as well as highlights the importance of understanding 
metabolic properties of AML cells. To further investigate this, we did a hierarchical cluster 
analyses, identifying a patient subset with high susceptibility to five metabolic inhibitors with 
overall significant effects (Figure 3B, upper 29 patients). This effect was independent of the 
proliferative capacity of the AML cells, the spontaneous or stress-induced in vitro apoptosis 
and the capacity of constitutive cytokine release by the AML cells and showed no association 
with any of the well-established risk factors for chemoresistance after conventional intensive 
chemotherapy or AML-free survival. Thus, the susceptibility to the antiproliferative effects of 
metabolic inhibitors at least partly depend on other cellular/molecular mechanisms than the 
susceptibility to conventional chemotherapy; this is supported by our findings of enhanced 
antiproliferative effects of metabolic inhibitors when tested in combination with AraC. 
Synergistic effects of drugs that target glycolytic activity in combination with 
chemotherapeutics have been considered as a potential therapeutic strategy in AML [51], and 
our data supports the further exploration of this treatment strategy. 
   The two patient subsets identified in our hierarchical cluster analysis of antiproliferative 
effects after treatment with metabolic inhibitors (Figure 3B) did not differ with regard to 
established biological and clinical characteristics associated with survival after intensive 
chemotherapy. We therefore tried to identify other AML cell characteristics associated with the 
antiproliferative effects of metabolic inhibitors. First, our proteomic comparisons suggest that 
the two patient subsets differ in metabolic regulation, and also in transcriptional regulation and 
possibly intracellular trafficking. We would emphasize that these proteomic results should be 
interpreted with great care because few patients were available for these studies. Second, our 
comparison of global gene expression profiles showed that the two patient subsets could be 
identified based on mRNA profiling, and these observations support the proteomic data and 
suggest that susceptibility to metabolic inhibitors is associated with differences in metabolic 
and transcriptional regulation.  
   The metabolic inhibitors decreased primary AML cell viability and had proapoptotic effects, 
and we could identify a subset of patients with increased susceptibility to the inhibitors (Figure 




constitutive release of growth factors by the AML cells, because the effects of the inhibitors on 
the constitutive release were divergent and relatively small compared with the persisting wide 
variation between individual patients.  
   MSCs have a cytokine-mediated supporting effect on AML cell growth and survival during 
in vitro culture [23], and MSCs also localize to the bone marrow in stem cell niches [52]. 2DG 
had a very strong antiproliferative effect for a majority of AML patients, and its antiproliferative 
effect could be maintained even in the presence of the AML-supporting MSCs. In addition, 
2DG also inhibited proliferation of cocultured normal MSCs, which was most likely mediated 
by a direct effect on the MSCs and not an indirect effect mediated by altered cytokine release 
by AML cells as 2DG had relatively weak effects on the constitutive cytokine release and the 
wide variation between patients persisted in the presence of 2DG (Figure 7). The metabolic 
inhibitors also had an antiproliferative effect on UCB cells. However, only one donor of MSCs 
and four UCB donors were tested, so the effects of metabolic inhibitors on normal cells should 
be investigated further, possibly also using CD34+ stem cells. Still, this shows that the 
antiproliferative effects of metabolic inhibitors are not specific to AML cells. AraC is one of 
the most effective drugs used in the treatment of AML, but has serious side effects. As with 
AraC, the maximal tolerated dose of a drug is not necessarily the most effective therapeutic 
dose. Furthermore, it may be more effective to combine chemotherapeutics with other drug 
candidates such as metabolic inhibitors, to combat AML.   
 
5. Conclusions 
Our present studies show that in vitro metabolic targeting has anti-leukemic effects for many 
patients; however, patients are heterogeneous with regard to susceptibility to such targeting. 
Metabolic targeting, in particular targeting of the glycolytic pathway and OXPHOS should be 
further investigated as a treatment strategy for AML. A future focus should include further 
characterization of patient heterogeneity and finding optimal concentrations and combinations 
of metabolic inhibitors, and/or metabolic inhibitors combined with chemotherapeutics. In our 
current study we did not characterize effect of metabolic drugs on LSCs, something that should 
be considered for future studies, to determine whether this therapeutic strategy can be effective 
in defined AML patient subsets.  
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Table S2. A comparison of the two patient subsets identified in the unsupervised hierarchical 
cluster analysis (Figure 3B) based on the antiproliferative effects of five metabolic inhibitors. The 
percent inhibition by each metabolic drug was estimated for each of the 69 patients showing detectable 
proliferation in the [3H]-thymidine incorporation assay (i.e. 7 days of suspension cultures). Hierarchical 
clustering was done based on the percent inhibition by metabolic drugs, and we then identified two 
clusters (Figure 3B), where the upper cluster included 29 patients that showed a strong antiproliferative 
effect towards drugs. We compared the effect of metabolic inhibitors for these two clusters (Figure 2). 
The table shows (from left to right); the inhibitor tested, the median relative proliferation (proliferation 
in drug-treated cultures relative to drug-free controls) and the p-value (Mann-Whitney U-test). 
Differences were regarded as statistically significant when p ≤ 0.05 (no corrections were made for the 
number of comparisons, significant p-values marked in bold).   
 
Inhibitor 
Cluster ( i.e. anti-
proliferative effect) 
Number of patients 
in each group 
Median proliferation, 
drug-treated cultures relative to 
the corresponding drug-free controls 
p-value 
 Metformin 
Weak effect 40 63.96  
Strong effect 29 48.57 0.024 
 2DG 
Weak effect 40 61.64  
Strong effect 29 12.25 0.000 
 6AN 
Weak effect 40 78.89  
Strong effect 29 26.47 0.000 
BPTES 
 
Weak effect 40 70.90  
Strong effect 29 47.18 0.003 
ST1326 
 
Weak effect 31 52.35  




Table S3. Proteomic comparison of primary AML cells derived from patients where AML cell 
proliferation is either strongly inhibited by metabolic inhibitors (6 patients) or AML cells show 
no or minimal antiproliferative effects by metabolic inhibitors (8 patients) (Figure 3B). The 
analysis identified 31 differentially expressed proteins, and the table shows a functional classification 
of the individual proteins (for a detailed description see Table S5). Some of the proteins are included in 
more than one functional class.  
 
Functional classification 
INCREASED in subset 
susceptible to metabolic 
inhibitors (18 proteins) 
DECREASED in subset 
susceptible to metabolic 
inhibitors (13 proteins) 
Metabolism (n=15)   
Protein/proteinases/molecular 
degradation/amino acid 
PRTN3, CFD, THEM6, HM13,  UBXN7, QRICH1, DDAH2, 
ISOC1 
Lipid SGPL1, AGPS  
Energy FDXR DDAH2, ISOC1, ACO1 
Detoxification SQRDL  
   
Mitochondria (n=4) SQRDL, FDXR DDAH2, ACO1 
   
Transcription, RNA (n=9) RNASE3, RNASE 2, SRPK1, 
ASCC3 
RFX1;RFX2, QRICH1, 
SMNDC1, GRWD1, ACO1 
   
DNA damage (n=2) ASCC3 GRWD1 
   
Cell cycle regulation, 
cytoskeleton (n=3) 
 NAE1, MAPRE2, MPP1 
   
Intracellular signaling (n=8) BST1, IL1RAP PIP4K2A, MPP1 
G protein coupled receptor SGPL1, CD97 RAPIGAP2 
Kinase/phosphatase SRPK1  
   
Intracellular transport, Golgi, 
endoplasmatic reticulum, 
microtubule (n=3) 
TMEM214, HM13,  MAPRE2 
   
Cell membrane, adhesion, 
migration (n=6) 
BST1, HLA-B, CD97, IL1RAP, 
CPNE2,  
MPP1 
   
Apoptosis (n=1) TMEM214  
   
Cancer association (n=7) BST1, CD97 RFX1, MAPRE2, GRWD1, 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S6. Identification of two patient subsets based on AML cell viability after treatment with 
metabolic inhibitors; a comparison of the two subsets identified in the unsupervised hierarchical 
cluster analysis (Figure 5B). The cell viability percentage was estimated for each of the 72 patients 
after treatment with each metabolic drug (48-hour treatment). Hierarchical clustering was done based 
on the percent reduction of viability, and then two clusters were identified; with the lower cluster of 48 
patients showing more viable cells (a weaker proapoptotic effect) after drug treatment while the upper 
cluster including 24 patients had a stronger reduction of viability after drug treatment (strong apoptotic 
effect). We compared the median viability found after drug treatment for these two patient clusters 
separately (Figure 5B). The table shows (from left to right) the inhibitor tested, the median relative 
viability (viability in drug-treated cultures relative to the drug-free controls) and the p-value (Mann-
Whitney U-test). Differences were regarded as statistically significant when p ≤ 0.05 (no correction for 
the number of comparisons, significant p-values marked in bold).   
 
 
Median viability (%), for drug-treated cultures 





effect (24 patients) 
Lower cluster 
Weak proapoptotic 
effect (48 patients)  
p-value 
Metformin 
95.85 92.55 0.076 
2DG 90.28 57.86 0.000 
6AN 
93.88 85.13 0.013 
BPTES 
96.52 94.55 0.202 
ST1326 
94.50 91.92 0.761 
Lonidamine 
90.55 89.28 0.515 
AZD3965 
99.57 99.68 0.662 
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UCB (n = 4)
AML (n = 17)
6AN (µM)






































































Figure S1. Initial screening of seven metabolic inhibitors; effects on proliferation of primary 
human AML cells and umbilical cord blood (UCB) mononuclear cells. The [3H]-thymidine 
incorporation assay was used to assess the effect of metabolic inhibitors on AML cell proliferation after 
7 days of treatment. Primary AML cells derived from 17 patients (solid line, filled circles) and umbilical 
cord blood (UCB) cells derived from four donors (stippled line, open squares) were tested. The drug 
concentrations are shown on the x-axis, while the y-axis shows percent proliferation compared to drug 
free controls (set as 100%). The drug-response of AML patient samples and UCB samples are presented 





Figure S2. Hierarchical cluster analysis based on AML cell proliferation in cultures with and 
without treatment of metabolic inhibitors. Proliferation was tested using the [3H]-thymidine 
incorporation assay, and the unsupervised hierarchical cluster analysis was based on effects of all 
metabolic inhibitors and drug concentrations. The proliferative responses for each inhibitor were 
normalized to the corresponding median before analysis. The metabolic inhibitors and the 
concentrations tested are shown at the top of the figure. We identified three main patient subsets: an 
upper subset generally showing low proliferation in all cultures compared to other patients (light grey), 
a lower subset showing generally high cytokine-dependent proliferation (dark grey color), and a large 






Figure S3. A comparison of global gene expression profiles for AML samples showing a strong 
antiproliferative effect towards metabolic inhibitors (based upon Figure 3B, upper cluster) versus 
no or minimal antiproliferative effect (based upon Figure 3B, lower cluster). We compared the 
global gene expression profiles that were available for 21 unselected AML patients; eight of these 
patients had strong antiproliferative effects by metabolic inhibitors (based on cluster Figure 3B), while 
13 patients had weaker antiproliferative or no effects (based on cluster Figure 3B). A feature subset 
selection (FSS) analysis based on R-score > ± 3.5 was performed and identified 265 differentially 
expressed (upregulated) genes. We further performed a hierarchical cluster analysis that separated both 
the genes (I and II) and the patients (A and B) into two separate subclusters, subcluster BI (weak 
antiproliferative effects after treatment with metabolic inhibitors) and subcluster AII (strong 
antiproliferative effects after treatment with metabolic inhbitors). Based on the identified upregulated 
genes, we performed gene ontology (GO) mapping based on the PANTHER database. By use of the 
categories Protein class and Biological process, we found several ontologies to be overrepresented in 















Gender  Male FAB  M0-2 Cytogenetics  Favorable 
Number of 
mutations 




  Female   M4-6   Intermediate   ≥ 3   High 
        Unfavorable      Missing values 
Age  ≥75 CD34  Positive >20%   Mutations  wt    
  <75   Negative <20%     Present    
           Not determined    
Figure S4. AML associated molecular genetics for 35 unselected patients, a summary of the overall 
results. 
The mutations are listed to the left in the figure, each column represent one patient and the presence of 
mutations is shown in red. Molecular genetics were analyzed for 35 patients, and as shown in the bottom 
row (drug effect), these patients included 13 patients with a generally strong antiproliferative effect 
toward the metabolic inhibitors (based on Figure 3B, upper cluster of 29 patients), while 17 patients 
showed a weaker antiproliferative effect (see Figure 3B) and the five last patients did not have detectable 
cytokine-dependent proliferation (> 1000 cpm). Patient gender, age, FAB classification, CD34 
expression and cytogenetics for each patient is shown at the top. A considerable heterogeneity can be 










































Figure S5. Flow cytometric analysis of AML cell viability; fraction of viable, apoptotic and late 
apoptotic/necrotic AML cells in control and metabolic inhibitor-treated cultures. These plots show 
the gating strategy used to define the percentage of viable, apoptotic and late apoptotic/necrotic cells, 
illustrated for one representative patient sample. The cells were incubated with medium alone (upper 
left panel, control), or treated with metabolic drugs for 48 hours. Cell viability, necrosis and apoptosis 
were measured by flow cytometry using the ApoptestTM–FITC kit and 10,000 events collected and 










Figure S6. Antiproliferative and proapoptotic effects of metabolic inhibitors on primary human 
AML cells. We investigated whether the proapoptotic and antiproliferative effects of the various 
inhibitors showed significant correlations. The correlation plots show the percent alteration of cytokine-
dependent proliferation (Y-axis) versus the percent alteration of AML cell viability (X-axis) for each 
drug treatment. Thus, both proliferation and viability are presented as percent (%) alteration after 
treatment with drugs compared with drug-free control cultures. Kendall`s τ test was used for correlation 
analyses. The strength of the associations is presented as Kendall`s τ (-1 = 100% negative association, 
1 = 100 % positive correlation), and the significance of correlation is presented as p-values (significant 
p-value < 0.05). Only 2DG and lonidamine showed a significant, but weak, correlation between 

























Kendall`s  = 0.066
P-value = 0.448
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Figure S7. Viability of UCB cells after 48-hours treatment with metabolic inhibitors compared to 
untreated controls. UCB mononuclear cells were cultured for 48 hours in suspension cultures in 
StemSpan medium supplemented with cytokines with or without metabolic inhibitors. The fraction of 
viable cells was then determined using the flow cytometric AnnexinV/PI assay. The percentage of viable 
cells for each UCB donor sample (after treatment relative to untreated controls) is shown for each drug 

















Figure S8. Unsupervised hierarchical cluster analysis of the constitutive release of soluble 
mediators by primary AML cells derived from 72 unselected patients.  The constitutive mediator 
release during 48 hours of in vitro culture was determined for 19 soluble mediators. The concentrations 
were normalized to the corresponding median before analysis. Low release of mediators is shown in 
blue, while green indicates higher release. Three patient subsets could be identified based on this 
analysis, indicated by the red column to the right of the cluster: an upper subset showing generally low 
release of cytokines, a lower subset with a high release of cytokines and a relatively large group of 
patients showing intermediate/divergent release. Antiproliferative and proapoptotic effects after 
treatment with metabolic inhibitors showed no association with the capacity of constitutive mediator 
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Abstract 
Autophagy is a highly conserved cellular degradation process that prevents cell damage and 
promotes cell survival, and autophagy inhibition is considered as a therapeutic strategy in 
cancer. Chloroquine (CQ) is a well-known antimalarial agent that inhibits late-stage autophagy. 
We evaluated the effects of CQ on cell viability and proliferation of AML cells derived from 
81 AML patients. Our results show that CQ decreased AML cell viability and proliferation for 
the majority of patients. Furthermore, a subgroup of AML patients showed a greater 
susceptibility to CQ, and using hierarchical cluster analysis, we identified 99 genes upregulated 
in this patient subgroup, including several genes related to leukemogenesis. Combination of 
CQ with low dose AraC had an additive inhibitory effect on AML cell proliferation. 
Furthermore, a small subset of patients had little or no effect of AraC, but still showed strong 
antiproliferative effect of CQ.  Using two leukemia cell lines, HL60 and MOLM-13, we further 
investigated the expression of reactive oxygen species (ROS), autophagic flux, apoptosis and 
cell cycle distribution after treatment with CQ, also in combination with the metabolic drugs 
metformin and 2DG. We observed a decrease in cell viability and a slight proapoptotic effect 
after treatment with CQ in both cell lines. None of the drugs had any effect on ROS levels. CQ 
did not alter the cell cycle distribution, however, metformin resulted in accumulation of HL60 
cells in G1 phase, which was further increased when combined with CQ treatment. Our results 
show that CQ inhibits autophagy in both AML cell lines, though responses varied, and both 
metformin and 2DG seem to further inhibit autophagy when used in combination with CQ. In 
summary, CQ has anti-leukemic activity and should further be investigated as a therapeutic 




Acute myeloid leukemia (AML) is the most common acute leukemia in adults. It is an 
aggressive malignancy characterized by accumulation of immature leukemic cells in the bone 
marrow [1]. Current treatment of AML relies largely on intensive chemotherapy, potentially 
followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), and this is the only 
curative treatment of the disease. However, the median age at diagnosis is 65-70 years, and 
patients >70 years have a dismal outcome with less than 5% long-term AML-free survival, as 
many elderly patients cannot tolerate this intensive therapy [2, 3]. The long-term AML-free 
survival is only 35-40 % even for younger patients who can tolerate the most intensive 
conventional chemotherapy [1]. Although advances in treatment have significantly improved 
outcome in younger patients, there is still a strong need for new effective agents, or efficient 
combinations of agents, with a less toxic effect, to treat AML, also including patients unable to 
tolerate intensive treatment [4]. 
   Targeting of autophagy is a therapeutic strategy being considered for treatment of cancer [5], 
including AML [6, 7]. Autophagy is a cellular recycle mechanism where cells digest their own 
cytoplasmic components; damaged proteins and organelles are thereby eliminated, and cellular 
homeostasis is maintained. The autophagic process can be tumor suppressive through removal 
of damaged organelles or oncogenic substrates [8, 9], but it can also contribute to carcinogenesis 
by providing energy and maintaining metabolism for cancer cells under stressful conditions 
[10], and sustain growth and survival when cancer cells are challenged by cytotoxic therapies 
[11]. Given its essential role in cell growth and survival, autophagy is therefore investigated as 
a target for therapeutic intervention.  
   Chloroquine (CQ) is a clinically available drug, that is shown to inhibit the last stage of 
autophagy. The drug was initially discovered and used to treat malaria, for which it has obtained 
approval from the Food and Drug Administration (FDA). These last decades, CQ has further 
been widely tested for its anti-cancer activity against a variety of cancer types [12]. The precise 
anti-cancer mechanism of CQ remains unclear, however, scientific reports suggest that the 
autophagy-specific mechanism of action of CQ is at least partially responsible, though other 
molecular mechanisms independent of autophagy may also contribute [13]. CQ inhibits 
autophagy by raising lysosomal pH that leads to inhibition of the fusion of autophagosomes 
with lysosomes, disrupting the lysosomal protein degradation [14]. CQ and its derivate 
hydroxychloroquine (HCQ) are currently the only FDA-approved drugs that also are 
autophagy-inhibitors, and they are therefore the main agents that have been tested in the clinic 
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to treat cancer through inhibition of autophagy. There are multiple ongoing clinical trials with 
these drugs alone or in combination with other anticancer agents [5, 15]. In addition, CQ has 
been shown to have an effect on chemosensitization of cancer cells, independent of its 
autophagy-dependent anticancer effects [16, 17]. 
   In this study, we aimed to evaluate the anti-leukemic effects of CQ, in particular effects on 
proliferation, survival and soluble mediator release of primary AML cells derived from a large 
group of consecutive AML patients. We also tested the anti-leukemic effects of CQ in 
combination with the chemotherapeutic agent Ara-C, and investigated whether we could 
identify a subset of patients that might benefit from treatment with CQ. Finally, we examined 
the effects of combining CQ with the glycolytic inhibitor 2-Deoxy-D-Glucose (2-DG) and the 
anti-diabetic drug metformin on AML cells. 
 
2. MATERIAL AND METHODS 
2.1 Preparation of primary AML cells  
   The study was conducted after approval by the Regional Ethics Committee (REK) III 060.02, 
(100602), REK Vest 2013-634 (190313), REK Vest 2015/1410 (190615) and samples collected 
after written informed consent from all patients. The characteristics of AML patients are shown 
in Table 1. Patients with the FAB M3 subtype of AML were excluded. Peripheral blood 
mononuclear cells were isolated from patients with at least 80% AML cells among circulating 
leukocytes. Leukemia cell preparation was performed using density gradient separation (density 
1.077 g/ml; Lymphoprep, Serumwerk Bernburg AG for Alere Technologies AS, Oslo, 
Norway), resulting in cell populations with >90% leukemia cells for all patients, where 
contaminating cells were mainly small lymphocytes [18-20]. The isolated AML blasts were 
immediately cryopreserved in RPMI 1640 medium (Sigma-Aldrich, St. Louis, Missouri, US) 
with 10% dimethylsulfoxide and 20% inactivated fetal calf serum (Biowest, Riverside, MO, 
US). Cells were stored in liquid nitrogen until the cryopreserved cells were thawed, counted 
and used directly in the experimental studies. 
2.2 Normal primary cells 
   Umbilical cord blood (UCB) cells were obtained from five donors after written informed 
consent (REK Vest 2015/1759 (051115), 2017/305 (070417)). Mononuclear cells were 
enriched in a similar manner to AML cell populations, by using density gradient separation, 
and stored in liquid nitrogen until used in experiments. 
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   Cryopreserved human primary mesenchymal stem cells (MSCs) the bone marrow of a healthy 
donor (MSC24539, 24-year old female Caucasian) were purchased from Lonza in passage two 
(Cambrex BioScience, Walkersville, MD, US) and were expanded in complete MSC growth 
medium (MSCGM™; Lonza) with 10% inactivated fetal bovine serum (Biowest, Riverside, 
MO, US) and 4 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, US).  
2.3 AML cell lines 
   The human AML cell lines, HL60 and MOLM-13, were maintained in RPMI-1640 medium 
(Sigma-Aldrich, St. Louis, MO, US), supplemented with Streptomycin-Penicillin (50 μg/mL), 
2mM L-glutamine (Sigma-Aldrich, St. Louis, MO, US) and 10% heat-inactivated fetal calf 
serum (Biowest, Riverside, MO, US), which was used in all experiments with cell lines. Both 
cell lines were mycoplasma negative (tested using MycoAlert™ detection kit, Lonza) and short-
tandem repeat (STR) profiling was used to confirm the identity of cells (American Type Culture 
Collection (ATCC) cell line authentication service, Virginia, US; 100% exact match of HL60 
to ATCC, and 100% exact match of MOLM-13 to Deutsche Sammlung von Mikroorganismen 
und Zellkulturen, (DSMZ)). HL60 cell line is a myeloblastic AML M2 subtype and has a 
biallelic deletion of the TP53 gene [21], and carries amplified MYC. MOLM-13 is a monocytic 
M5 subtype leukemia cell line expressing an internal tandem duplication (ITD) of FLT3, both 
a mutated and wild-type allele, with no activation of FLT3 protein [22] and also carries the 
MLL-AF9 fusion protein [23].  
2.4 AML and UCB cell culture medium  
   Serum-free Stem Span SFEM™ medium (Stem Cell Technologies, Vancouver, BC, Canada) 
supplemented with exogenous granulocyte-colony stimulating factor (G-CSF), stem cell factor 
(SCF) and fms-related tyrosine kinase 3 ligand (FLT3-L) was used in all cell culture 
experiments with patient AML cells except coculture studies (described below), and also in 
experiments with UCBs. All three cytokines were purchased from Peprotech (Rocky Hill, NJ, 
US) and used at a final concentration of 20 ng/mL. 
2.5 Reagents 
   Stock solutions of CQ (C6628), metformin hydrochloride (PHR1084) and 2-Deoxy-D-
Glucose (154-17-6) were purchased from Sigma-Aldrich (St. Louis, MO, US), while cytarabine 
(Ara-C) was obtained from Pfizer (NY, US). All drugs were prepared according to datasheets 
provided from the distributors. Stock solutions were sterile-filtered (0.22 µm) and stored in 
small aliquots at -20°C until used. Aliquots were thawed only once and diluted with their 
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respective solvents to obtain the desired final concentrations. The concentration of solvents 
alone did not affect cell proliferation nor viability. 
2.6 In vitro culture studies of primary cells  
   Suspension cultures of AML cells alone. Cells were seeded in triplicates (1 x 106 /ml, 200 μl 
medium/well) in flat-bottomed 96-well microtiter plates (Nucleon™; Nunc, Roskilde, 
Denmark), and cultures were then incubated with or without drugs in StemSpan medium 
supplemented with exogenous cytokines. AML cell proliferation was investigated using a [3H]-
thymidine incorporation assay [24]. After 6 days of incubation at 37ºC in a humidified 
atmosphere of 5% CO2, 20 μL of 37 kBq [
3H]-thymidine (TRA 310, Amersham, UK) in saline 
was added per well, and nuclear incorporation was determined 22 hours later. For each drug 
concentration, the effect on proliferation was calculated by comparing cell proliferation (cpm 
values) as the percentage of untreated cultures. The median of triplicate cultures was used for 
all calculations, and detectable incorporation was defined as >1000 counts per minute (cpm).     
   Cocultures of AML cells and primary mesenchymal stem cells (MSCs).  The MSCs were 
trypsinated and used in cocultures in passage four. Cocultures were prepared as described 
previously [25], by adding MSCs to the lower chamber and AML cells to the upper chamber of 
transwell plates (Costar 3401; 0.4 µm pore size, Costar, Cambridge, MA, US) in complete MSC 
medium, thus allowing no direct MSC-AML cell contact. Cocultures were incubated for 2 days 
with or without 5 µM CQ before 280 kBq/well [3H]-thymidine was added, and proliferation of 
MSCs and AML cells after 3-day coculture was determined as described in detail previously 
[26]. For cocultures, the median value of three samples derived from the same transwell culture 
was used in all calculations. 
   Analysis of cytokine levels in culture and coculture supernatants. AML cells were cultured 
for 48 hours in cytokine-supplemented Stem Span SFEM™ medium (1 x 106 /ml, 1 ml per well) 
in 24-well culture plates (Nucleon™; Nunc) with or without 5 µM CQ. Supernatants were 
collected and stored at -80°C. In addition, cell culture supernatants were harvested from MSC-
AML cocultures (prepared in MSC medium) with or without 5 µM CQ for two days.  
Subsequently, 19 mediators were analyzed by Luminex® bead-based multiplex assays strictly 
according to the distributors protocol (LXSAHM-17, R&D Systems; Minnesota, MN, US).    
2.6 RNA preparation, labeling and microarray hybridisation 
   All microarray experiments were performed using the Illumina iScan Reader, which is based 
upon fluorescence detection of biotin-labeled cRNA. 300 ng of total RNA from each sample 
was reversely transcribed, amplified and Biotin-16-UTP–labeled, using the Illumina® 
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TotalPrep™ RNA amplification kit (Applied Biosystems/Ambion, CA, US). Amount and 
quality of the biotin-labeled cRNA was controlled by both NanoDrop® spectrophotometer 
(NanoDrop Technologies, Inc. Delaware, US) and Agilent 2100 Bioanalyzer (Agilent 
Technonlogies, Inc. CA, US). 750 ng of biotin-labeled cRNA was hybridized to the HumanHT-
12 V4 Expression BeadChip according to manufacturer’s instructions. The HumanHT-12 V4 
BeadChip targets 47,231 probes derived primarily from genes in the NCBI RefSeq database 
(Release 38). The data from the scanning of arrays on Illumina iScan Reader was investigated 
in GenomeStudio (Illumina Inc. CA, US) and J-Express 2012 (MolMine AS, Bergen, Norway) 
for quality control measures [27]. Before being compiled into an expression profile data matrix, 
all arrays within each experiment were quantile normalized to be comparable. We used the 
analysis of variance (ANOVA), and by setting an F-score >1.0 and a fold change (FC) value 
>1.0, we identified genes differently expressed between the two patient populations. The genes 
encoding proteins with a known function were classified using the PANTHER (protein 
annotation through evolutionary relationship) classification system (version 14.0) [28]. 
2.7 Flow cytometric analyses of cell viability and cell cycle progression 
   Cell viability analysis. The percentage of viable, apoptotic and necrotic primary AML cells 
were determined by flow cytometry using the ApoptestTM–FITC kit (NeXins Research, 
Kattendijke, the Netherlands) as previously described [29].  AML cell lines, HL60 and MOLM-
13, were analysed using the Pacific Blue™ AnnexinV apoptosis detection kit with propidium 
iodide (PI) (BioLegend®, San Diego, CA, US). Cell lines were analysed in accordance with the 
manufacturer’s instructions. Briefly, cells were seeded in medium at 106 cells/ml in flat-
bottomed 24-well plates (Nucleon™, Nunc, Roskilde, Denmark), and different concentrations 
of CQ were added cultures, or CQ in combination with either metformin or 2DG at different 
concentrations. Cells cultured in medium alone were used as controls. After 24 and 48 hours of 
incubation (37ºC, humidified atmosphere of 5% CO2), cells were analysed using a BD 
FACSVerse 8-color flow cytometer (BD Biosciences; Franklin Lakes, NJ, US). Doublets    were 
excluded by gating forward scatter (FSC) height and FSC-area, and side scatter (SSC)-height 
and SSC-area. 10,000 events were collected for each sample. 
   Cell cycle analysis. HL60 and MOLM-13 cells were seeded in medium at 106 cells/ml in flat-
bottomed 24-well plates and treated with drugs for 24 and 48 hours before cells were harvested, 
washed with ice-cold phosphate-buffered saline (PBS) and then fixated in 70% ethanol. The 
cells were thereafter stored at -20ºC until analysed by flow cytometry. On the day of analysis, 
the cells were washed twice with PBS, and re-suspended in PBS containing 100 µg/mL RNaseA 
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(Sigma Aldrich) and 50 µg/ PI. The cells were incubated for 30 minutes at 37ºC in the dark 
before being analysed using a BD FACSVerse 8-color flow cytometer (BD Biosciences), and 
10,000 events were collected for each sample using low acquisition flow rate. 
2.8 Flow cytometric analysis of reactive oxygen species (ROS)  
   HL60 and MOLM-13 cells were seeded into 24-wells plates (Nucleon™; Nunc) and incubated 
for 6 hours in the presence or absence of drugs; this incubation time was based on pilot studies 
performed to optimize the assay. The CellROX® Green flow cytometry assay kit (Invitrogen 
by Thermo Fisher Scientific, Eugene, OR, US) was used to measure levels of ROS. The 
CellROX® assay kit is specifically formulated for flow cytometry, where the cell-permeable 
CellROX® Green reagent stains the cell nucleus and mitochondria. It is essentially non-
florescent while in reduced state, but exhibits a strong fluorogenic signaling upon oxidation, 
providing a reliable measure of ROS generation in live cells. Three controls were included in 
all experiments; (i) cells incubated in medium alone, (ii) cells cultured with tert-Butyl 
hydroperoxide (TBHP) (final concentration 300 µM) as a positive control, and (iii) cells 
cultured with N-acetylcystein (NAC) (final concentration 10 mM) as a negative control. The 
assay was performed strictly in accordance with the manufacturer’s instruction, and analysed 
using a BD FACSVerse 8-color flow cytometer (BD Biosciences). For each sample, 10,000 
events were collected. 
2.9 Flow cytometric assay for detection of autophagy 
   HL60 and MOLM-13 cell lines were seeded at 106 cells/ml in 24-well plates (Nucleon™; 
Nunc) for 18 hours with or without drugs before the level of autophagy was measured using the 
CytoID® autophagy detection kit (ENZO Life Sciences, Farmingdale, NY, US). The assay was 
performed strictly in accordance with the manufacturer’s instructions. After incubation, cells 
were harvested and washed in PBS before being resuspended in 250 µL of diluted CytoID® 
stain solution and incubated for 30 minutes at room temperature in the dark. The cells were 
thereafter pelleted, washed with assay buffer, then resuspended in fresh assay buffer and finally 
analyzed by flow cytometry. Rapamycin 0.5 µM was included as a positive control (autophagy 
inducer) in all experiments, CQ 60 µM was added as an inhibitor of autophagy. Vesicles 
produced during autophagy become brightly fluorescent after staining with CytoID, and the dye 
allows for minimal staining of lysosomes while exhibiting bright fluorescence upon 
incorporation into autophagic compartments.  
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2.10 Statistical analysis 
   Mann-Whitney U, Wilcoxon signed rank test and Kruskal-Wallis H-test with Dunn´s post hoc 
test, and Fisher´s exact test were used for statistical comparisons of AML patient cells, and 
paired t-test and ANOVA with Dunnett´s or Tukey post hoc test for cell lines. ANOVA, using 
F-score >1.0 and a fold change (FC) value >1.0, was used to identify genes, in our gene 
expression analysis. Analysis and graphical presentations were done using IBM Statistical 
Package for the Social Sciences® (SPSS®) v.23.0 (IBM SPSS statistics Inc., Chicago, IL, US) 
and GraphPad® prism version software v.5.02 (Graph Pad Software, Inc., San Diego, CA, US). 
The flow cytometry data was analyzed using FlowJo™ v.10.3 software (Tree Star, Inc., 
Ashland, OR, US). Differences were regarded as significant when p < 0.05. 
 
3 RESULTS 
3.1 Initial in vitro screening study of CQ on the proliferation of AML primary cells and 
UCB mononuclear cells 
   Initial studies to evaluate the effects of various concentrations of the drug CQ (2.5 µM - 100 
µM) were conducted using the [3H]-thymidine assay for AML cells derived from 17 patients 
and UCB cells derived from 5 donors, though only 4 UCB donors had detectable proliferation 
in untreated controls. CQ had dose-dependent antiproliferative effects both for primary AML 
cells and UCB cells, although the sensitivity towards drugs varied considerably between AML 
patients at the lowest concentrations of 2.5 µM and 5 µM (Supplementary Figure 1). None of 
the AML patient cells showed any proliferation after treatment with 50 µM CQ or higher 
concentrations (Supplementary Figure 1).  
3.2 AML cell proliferation is inhibited by CQ alone and in combination with AraC 
   We expanded our initial study and investigated the effects of CQ alone (2.5 and 5 µM) on 
AML cell proliferation for 81 patients, using the [3H]-thymidine incorporation assay. The two 
lowest concentrations (2.5 and 5 µM) were chosen for further assays, to characterize patient 
heterogeneity and also to be able to test CQ in combination with Ara-C. Detectable cell 
proliferation (>1000 cpm) was observed in drug free controls (cells cultured in medium alone) 
for 69 patients, and further statistical analysis was therefore based on the results for these 
patients. A highly significant antiproliferative effect of CQ was observed with both 
concentrations of CQ compared to untreated control cultures (p-value < 0.0001, Mann Whitney 
U-test; Figure 1). As expected, AraC (0.0125 µM) also had a significant inhibitory effect on 
AML cell proliferation compared to untreated controls (Figure 1). However, the effect of AraC 
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was not significantly different from any of the CQ concentrations tested alone when comparing 
overall effects on all patients (Kruskal Wallis test, Dunn´s post hoc test; Figure 1). Furthermore, 
we combined CQ (2.5 and 5 µM) with AraC (0.0125 µM), and both concentrations of CQ in 
combination with AraC 0.0125 µM showed an additive effect compared to CQ or AraC alone 
(p-value < 0.05, Kruskal Wallis test, Dunn´s post hoc test; Figure 1). 
3.3 CQ inhibits AML cell proliferation in cocultures with MSCs 
We further investigated the antiproliferative effect of CQ on AML cells when AML cells were 
cocultured in the presence of normal MSCs. Cocultures allowed no direct cell contact between 
AML cells and MSCs, and the [3H]-thymidine incorporation assay was used to measure 
proliferation of cells in cocultures after incubation with or without 5 µM CQ for three days. Of 
the 18 AML patients tested, 14 showed detectable AML cell proliferation in untreated controls 
(cpm >1000). MSCs increased AML cell proliferation for the majority of patients (data not 
shown). Still, AML cell proliferation was decreased after treatment with 5 µM CQ in cocultures 
for the majority of AML patients (p-value = 0.017, Wilcoxon signed rank test) (Supplementary 
Figure 2). CQ also inhibited MSC proliferation and the antiproliferative effect was stronger for 
the MSCs (derived from one donor) than for the AML cells (Supplementary Figure 2). 
3.4 An antiproliferative effect of CQ is detected for most patients and even for patients 
insensitive to cytarabine 
   We performed an unsupervised hierarchical cluster analysis where we compared the AML 
cell proliferation (i.e. normalized to the median cpm value for each group) after cells had been 
cultured in medium alone, in the presence of CQ or after combined treatment with CQ and AraC 
for 7 days. In this analysis we only included the 69 patients demonstrating detectable 
proliferation (>1000 cpm) in untreated control cultures. We could then detect three patient 
subsets: a small subset with generally low proliferation in untreated cultures as well as in drug-
treated cultures (upper blue subcluster, light gray column, Figure 2A), a larger subset with 
generally strong proliferation in both treated and untreated cultures (bottom green subcluster, 
shown as a dark gray column, Figure 2A), and an intermediate subset with diverse proliferation 
in both untreated and drug-treated cultures (middle subcluster, shown as a gray column, Figure 
2A).  
   Next, we performed an unsupervised hierarchical clustering analysis based on the relative 
proliferation of the drug-treated cell cultures, i.e. the proliferation in drug-treated cultures (CQ 
or AraC) relative to the proliferation in the control cultures prepared in medium alone after 
seven days of culture (Figure 2B). Patients showed a varied response to drug treatment. Effects 
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on cell proliferation after treatment with both CQ (5 µM) and AraC (0.0125 µM) alone ranged 
from 0 - 99% inhibition, with a median inhibitory value of 83.4% and 57.9% compared to 
control cultures, respectively. Sixty-two of the 69 patients treated with CQ 5 µM, and 58 of the 
69 patients treated with CQ 2.5 µM demonstrated an antiproliferative effect (> 20% inhibition 
compared to untreated controls), whereas the last nine patients had no or minor effects of both 
drugs (Figure 2B, lower patient sub-cluster). However, we also identified a subset of patients 
that were sensitive towards CQ (strong antiproliferative effect), although no or low inhibitory 
effects on cell proliferation were seen after treatment with AraC (Figure 2B, the upper 16 
patients).  
   The antiproliferative effect of CQ showed no significant associations with age, cause of AML 
(de novo versus secondary), morphological signs of differentiation (FAB classification), 
expression of the stem cell marker CD34, karyotype, or FLT3-ITD or NPM1 mutations (data 
not shown). 
3.5 The AML antiproliferative effect of CQ is associated with a distinct gene expression 
profile 
   Based on the antiproliferative effects of 2.5 µM CQ we created a heat map, which sorted the 
patients according to the antiproliferative effects of CQ on AML cell proliferation compared to 
control cultures. The heat map indicates a strong antiproliferative effect to the right (high 
sensitivity to CQ) and patients with the lowest antiproliferative effect of CQ to the left (low 
sensitivity to CQ) (Figure 3, upper part). Next, we divided the patient cohort into four quartiles, 
and compared gene expression profiling (GEP) data from the lowest and highest quartiles; i.e. 
patient with strong antiproliferative effects and patients with low or no antiproliferative effects 
of CQ (Figure 3, upper part). GEP data was available for six patients with high sensitivity to 
CQ, and 11 patients with low sensitivity to CQ treatment (marked in boxes).  Based on ANOVA 
(F-score >1.0 and FC value >1.0), we identified 99 genes upregulated among patients with high 
sensitivity (Supplementary Table 1). Among the 99 identified genes, several have previously 
been linked to AML leukemogenesis, and the full list with references to AML involvement is 
presented in Supplementary Table 1. Furthermore, we did an unsupervised hierarchical cluster 
analysis that illustrates the upregulated genes in the group of patients with the highest or lowest 
sensitivity to CQ. Finally, we used the PANTHER classification system to further classify the 
upregulated genes, and we then selected the category molecular function, which included 
catalytic activity and binding as the largest subterms within this category (Figure 3, lower part). 
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We further identified single genes belonging to these subterms (Figure 3, lower part and 
Supplementary Table 1). 
3.6 Treatment with CQ significantly decreased primary AML cell viability and increased 
apoptosis and necrosis  
   Primary cells derived from 78 of the 81 consecutive AML patients were cultured with or 
without CQ 5 µM for 48 hours before the percentages of viable, early apoptotic and late 
apoptotic/necrotic cells were determined by flow cytometry. Six patients showed less than 5% 
viable cells in untreated controls and were excluded from the statistical analyses. There was a 
wide variation between patients with regard to the percentage of viable (AnnexinV-PI-) cells in 
drug-free control cultures, with only a slight decrease in overall viability after treatment with 
CQ (median 55.7%, range 5.9-89.1%) and the CQ-treated cultures (median 52.0%, range 4.8-
88.9%) (Figure 4A). The percentage of early apoptotic cells (AnnexinV+PI-) was generally low 
for both treated and untreated cultures, with a slight increase in apoptosis after CQ-treatment 
(Figure 4A). When comparing samples pairwise, there was a small but statistically significant 
decrease in the percentage of viable cells after CQ treatment (p-value < 0.0001, Wilcoxon 
signed rank test) and an increase om the percentage of early apoptotic cells (p-value = 0.0008, 
Wilcoxon signed rank test). The effect of 5 µm CQ on AML cell viability was relatively weak, 
certain exceptional patients showed a small increase in the percentage of viable AML cells, and 
patients with a high viability in untreated control cultures generally showed the highest viability 
also in the presence of the drug (Figure 4B, p-value = 0.0001, Wilcoxon signed rank test). 
Finally, neither the AML cell viability in control cultures nor the effect of CQ on AML cell 
viability (i.e. increased versus decreased viability compared to median) showed significant 
associations with age, cause of AML (de novo versus secondary), morphological signs of 
differentiation (FAB classification), expression of CD34, karyotype, FLT3-ITD or NPM1 
mutations (data not shown).  
3.7 CQ alters the constitutive release of only a few soluble mediators by primary human 
AML cells  
   The effect of CQ on the constitutive soluble mediator release by primary AML cells after 48 
hours of culture was investigated for the same 72 patients tested in the viability assay. No 
significant changes were found between mediator levels when comparing overall results, but 
when comparing pairwise samples (untreated versus CQ-treated), a significant effect of CQ on 
the release of mediators was observed for four mediators, MMP9, MMP2, cystatin-C and CCL2 
(Supplementary Figure 3; p-value < 0.05, Wilcoxon signed rank test). 
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   Furthermore, we performed a hierarchical cluster analysis that identified a subset of 18 
patients where treatment with CQ generally increased the mediator levels, whereas CQ had 
divergent effects for the other patients with unaltered or decreased levels after CQ treatment for 
most mediators and patients (Figure 5). The three main subsets identified in the cluster analysis 
showed no significant differences with regard to age, cause of AML (de novo versus secondary), 
morphological signs of differentiation (FAB classification), expression of CD34, karyotype, 
FLT3-ITD or NPM1 mutations (data not shown).  
3.8 High CQ-mediated soluble mediator release shows a gene expression profile associated 
with genes involved in metabolic processes 
   Gene expression profiling (GEP) data was available for a total of 33 patients that were 
examined for their release of soluble mediators after CQ treatment. Nine of these 33 patients 
belong to the previously identified group of patients with high CQ-mediated mediator release, 
while the remaining 24 belong to the group of patients with intermediate or low cytokine release 
(Figure 5). Using ANOVA (F-score >1.0 and FC value >1.0) we identified 74 genes upregulated 
among patients with high CQ-mediated mediator release (Supplementary Table 2). We 
investigated if these genes were able to separate the two patient groups by performing a 
hierarchical cluster analysis. Only two of the nine patients with high CQ-mediated mediator 
release clustered outside the identified subcluster including patients with high CQ-mediated 
mediator release (p-value = 0.001, Fisher´s exact test) (Supplementary Figure 4). Among the 
74 genes that were upregulated among patients with high CQ-mediated release of mediators 
were several genes encoding proteins found to be involved in AML pathogenesis. All genes are 
presented in Supplementary Table 2. To investigate a broader biological context of the 
upregulated genes, we used the PANTHER classification system to further classify these genes. 
The four most frequent subterms were metabolic process, cellular process, localization and 
response to stimulus when using the main category biological process. We further identified 
single genes belonging to these subterms, which included genes known for involvement in 
AML leukemogenesis, noteworthy, SNX2, FLT3, PFKP and CCL23 (Supplementary Figure 4, 
Supplementary table 2). 
3.9 Effects of CQ alone or in combination with 2DG or metformin on cell viability, 
apoptosis and cell cycle of AML cell lines 
   We investigated the effects of CQ (5-40 µM) on the viability of HL60 and MOLM-13 cell 
lines using flow cytometry. Treatment with CQ alone for 24 or 48 hours did not significantly 
alter the cell viability of HL60 nor MOLM-13, even at the highest concentration of 40 μM 
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compared to untreated controls (Figure 6; data shown for 48 hours’ treatment). Both cell lines 
were also treated with CQ in combination with two other metabolic inhibitors (2DG and 
metformin). 2DG alone (0.6-4.8 mM) had only minor effects on cell viability except for the 
highest concentration, where 4.8 mM 2DG decreased cell viability for both HL60 and for 
MOLM-13 (changes were not significant compared to untreated controls, Figure 6, upper part 
of figure), and CQ did not have any additional effects on cell viability when combined with 
2DG (Figure 6). In contrast, treatment with metformin alone caused a significant and dose-
dependent decrease in viability of HL60 cells, with an additive effect in combination with CQ 
(Figure 6, lower part of figure); though metformin showed a less effect on the viability of 
MOLM-13 cells, which was not additionally decreased by combination with CQ (Figure 6). 
The ability of CQ, 2DG and metformin to induce apoptosis in cell lines was also examined. The 
drugs, in particular CQ seemed to induce apoptosis in MOLM13 cells with higher 
concentrations, and metformin increased apoptosis in HL60 and MOLM13 cells, though none 
of these differences were statistical significant. (Supplementary Figure 5).  
   We also examined cell cycle phase distribution following treatment of cell lines with CQ 
alone or when CQ was combined with 2DG or metformin. Both cell lines had rapid cell growth; 
the doubling time for HL60 and MOLM-13 was approximately 24 hours and 48 hours, 
respectively, during our culture conditions. For HL60 cells, cell cycle phase distribution did not 
differ after treatment with any drug, alone or in combination, after 24 hours’ treatment; 
however, after 48 hours’ drug-treatment, a significant accumulation of cells in S phase was seen 
after treatment of HL60 cells with metformin alone and also when metformin was combined 
with CQ (Figure 7C, one-way ANOVA with Dunnett`s multiple comparison test, p < 0.05). The 
G2/M phase of HL60 cells was also significantly decreased after treatment with metformin, 2-
DG, and the combination of CQ with metformin, and also CQ combined with 2-DG (one-way 
ANOVA with Dunnett`s Multiple Comparison Test, p < 0.05). For MOLM-13 cells, the cell 
cycle phase distribution was not altered after treatment with drugs for 24 or 48 hours (Figure 
7E and 7F). A slight increase in the number of cells in fraction sub G1 was seen both after 24 
and 48 hours of treatment with CQ (data not shown), and representative figures of the 
distribution of cell cycle phases are shown in Supplementary Figure 6. 
3.10 Effects of CQ on levels of reactive oxygen species and autophagy 
   We investigated the effect of CQ (5 µM, 10 µM, 20 µM), metformin (2.5 mM, 5 mM, 10 
mM) and 2DG (0.6 mM, 2.4 mM, 4.8 mM) on the generation of ROS in both cell lines during 
6 hours of in vitro culture. This time interval was based on pilot experiments investigating 
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different time intervals (data not shown), however, none of the drugs had any significant effects 
on cellular levels of ROS (Supplementary Figure 7).  
   We used a flowcytometric-based method to detect autophagy in cells. CQ is a well-known 
inhibitor of late-stage autophagy [30-32], and treatment with CQ resulted in a significant 
accumulation of lysosomal vesicles in a dose-dependent manner for both HL60 and MOLM-13 
(p-values < 0.05), although MOLM-13 seems to have a higher autophagic flux than HL60 (one-
way ANOVA, with Dunnett´s multiple comparison test) (Figure 8A). Both metformin and 2DG 
caused a further dose-dependent inhibition of autophagy in combination with CQ, though 
changes were not statistically significant (Figure 8B and C).  
 
4. DISCUSSION 
   Today, the main treatment for AML consists primarily of intensive chemotherapy followed 
by consolidation therapy or allo-HSCT. However, a large portion of adults with AML, mostly 
older adults, is not given the standard intensive chemotherapy due to treatment-related toxicity 
and comorbidities [4]. There is a strong need for new effective agents, or efficient combinations 
of agents, to treat AML including those patients unable to tolerate intensive treatment. 
Repurposing of antimalarials as inhibitors of autophagy to treat cancer is gaining immense 
interest, in particular in combination with other therapies [33]. This may also become a potential 
therapy in AML [34], and we therefore investigated the potential of chloroquine as an anti-
leukemic drug.  
   CQ has been reported to arrest the last step of autophagy i.e. fusion of autophagosomes with 
lysosomes, and lysosomal protein degradation (Supplementary Figure 8), thus it inhibits 
autophagy mainly by targeting the lysosomes [35]. As far as we know, this is the first study to 
investigate effects of CQ on a relative large group of consecutive AML patients. First, we tested 
the effect of CQ over a wide concentration-range of the drug on leukemia cells derived from 17 
AML patients and mononuclear UCB cells from four individuals. CQ had an inhibitory effect 
on proliferation for all patients, and based on these experiments we selected the concentrations 
used in further experiments with primary AML cells. The inhibitory effect of CQ on cell 
proliferation was not specific for AML cells; the drug had a similar effect for all umbilical cord 
cell donors. Although CQ is FDA-approved and considered well-tolerated as an antimalarial 
drug, higher doses of CQ can be toxic and hematological effects have been reported, including 
leukopenia and agranulocytosis [36]; and future studies of CQ in AML therapy should 
investigate the toxicity of this treatment carefully. We further evaluated CQ on cells derived 
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from 81 AML patients, and found that CQ inhibited cell proliferation for the majority of AML 
patients, though with a wide variation between patients. 
   To assess the efficacy and clinical relevancy of CQ against blasts, we used concentrations 
within the clinical recommendations for patients treated with CQ over longer periods (250-500 
mg CQ, with reported plasma levels of 2.5 – 12.5 uM), as is common for inflammatory and 
dermatologic conditions [37, 38]. In addition, we tested higher concentrations that are closer to 
what is seen in patients’ plasma during treatment of malaria (ranging from an area under the 
curve (AUC) of 8.2-140 µg/mL, equivalent to 25-440 µM over three days) [39]. In this study, 
we also examined the anti-leukemic effects of CQ combined with the metabolic drugs 
metformin and 2DG. With regard to metformin, serum levels obtained at clinical doses are 
highly dependent on kidney function [40]. When metformin accumulates in the plasma due to 
kidney failure, toxic plasma concentrations over > 5 mg/L can be seen, and is found when 
metformin is implicated as cause of lactic acidosis [41]. This may be  challenging when trying 
to transfer results from in vitro studies, which commonly use higher doses  (including our 
current study), to in vivo studies [42-46]. For 2DG, the concentrations used in our present study 
correspond to plasma concentrations that are found tolerable in clinical studies [47]. The same 
applies for cytarabine, were the concentrations tested on AML blasts in our present experiments 
correspond to the serum concentrations reached during low-dose subcutaneous cytarabine 
therapy [48].  Thus, the drug concentrations used in our experimental studies are likely within 
clinical relevant concentrations, though several factors can influence drug concentrations 
tolerated in humans [49]. 
   For our proliferation studies, we used a seven-day [3H]-thymidine incorporation assay, i.e. 
the cells were cultured for six days before [3H]-thymidine was added for additional 24 hours 
and then cell proliferation was assessed. During the first six days of in vitro culture of blasts, 
an increasing spontaneous or stress-induced apoptosis is generally observed [29]. Thus, our 
[3H]-thymidine incorporation assay reflects the characteristics of the minor subset of cells that 
are able to survive and still proliferate after seven days of in vitro culture. Our results showed 
that CQ had a significant and dose-dependent effect on AML cell proliferation for a large 
majority of patients, though the inhibitory effect varied between patients and was absent for a 
small minority. In addition, CQ had an additive antiproliferative effect on leukemia cells when 
tested together with cytarabine. These results are supported by the literature, were several 
studies have shown that both leukemic stem cells (LSCs) and leukemic blasts can utilize 
autophagy to counteract chemotherapeutic-induced stress, and that blocking autophagy can 
enhance sensitivity to standard chemotherapy, thus killing cancer cells [34]. As expected, 
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cytarabine also had an antiproliferative effect for a majority of patients, however, the 
antiproliferative effect of CQ could be detected also for a few patients who showed no effect of 
low-dose cytarabine. Furthermore, CQ decreased AML cell viability partly through induction 
of apoptosis, but this effect showed no significant association with the antiproliferative effect 
of the drug. 
   In the present study we included a consecutive group of AML patients with relatively high 
percentage of AML cells among circulating leukocytes, thus there is a selection of patients only 
based on the degree of leukemization, and our results may therefore be representative only for 
this subset of patients with peripheral blood leukemization. Differences may also be present 
between samples taken from bone marrow and peripheral blood, however, a previous study 
reported that no significant difference in autophagy flux was shown between AML cells derived 
from bone marrow compared to peripheral blood [50]. However, it is plausible that the effect 
of CQ, as a lysosomal inhibitor, may depend on the autophagic activity of AML cells. A study 
by Folkerts et al. [50] showed that the basal levels of autophagy vary among leukemic cell lines 
and also in human CD34+ leukemia cells, with a large variability between AML patients. In 
this study, higher levels of genes related to autophagy were found in AML patients classified 
as poor risk (complex karyotype) and they also had a higher autophagic flux; though no 
differences in autophagy levels were seen in AML samples harboring prognostic mutations. In 
our study, we did not observe any associations between the effect of CQ and mutational status 
of AMLs, nor were effects of CQ associated with karyotype or changes of gene involved in 
autophagy when comparing gene expression profiles of patients with strong antiproliferative 
effects towards CQ with low or none antiproliferative effects of CQ; however some reports 
have shown anti-leukemic effects of CQ which seem to be independent of its autophagy-
inhibitory mechanisms [13, 35]. 
   We investigated the effect of CQ on the constitutive extracellular release of soluble mediators 
by AML cells, and found significantly decreased levels only for MMP-2, MMP-9, Cystatin C 
and increased levels of CCL2 when comparing samples pairwise with and without CQ 
treatment. CQ has been reported in other studies to affect the matrix metalloproteinase network  
[51] and may also induce expression of chemokines through NF-kappaB activation [52]. 
However, the mediator levels showed no significant differences between treated and untreated 
cultures when comparing overall results; this may possibly be explained by the finding of a 
subset of patients with generally increased release of soluble mediators after treatment with CQ, 
while another subset showed decreased or no alteration of soluble mediator release after CQ 
treatment. To investigate the effect of CQ on the release of soluble mediators further, we 
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examined the global gene expression profiles for 33 of the patients included in this study, nine 
of which showed a generally higher mediator release after CQ treatment, while the others had 
decreased or no changes in mediator levels. Among the identified genes upregulated in the 
subset with increased levels of mediator were several genes known for involvement in AML 
leukemogenesis, SNX2, FLT3, PFKP and CCL23. Furthermore, CQ also altered the release of 
soluble mediators after coculture of AML cells with mesenchymal stromal cells (MSCs). We 
have previously shown that MSCs can support the growth and survival of AML cells through a 
cytokine-mediated crosstalk  between AML cells and MSCs [25], and effects of CQ on the 
release of soluble mediators by the leukemia-supporting nonleukemic stromal cells may 
possibly further influence the direct anti-leukemic effects of CQ on the leukemic cells [29].  
   Other metabolic inhibitors such as the AMPK inhibitor metformin and the inhibitor of 
glycolysis 2DG have been shown to have anti-leukemic effects that are increased by 
combination therapy [42, 43, 53-56], and in addition a recent clinical trial with metformin and 
CQ was described for glioblastoma, implying a potential role for IDH1/2 mutations with regard 
to sensitivity towards CQ [57],  and for this reason we also investigated the anti-leukemic effect 
of combining these two metabolic inhibitors with CQ. These experiments were performed using 
two AML cell lines, which then avoids the influence of spontaneous or stress-induced apoptosis 
that occurs during in vitro culture of primary human AML cells [29]. CQ increased the 
accumulation of lysosomal vesicles in both MOLM-13 and HL60 in a dose-dependent manner. 
Furthermore, the autophagic activity decreased after combination treatment with 2DG and 
metformin. One of the most important activators of autophagy is glucose deprivation that leads 
to activation of the unfolded protein response (UPR) and thereby autophagy. Metformin inhibits 
mTOR indirectly through inhibition of AMPK; an effect that one would expect to increase 
autophagy. However, our results for both cell lines showed that metformin decreased autophagy 
(Figure 8B and 8C). Decreased autophagy together with increased apoptosis after exposure to 
metformin, has also been described in myeloma cells through suppressed induction of the 
critical UPR effector glucose-regulated protein 87 (GRP78) [46]. Another experimental study 
confirmed that metformin could be an autophagy inhibitor through this mechanism [45]. 
Furthermore, 2DG inhibits glucose metabolism through inhibition of hexokinase, the first and 
rate limiting step of glycolysis, and thereby induces autophagy [58]. In contrast, our present 
results showed that 2DG decreased autophagy in the presence of CQ. Furthermore, a previous 
study of prostate cancer cells described a synergistic anti-autophagy effect of 2DG when 




   In conclusion, our study shows that CQ has anti-leukemic activity, and recent findings that 
other mechanisms besides CQ`s autophagy-inhibitory effect can explain the anti-cancer 
activities of CQ necessitate a further investigation of this drug as an anti-cancer agent. Therapy 
utilizing CQ in combination therapy should be evaluated further as a strategy for the treatment 
of AML.  
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LEGENDS TO FIGURES 
Figure 1.  
   Effect of chloroquine, alone or in combination with AraC, on cytokine-dependent AML cell 
proliferation. AML cells from 81 consecutive patients were cultured for seven days in medium alone 
(control cultures), or treated with CQ (2.5 µM and 5 µM), AraC (0.0125 µM) or CQ in combination 
with AraC. The [3H]–thymidine assay was used to measure cell proliferation. Detectable proliferation 
defined as >1000 cpm in untreated control cultures, was observed for 69 patients. Proliferation is shown 
as the median levels (with 25-75% percentiles) for patients, and proliferation in treated cultures is shown 
as percent proliferation of the drug-free controls (set to 100%). Significant effects were calculated using 
Mann-Whitney U-test for comparison to untreated controls (shown as asterisks directly above bars), and 
Kruskal Wallis with Dunn´s post hoc test for comparison between the different groups (asterisks above 
brackets) (ns = not significant, * p-value = 0.05, *** p-value = 0.0001).  
 
Figure 2.  
   An unsupervised hierarchical cluster analysis based on the effect of CQ and AraC on AML cell 
proliferation.  AML cells from 81 consecutive patients were cultured for seven days with CQ (2.5 µM 
and 5 µM), AraC (0.0125 µM), CQ in combination with AraC or medium alone (control). Proliferation 
was investigated using [3H]-thymidine incorporation assay. Detectable proliferation was defined as 
>1000 cpm, and data is presented for the 69 patients with detectable proliferation. A) The cluster 
illustrates the cytokine-dependent AML cell proliferation for the untreated controls and drug-treated 
cultures (CQ or a combination of CQ and AraC) after results were normalized to the corresponding 
median for each group. The cluster could be divided into three main subsets based on the degree of 
proliferation as illustrated in the first column to the right: (i) low proliferation (light gray), (ii) 
intermediate proliferation (gray), and (iii) high proliferation (dark gray). The figure also shows the 
distribution of biological and clinical characteristics for each individual patient (columns on the right 
part of figure). B) The cluster shows the relative AML cell proliferation (i.e. percent proliferation 
compared to untreated controls) for the 69 AML patients after treatment with CQ and AraC. As shown 
in the cluster, the majority of patients had a strong inhibitory effect of CQ, AraC or both drugs (two top 
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subclusters, shown as blue and dark blue in the column to the right) a strong inhibitory effect of CQ, 
AraC or both. A small subcluster of nine patients (bottom subcluster, shown as light blue in the column 
to the right) had little or no effect of these treatments. Shown in different columns to the right of the 
figure are different patient subsets based on clustering of cytokine-dependent proliferation (based on 
Figure 2A), proapoptotic effects, CQ-mediated cytokine release (based on Figure 5), and survivors.   
 
Figure 3.  
   Profiling of gene expression data based on antiproliferative effects of CQ on primary AML cells.  
For 69 AML patients, the proliferation of AML cells after treatment with 2.5 µM CQ was compared to 
the AML cell proliferation of untreated controls. Proliferation was analyzed using the [3H]-thymidine 
incorporation assay, and we used the log2 ratio of the proliferation values to create a heat map (illustrated 
in upper part of figure). Based on this heat map, the patient cohort was further divided into quartiles, 
where the quartile at the far left side of the heat map (shown in red) included patients that had the most 
decreased proliferation after CQ treatment (high sensitivity to CQ), while the quartile to the far right 
(shown in blue) had unaltered or high proliferation after CQ treatment (low sensitivity to CQ). Gene 
expression data for six patients found in the quartile with high sensitivity to CQ was then compared with 
11 patients found in the quartile with low sensitivity to CQ.  Based on ANOVA (F-score >1.0 and FC 
value >1.0), we identified 99 genes upregulated among patients that were highly sensitive to CQ (a 
strong antiproliferative effect), illustrated by the unsupervised hierarchical cluster analysis shown in the 
middle part of the figure. The genes encoding proteins with a known function were classified using the 
PANTHER database, by using the term molecular function we identified the subcategories Catalytic 
activity and Binding as the two most prominent terms among the upregulated genes. Furthermore, we 
identified the three largest subterms belonging to these subcategories, and the figure show the genes 
upregulated in each subterm (see colored circles at bottom of figure). All 99 identified genes are listed 






Figure 4.  
   Effect of 5 µM CQ on primary AML cell viability, apoptosis and necrosis after 48 hours of 
culture. Primary cells from 78 consecutive AML patients were cultured with or without 5 µM CQ for 
48 hours before viability, early apoptosis and late apoptosis/necrosis were determined by flow cytometry 
using the AnnexinV/Propidium iodide (PI) assay. A) The figure shows the overall results for the 72 
patients with more than 5% viable cells in drug-free controls. The percentage of viable (AnnexinV- PI-
), early apoptotic (AnnexinV+ PI-) and end stage apoptotic and necrotic cells (AnnexinV+ PI+) were 
determined in patient samples after treatment with 5 µM CQ (white boxes) and after culture in medium 
alone (gray boxes) for 48 hours. Data is presented as median levels, 25/75 percentiles and 5/95 percentile 
whiskers, • = outliers. The overall effect of CQ on viability/apoptosis/necrosis was not significant 
(Mann-Whitney U-test), but when analyzing samples pairwise, treatment with 5 µM CQ significantly 
decreased viability (p-value < 0.0001), and increased apoptosis and late apoptosis/necrosis (p-values = 
0.0008 and < 0.0001, respectively; Wilcoxon signed rank test). B) The percentage of viable primary 
AML cells cultured in medium alone compared to treatment with 5 µM CQ for 48 hours. A wide range 
of cell viability is seen among patients, with a significant decrease in viability after treatment with 5 µM 
CQ (p-value = 0.0001, Wilcoxon signed rank test).    
 
Figure 5. 
   Unsupervised hierarchical cluster analysis based on alterations in the release of soluble 
mediators by primary AML cells derived from 72 unselected patients after treatment with 5 µM 
CQ for 48 hours. Primary AML cells were cultured with 5 µM CQ or medium alone for 48 hours, 
before the levels of soluble mediators in harvested supernatants were determined using luminex analysis. 
A hierarchical cluster analysis was performed based upon the alteration of soluble mediators compared 
to untreated controls (control set to 100%). The cluster analysis identified three patient subsets: (i) a 
subset with increased release of soluble mediators after treatment with CQ (upper subset, shown as dark 
green in first column to the right), (ii) one intermediate subset, with divergent release of soluble 
mediators (middle subset, shown as turquoise in column to the right), and (iii) a subset of patients with 
decreased release of soluble mediators after treatment with CQ (light turquoise). There is one outlier at 
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the bottom of the cluster with very high cytokine release of all soluble mediators after treatment with 
CQ (marked in dark green).    
 
Figure 6.  
   Effect of CQ combined with the metabolic drugs 2DG and metformin on the viability of AML 
cell lines HL60 and MOLM-13. The cells were treated with CQ (5 µM, 10 µM, 20 µM and 40 µM), 
metformin (2.5 mM, 5 mM, 10 mM and 20 mM), and 2DG (0.6 mM, 1.2 mM, 2.4 mM and 4.8 mM), 
alone and in combination for 48 hours. Cell lines incubated in medium alone were used as drug-free 
controls. Viability was measured using the flow cytometric AnnexinV/PI assay and 10,000 events were 
collected per sample. CQ and 2DG did not significantly alter the viability of cell lines alone or as drug 
combinations when compared to control cultures, however HL60 cells were sensitive to treatment with 
metformin (p-value = 0.015), especially when used in combination with CQ (p-value = 0.002, compared 
to control cultures). The results are shown as mean values (±SD) of three repeated experiments. (* = p-
value < 0.05, ** = p-value < 0.01, *** = p-value < 0.0001; one-way ANOVA, with Tukey's multiple 
comparison posttest).  
 
Figure 7.  
Effect of CQ combined with the metabolic drugs 2DG and metformin on cell cycle distribution of 
HL60 and MOLM-13 cells lines after 24 and 48 hours’ culture. Cell lines were cultured for 24 and 
48 hours in the presence or absence of drugs and cell cycle analysis was performed using flow cytometry. 
Drug concentrations tested were: CQ 40 µM, metformin 20 mM, 2DG 4.8 mM, and CQ 40 µM in 
combination with either metformin 20 mM or 2DG 4.8 mM. A) and D) The histogram plots shows the 
gating used to determine the distribution of cells in sub-G1, G0/G1, S and G2/M phase in HL60 and 
MOLM-13 cell lines, respectively, B) and C) show the cell cycle distribution in HL60 cells while E) 
and F) show the cell cycle distribution in MOLM-13 cells for each drug and drug combination tested 
after 24 and 48 hours culture.  CQ alone did not alter the cell cycle distribution. Only HL60 cells showed 
a significant increase in S-phase when treated with metformin alone for 48 hours, which was also seen 
when cells were treated with metformin in combination with CQ. In addition, a significant decrease of 
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G2/M phase in HL60 cells was seen after treatment with metformin alone and in combination with CQ. 
A significant alteration of the G1 phase and G2/M phase was also seen for HL60 cells treated with CQ 
in combination with 2DG.  The results are shown as mean values (±SD) of three repeated experiments. 
(* = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.0001 (one-way ANOVA, with Dunnett´s 
multiple comparison posttest).  
 
Figure 8.  
Differences in autophagic activity after treatment of HL60 and MOLM-13 cell lines with CQ alone 
or in combination with metabolic drugs. The CytoID® autophagy detection kit for flow cytometry 
was used to detect changes in autophagic activity of HL60 and MOLM-13 cells after treatment with CQ 
alone and in combination with metformin and 2DG for 18 hours. A) Cell lines were treated with different 
concentrations of CQ (2.5-60 µM) (shown on the X-axis) and autophagy measured as fluorescence 
(percent of untreated controls set as 100% on the Y-axis). CQ resulted in a significant accumulation of 
lysosomal vesicles in a dose-dependent manner for MOLM-13 cells, and MOLM-13 seems to have a 
higher autophagic flux than HL60 (* = p-value < 0.05, *** = p-value < 0.0001, one-way ANOVA, with 
Dunnett´s multiple comparison post test). Results are shown as mean values (±SD) of three repeated 
experiments. B) HL60 and MOLM-13 cells were treated with 30 µM CQ in combination with metformin 
at the following concentrations: (1) 2.5 mM, (2) 5 mM, (3) 10 mM and (4) 20 mM, or 2DG at the 
following concentrations: (1) 0.3 mM, (2) 0.6 mM, (3) 1.2 mM and (4) 2.4 mM. Autophagic activity 
decreased in a dose dependent manner after treatment with both metformin and 2DG for both cell lines, 
but there were no significant differences (p-value < 0.05) between untreated controls and cells treated 
with CQ in combination with metformin or 2DG (pairwise t-test). CQ 60 µM in combination with the 
mTOR inhibitor Rapamycin 500 nM was used as positive control in all experiments (upper stippled 
line), and cells cultured in medium alone were used as controls. Results are shown as mean values (±SD) 










Abbreviations: CMML, Chronic myelomonocytic leukemia; FAB, French-American-British; INS, insertion; ITD, internal 
tandem duplication MDS, Myelodysplastic syndrome; nd, not determined; TKD, tyrosine kinase domain; wt, wild type; yrs, 
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Supplementary Figure 1. Initial in vitro drug screening study of chloroquine (CQ) on patient-
derived AML cells and UCB mononuclear cells. Cells were treated with CQ for six days before [3H]-
thymidine was added to cultures for an additional 22 hours of incubation, before proliferation (nuclear 
incorporation) was determined by liquid scintillation counting. A) Leukemic cells derived from 17 AML 
patients were treated with CQ at six different concentrations (2.5 µM, 5 µM, 10 µM, 25 µM, 50 µM and 
100 µM), and B) UCB mononuclear cells from four donors were treated with CQ at five different 
concentrations (2.5 µM, 5 µM, 10 µM, 25 µM and 50 µM). Detectable incorporation was defined as > 
1000 counts per minute (cpm). Results are shown as the percent proliferation of CQ-treated cultures 
compared to the respective untreated control cultures (set to 100%). At lower concentrations (2.5 µM 
and 5 µM) there was a varied sensitivity towards CQ, but at higher concentrations (10 µM - 100 µM) 
all samples showed decreased proliferation compared to untreated controls, * = p-value < 0.05, ** = p-
value < 0.01, *** = p-value < 0.0001, Kruskal-Wallis, Dunn´s post-hoc test. C) The figure shows the 
overall mean cell proliferation with SD, for all 17 AML patients and four UCB donors. There were no 



































Supplementary Figure 2.  The effect of CQ on cell proliferation of primary AML cells and normal 
MSCs grown in coculture. Cocultures of AML cells derived from 14 patients and normal MSCs 
derived from one donor were treated with 5 µM CQ for three days. Proliferation was measured using 
the [3H]-thymidine incorporation assay, and percent proliferation was then determined for both AML 
cells and MSCs in cocultures, with and without CQ-treatment. The results are shown as percent 
proliferation of CQ-treated cocultures compared to untreated cocultures. CQ inhibited proliferation of 





Supplementary Figure 3. Effect of chloroquine treatment on the constitutive release of soluble 
mediators in AML cell cultures and in AML-MSC cocultures. A) Primary AML cells from 72 
patients were incubated for 48 hours with CQ 5 µM or medium alone before supernatants were harvested 
and the concentrations of the soluble mediators were determined. The results are presented as the median 
levels, 25/75 percentiles (box), 5/95 percentiles (whiskers) and outliers, for CQ treated cultures (CQ) 
and untreated cultures (Ctrl). Significant alterations are shown in the figure (Wilcoxon signed rank test). 
B) Primary AML cells derived from 14 patients were cocultured with normal MSCs derived from one 
donor. The cells were cultured together in transwell cocultures, i.e. the two cell types have no direct 
contact. After 48 hours’ incubation with CQ 5 µM or in medium alone, supernatants were harvested and 
the concentrations of the soluble mediators were determined. The results are presented as the median 
levels, 25/75 percentiles (box), 5/95 percentiles (whiskers) and outliers, for CQ treated cocultures (CQ 
- Coculture) and untreated cocultures (Ctrl - Coculture). Significant alterations (p-value <0.05) are 





Supplementary Figure 4. Gene expression profiles associated with levels of soluble mediators 
released by AML cells after CQ treatment. Total gene expression profiling was available for 33 AML 
patients included in the study, and we compared the 24 patients with low/intermediate cytokine release 
after CQ-treatment (Figure 4, the two lower subclusters) with the nine patients showing high cytokine 
release (Figure 4, top subcluster). Using ANOVA, and by setting an F-score >1.0 and a fold change 
(FC) value >1.0, we identified 74 genes differently expressed between the two patient populations. 
These genes were used to perform an unsupervised hierarchical cluster analysis (Euclidean distance 
matrix, with complete linkage), which could discriminate the two patient’s subsets (Upper part). Patients 
with high release of soluble mediators after CQ-treatment are shown in blue, while patients with 
low/intermediate release are shown in green. The genes encoding proteins with a known function were 
classified using the PANTHER database. By using the term biological process, we identified metabolic 
process, cellular process, localization and response to stimulus as the four most frequent subgroups. 
Finally, we searched for GO-terms in these four subgroups and the singles genes for each of these 
subgroups are shown in the colored circles (lower part). 
 
Supplementary Figure 5. Apoptosis in HL60 and MOLM-13 cell lines after treatment with 
increasing concentrations of drugs. Apoptosis was measured by flow cytometry after treatment of cell 
lines for 48 hours with drugs alone (CQ, 2DG or metformin) or drugs in combination (CQ combined 
with either 2DG or metformin). Increasing concentrations (2x) of drugs were tested: (1) CQ 5 µM, 
metformin 2.5 mM and 2DG 0.6 mM, (2) CQ 10 µM, metformin 5 mM and 2DG 1.2 mM, (3) CQ 20 
µM, metformin 10 mM and 2DG 2.4 mM and (4) CQ 40 µM, metformin 20 mM and 2DG 4.8 mM. 
Cells incubated in medium alone were used as drug-free controls (illustrated with stippled line at 100%). 
The flow cytometric Annexin V/PI assay was used to measure apoptotic cells. No significant differences 
were found using statistical analyses (one-way ANOVA, with Dunnett´s multiple comparison posttest), 
but as illustrated in the figure, there was a dose dependent increase in apoptosis after treatment of HL60 
cells with all drugs except CQ, though CQ induced apoptosis in MOLM-13 cells. Data is shown as mean 
values (percent of untreated controls) ±SD, of three repeated experiments.  













































































Supplementary Figure 6.  Cell cycle distribution of cell lines with and without drug treatment. 
Representative results of three repeated experiments, showing the distribution of cells in sub-G1, G1, S 
and G2/M phase in HL60 and MOLM-13 cells treated with CQ (5 µM, 10 µM, 20 µM and 40 µM), 
metformin (2.5 mM, 5 mM, 10 mM and 20 mM), and 2DG (0.6 mM, 1.2 mM, 2.4 mM and 4.8 mM), 
alone and in combination for 48 hours. Cell cycle distribution was analyzed using flow cytometry after 















































































































Supplementary Figure 7. No significant alteration in ROS production in cell lines after treatment 
with CQ, metformin or 2DG, alone or in combination. Levels of ROS were measured in HL60 and 
MOLM-13 cells using the CellROX flow cytometric assay. A) HL60 and B) MOLM-13 cells were 
incubated with CQ 5 µM, metformin 2.5 mM and 2DG 0.6 mM alone and in combination for 6 hours 
before measuring ROS levels. A slight non-significant decrease in ROS production was seen after 
treatment with the metabolic drugs alone for both HL60 and MOLM-13 cells; however, combination of 
drugs did not alter ROS production. Cells treated with TBHP 300 µM were used as a positive control 
(indicated with a stippled line at the top) which greatly induced ROS generation in both cell lines. The 
data are presented as percent of untreated controls (indicated with the lower stippled line), each column 
represents mean of three repeated assays, with SD.  
 
Supplementary Figure 8. Schematic illustration of the main steps of autophagy, including the 
target points for chloroquine, metformin and 2DG. Cytosolic material is sequestered by an expanding 
membrane sac, the phagophore. The phagophore expands into a double membrane vesicle, an 
autophagosome. The outer membrane of the autophagosome subsequently fuses with the lysosome, 
forming an autolysosome, this leads to degradation of the material inside the autophagosomes, as well 
as vesicle degradation. Chloroquine inhibits autophagy by raising the lysosomal pH, prohibiting the 
fusions of autophagosomes with lysosomes and disrupting lysosomal protein degradation. Metformin is 
reported to have conflicted roles in autophagy, it activates AMPK, indirectly inhibiting mTOR and 
activating ULK1. At the same time, it has been shown to directly inhibit ULK1. 2DG triggers glucose 
starvation, activating autophagy through AMPK. However, in contrast, in combination with other 














Supplementary Table 1. The complete list of 99 significantly increased genes (F-score >1.0 and FC value 
>1.0) in patient samples with high sensitivity towards CQ. List is shown in alphabetical order.   
GENE ID FULL NAME POTENTIAL ROLE IN AML 
PUBMED 
ID 
ADA Adenosine deaminase 
High levels of adenosine deaminase are 
associated with unfavourable outcome in 
AML 
7049266 
AHCY Adenosylhomocysteinase    
AK2 Adenylate kinase 2   
APRT Adenine phosphoribosyltransferase   
ARMET/ 
MANF 
Mesencephalic astrocyte derived 
neurotrophic factor 
  
ATP5G1 ATP synthase membrane subunit c locus 1    
C11orf1 Chromosome 11 open reading frame 1   
C5orf15 Chromosome 5 open reading frame 15   
CCDC56/ 
COA3 
Cytochrome c oxidase assembly factor 3   
CCL23 C-C motif chemokine ligand 23 Chemokine involved in leukemogenesis 17339182 
CNST Consortin, connexin sorting protei Connexins are expressed in AML 25529637 
COPB1 COPI coat complex subunit beta 1    
CTSC Cathepsin C   
CWC15 
CWC15 spliceosome associated protein 
homolog 
  
DCTN3 Dynactin subunit 3    
DKC1 Dyskerin pseudouridine synthase 1   
DNTT DNA nucleotidylexotransferase    
DUSP23 Dual specificity phosphatase 23    
EBNA1BP2 EBNA1 binding protein 2   
EBPL EBP like   
FMC1 
Formation of mitochondrial complex V 
assembly factor 1 homolog 
  
GAPT 
GRB2 binding adaptor protein, 
transmembrane  
  
GLO1 Glyoxalase I 
Decrease of glyoxalase I activity is associated 
with differentiation in AML 
3166382 
GNG10 G protein subunit gamma 10   
GNL2 G protein nucleolar 2   
GPR56 G protein-coupled receptor 56 Possible involvment in AML leukemogenesis 27063597 
GSTM1 Glutathione S-transferase mu 1 
Polymorphisms in GSTM1 increase the risk 
of developing AML 
24854448 
GSTM2 Glutathione S-transferase mu 2   
GUCY1A3 Guanylate cyclase 1 soluble subunit alpha 1 
Associated with a leukemic stem cell gene 
signature in AML 
21177505 
HIST1H1C H1.2 linker histone, cluster member   
HSH2D Hematopoietic SH2 domain containing   
HSPA9 
Heat shock protein family A (Hsp70) 
member 9 
HSP70 inhibitors have antileukemic activity 23586877 
HSPD1P5 
Heat shock protein family D (Hsp60) 
member 1 pseudogene 5 
  
IGLL3 
Immunoglobulin lambda like polypeptide 3, 
pseudogene 
  
ITGAE Integrin subunit alpha E   
ITGB1BP1 Integrin subunit beta 1 binding protein 1   
LAT2 
Linker for activation of T cells family 
member 2 
Possibly involved in the t(8;21)((q22;q22)) 
translocation in acute leukemia 
21488857 
LPIN1 Lipin 1    
LYRM1 LYR motif containing 1   
LYSMD2 LysM domain containing 2   
MAGED1 MAGE family member D1 An AML-associated antigen 25092142 
MAP4K1 
Mitogen-activated protein kinase kinase 
kinase kinase 1 
High expression of MAP4K1 has been 
associated to poor prognosis in AML 
31522654 
MIR155HG MIR155 host gene 
miR-155 has potentail negative prognostic 
impact in AML 
23650424 
MRPL21 Mitochondrial ribosomal protein L21   
MRPL24 Mitochondrial ribosomal protein L24   
MRPL36 Mitochondrial ribosomal protein L36    
MRPL45 Mitochondrial ribosomal protein L45   
MRPL54 Mitochondrial ribosomal protein L54    
NDUFA13 








NADH:ubiquinone oxidoreductase subunit 
B6 
  
NENF Neudesin neurotrophic factor   
NME4 
NME/NM23 nucleoside diphosphate kinase 
4  
  
NT5C3 5'-nucleotidase, cytosolic IIIA 
NT5C3 polymorphism associated with 
response to chemotherapy in AML 
25000516 
NUDT1 Nudix hydrolase 1   







PARP1 Poly(ADP-ribose) polymerase 1 
High PARP-1 expression is a predictor for  
poor survival in AML patients 
30472087 
PBX3 PBX homeobox 3 Found to interact in MLL-rearranged AML 26747896 
PDLIM1 PDZ and LIM domain 1   
PFKP Phosphofructokinase, platelet    
PHB2 Prohibitin 2   
PIM1 
Pim-1 proto-oncogene, serine/threonine 
kinase 




Peptidylprolyl cis/trans isomerase, NIMA-
interacting 1  
Increased expression in AML, and a potential 
pharmacological target 
29848341 
POLR3GL RNA polymerase III subunit G like    
PRMT1 Protein arginine methyltransferase 1 
Promotes survival and growth of FLT3-ITD+ 
AML cells 
3121718 
PROK2 Prokineticin 2   
PSMD4 Proteasome 26S subunit, non-ATPase 4   
RAB37 RAB37, member RAS oncogene family   
RPA3 Replication protein A3   
RPL12P6 Ribosomal protein L12 pseudogene 6    
RPS26P2 Ribosomal protein S26 pseudogene 2   
RPS26P53 
RPS26P53 ribosomal protein S26 
pseudogene 53 
  
RPS26P55 Ribosomal protein S26 pseudogene 55   
SELS    
SLC2A5 Solute carrier family 2 member 5 
Enhanced fructose utilization in AML cells , 
and a potential therapeutic target 
27746145 
SLC39A3 Solute carrier family 39 member 3   
SLC9A3R1 SLC9A3 regulator 1    
SMC4 Structural maintenance of chromosomes 4  
Involved in leukemogenesis related to 
chromosomes condensing 
29043883 
SOCS2 Suppressor of cytokine signaling 2 
High expression of SOCS2 associated with 
negative outcome in AML 
24559289 
SPOP Speckle type BTB/POZ protein   
SSB 




Succinate-CoA ligase GDP/ADP-forming 
subunit alpha 
Associated with possible prognostic gene 
profile in AML 
29138577 
TBCB Tubulin folding cofactor B    
TECR Trans-2,3-enoyl-CoA reductase   
TMED9 Transmembrane p24 trafficking protein 9   
TOMM22 
Translocase of outer mitochondrial 
membrane 22 
  
TSEN34 tRNA splicing endonuclease subunit 34   
UCKL1 Uridine-cytidine kinase 1 like 1    
UQCRC1 
Ubiquinol-cytochrome c reductase core 
protein 1 
  
WDR61 WD repeat domain 61   
ZMYM6 Zinc finger MYM-type containing 6    













































Supplementary Table 2. The complete list of 74 significantly increased genes (F-score >1.0 and FC value 
>1.0) in patient samples with upregulated release of soluble mediators after CQ treatment. List is shown in 
alphabetical order.   





Arf GAP with dual PH domains 1   
ANXA2P1 Annexin A2 pseudogene 1   
ANXA5 Annexin A5   
ARL4A ADP ribosylation factor like GTPase 4A   
BLOC1S1 
Biogenesis of lysosomal organelles 
complex 1 subunit 1 
  
BLOC1S1 
Biogenesis of lysosomal organelles 
complex 1 subunit 1 
  
C5orf15 Chromosome 5 open reading frame 15    
CCL23 C-C motif chemokine ligand 23 Chemokine involved in leukemogenesis  
CDKN1A Cyclin dependent kinase inhibitor 1A    
CKS1B 




Cornichon family AMPA receptor auxiliary 
protein 4 
  
COMMD8 COMM domain containing 8   
CRLS1 Cardiolipin synthase 1   
CTSH Cathepsin H   





DYNLT1 Dynein light chain Tctex-type 1 
Possible involved in the t(7;11)(p15;p15) 
translocation in acute leukemia 
12446457 
EAF2 ELL associated factor 2  
Possible involved in the (11;19)(q23;p13.1) 
translocation in acute leukemia 
12446457 
EIF5A Eukaryotic translation initiation factor 5A-2 Involved in chemoresistance in AML 30745844 
EVI2A Ecotropic viral integration site 2A   
FABP5 Fatty acid binding protein 5   
FAM45A Family with sequence similarity 45   
FGL2 Fibrinogen like 2   
FLT3 Fms related tyrosine kinase 3 
Both FLT3 mutation and FLT3 
overexpression have prognostic impact in 
AML 
 
FUT4 Fucosyltransferase 4    
GLB1 Galactosidase beta 1   
GRN Granulin precursor   
GTF2H5 General transcription factor IIH subunit 5    
HEBP2 Heme binding protein 2   
HLA-
DQA1 
Major histocompatibility complex, class II, 
DQ alpha 1 
  
HLA-DRB5 
Major histocompatibility complex, class II, 




High mobility group box 1 pseudogene 37   
IAH1 Isoamyl acetate-hydrolyzing esterase   
IGFBP7 Insulin like growth factor binding protein 7 
Induces differentiation and loss of survival 
in LSCs  
30540936 
IRF8 Interferon regulatory factor 8 
Possible tumor-suppressor role for IRF8 in 
AML 
30266821 
ITGAE Integrin subunit alpha E   
KYNU Kynureninase 




U6 small nuclear RNA and mRNA 
degradation associated pseudogene 4 
  
LY86 Lymphocyte antigen 86 
Identified in gene signature for LSCs, 
associated with chemoresistance 
20371479 
LY96 Lymphocyte antigen 96   
MAPBPIP 
Late endosomal/lysosomal adaptor, MAPK 




Mitochondrial calcium uniporter dominant 
negative subunit beta 
  
MMADHC Metabolism of cobalamin associated D   
MNDA Myeloid cell nuclear differentiation antigen 
Correlated with myeloid and monocytic 
differentiation in acute leukemia 
2259228 
MRPL13 Mitochondrial ribosomal protein L13   
MRPL36 
Mitochondrial 54S ribosomal protein 
YmL36 
  
MS4A7 Membrane spanning 4-domains A7   
NDUFA13 




NADH: ubiquinone oxidoreductase subunit 
B9 
  
NUDT5 Nudix hydrolase 5   
PECAM1 
Platelet and endothelial cell adhesion 
molecule 1  
Bone marrow retention of AML cells 
depends on PECAM1 expression 
17875702 
PFKP Phosphofructokinase, platelet    
PGAM1 Phosphoglycerate mutase 1   
PPP2R3C 
Protein phosphatase 2 regulatory subunit 
B''gamma 
  
PQLC3 Solute carrier family 66 member 3   
PSMB8 Proteasome 20S subunit beta 8 
Immunoproteasome subunits critical for 





RAB11 family interacting protein 1   
RPL21P14 Ribosomal protein L21 pseudogene 14   
SCPEP1 Serine carboxypeptidase 1   
SERPINB2 Serpin family B member 2 
Important for stem cells in response to 
various existing chemicals 
29925837 
SLC35A1 Solute carrier family 35 member A1   
SLC7A7 Solute carrier family 7 member 7    
SMYD3 SET and MYND domain containing 3   
SNHG8 Small nucleolar RNA host gene 8   
SNX2 Sorting nexin 2 Found to interact in MLL-rearranged AML 11438682 
TRAPPC5 Trafficking protein particle complex 5   
UCP2 Uncoupling protein 2   
UQCRC1 
Ubiquinol-cytochrome c reductase core 
protein 1 
  
UTP6 UTP6 small subunit processome component   
VCAN Versican  Possible prognostic biomarker in AML 29861382 
VPS28 VPS28 subunit of ESCRT-I    
WDR61 WD repeat domain 61   
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Abstract: Acute myeloid leukemia (AML) is an aggressive malignancy, and many elderly/unfit
patients cannot receive intensive and potentially curative therapy. These patients receive low-toxicity
disease-stabilizing treatment. The combination of all-trans retinoic acid (ATRA) and the histone
deacetylase inhibitor valproic acid can stabilize the disease for a subset of such patients. We performed
untargeted serum metabolomic profiling for 44 AML patients receiving treatment based on ATRA and
valproic acid combined with low-dose cytotoxic drugs (cytarabine, hydroxyurea, 6-mercaptopurin)
which identified 886 metabolites. When comparing pretreatment samples from responders and
non-responders, metabolites mainly belonging to amino acid and lipid (i.e., fatty acid) pathways
were altered. Furthermore, patients with rapidly progressive disease showed an extensively altered
lipid metabolism. Both ATRA and valproic acid monotherapy also altered the amino acid and lipid
metabolite profiles; however, these changes were only highly significant for valproic acid treatment.
Twenty-three metabolites were significantly altered by seven-day valproic acid treatment (p < 0.05,
q < 0.05), where the majority of altered metabolites belonged to lipid (especially fatty acid metabolism)
and amino acid pathways, including several carnitines. These metabolomic effects, and especially
the effects on lipid metabolism, may be important for the antileukemic and epigenetic effects of
this treatment.
Keywords: acute myeloid leukemia; all-trans retinoic acid; lipids; metabolomics; valproic acid
1. Introduction
Acute myeloid leukemia (AML) is an aggressive malignancy [1], and the only possible cure is
intensive therapy possibly including stem cell transplantation [2]. The median age at first diagnosis is
65–70 years [3,4], and the elderly patients above 70–75 years of age have an increased frequency of
high-risk disease [4] where remission is unlikely [5,6]. In addition, these patients are often not eligible
to receive intensive treatment [7]. Furthermore, intensive chemotherapy is not always recommended
for patients with refractory or relapsed disease either [8]. Such patients may instead receive low-toxicity
AML-stabilizing treatment, e.g., a histone deacetylase (HDAC) inhibitor combined with all-trans
retinoic acid (ATRA) and low-dose cytotoxic drugs [9].
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HDAC inhibitors increase acetylation of various proteins, including histones [10], and this last effect
increases gene transcription [11], especially in AML cells where HDACs often are overexpressed [12].
Valproic acid is a short-chain fatty acid that functions as an HDAC inhibitor [13] and has antiproliferative
and proapoptotic effects in AML cells [14–18]. The toxicity of this drug is low, and its antileukemic
activity alone or in combination with ATRA has been documented in several clinical studies [19,20].
ATRA is a derivative of vitamin A that binds to retinoid-responsive nuclear receptors [12,21]; it has
antileukemic activity [22–24] and seems to increase the antileukemic effects of HDAC inhibitors [25,26].
Thus, the combination of ATRA and valproic acid seems to be a low-toxicity AML-stabilizing treatment;
30–40% of the patients respond to this therapy and responses may last up to one to two years [19,20].
This treatment can also be used in elderly and unfit patients [19,27]. Finally, AML cell metabolism
is important for chemosensitivity in AML [28,29], and both ATRA and valproic acid can modulate
cellular and/or systemic metabolism [30–37].
Even though the antileukemic in vivo effects of both ATRA and valproic acid are limited,
both drugs should still be regarded as candidates for the treatment of non-acute promyelocytic
leukemia (non-APL) variants of AML, especially in combination with other antileukemic agents
in selected subsets of patients. First, although a large clinical study could not find a general
improvement of overall survival when ATRA was added to intensive chemotherapy, increased
survival was observed for subsets of patients, especially patients with a favorable prognosis (i.e.,
patients with genetic abnormalities affecting epigenetic regulation) [38]. A preliminary report from
the randomized DECIDER study suggests that ATRA improves survival of AML patients receiving
hypomethylating agents [39], and recent experimental studies also suggest that ATRA induces
degradation of the mutated NPM1 protein [40], sensitizes AML cells to FLT3 inhibitors [41], and is
effective in AML cells carrying the metabolism-modulating IDH mutations [42]. Second, clinical
studies suggest that valproic acid improves survival in certain AML subsets (i.e., patients with
NPM1 mutations) [43], and recent experimental studies suggest that it has synergistic effects when
combined with autophagy-inhibiting chloroquine [44] or inhibitors of DNA methyltransferase [45].
HDAC-induced epigenetic reprogramming may also increase the susceptibility to ATRA [46]. For future
studies, predictive molecular networks may become important to identify responders to valproic
acid [47].
Metabolomics is emerging as a powerful approach to study cancer metabolism, and a metabolomics
study showed that systemic metabolic markers (i.e., an altered glucose metabolism signature) was
associated with prognosis in AML [28]. Such metabolomic signatures probably reflect both the
characteristics of the AML cells/disease and the influence of a severe disease on systemic metabolic
regulation. The overall systemic metabolomic profiles may also be important for leukemic growth and
chemosensitivity. AML cells show metabolic plasticity; however, leukemia growth and chemosensitivity
also seem to depend on the environmental context, possibly including the systemic supply of nutrients
and especially amino acid and fatty acid metabolism [48,49]. The systemic metabolomic effects of
ATRA and valproic acid may thus further contribute to the effects of these agents on AML cells.
In this context, we have performed systemic metabolomic profiling of AML patients treated with the
combination of ATRA, valproic acid, and low doses of conventional cytotoxic drugs, and we also
examined the effects of both ATRA and valproic acid monotherapy on systemic metabolite profiles
of AML patients. In our present study, we have focused on metabolite pathways rather than single
metabolites. The aims of our study were to compare the pretreatment metabolomic profiles found
in responders and non-responders to the AML-stabilizing treatment, and to characterize how these
profiles are altered during the early period of this antileukemic treatment (two-day or seven-day
monotherapy with either ATRA or valproic acid, respectively).
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2. Materials and Methods
2.1. Patients
The study was approved by the Regional Ethics Committee (REK 2017/305 070417, REK Vest
2015/1410 190615, 215.03 120504, 231.06 150307) and included 44 elderly or unfit patients (25 men
and 19 women; median age 76.4 years with range 61–86 years) with high-risk leukemia, i.e., AML
relapse, secondary AML, complex karyotype and/or TP53 mutations (Table S1). Patients with APL
were excluded. The patients represent an unselected subset of the consecutive patients included in
two clinical studies [19,27]. Eighteen of the patients were classified as responders to the treatment
according to the myelodysplastic syndrome (MDS) criteria [50]; the others 26 patients did not respond
to the treatment and six of them showed a rapidly progressive disease (patients 39–44).
2.2. The Antileukemic Treatment Based on ATRA, Valproic Acid, and Low-Dose Cytotoxic Drugs
All serum samples were collected from patients included in two previously published clinical
studies conducted at Haukeland University Hospital in Bergen, based on combined treatment with
oral ATRA (22.5 mg/m2 twice daily for 14 days every 12th week), continuous valproic acid therapy
at maximal tolerated doses, and low-dose therapy with hydroxyurea, 5-mercaptopurine, and/or
cytarabine [19,27]. Samples were taken prior to treatment, and also after receiving ATRA alone (after
two days of treatment) or valproic acid alone (after seven days of treatment), as described in the
following sections (see Figure S1).
Patients included in the first study [27] received oral ATRA as described above. On day three
of the first cycle the patients received valproic acid as an initial intravenous infusion with a loading
dose (5 mg/kg) followed by continuous infusion (28 mg/kg/24 h), and theophylline with a loading dose
(5 mg/kg) followed by continuous infusion (0.65 mg/kg/hour). After five days (day 8), the patients
received oral valproic acid (serum levels between 300–600 µmol/L) and oral theophylline adjusted to
reach the therapeutic level of 50–100 µM. Patients with (i) peripheral blood blasts exceeding 50 × 109/L
at diagnosis or (ii) later increasing blast counts received cytotoxic drugs to control leukocytosis.
Patients included in the second study [19] received valproic acid monotherapy for the first
seven days with loading dose and subsequent continuous infusion for 24 h before oral valproic acid
treatment (serum levels 300–600 µmol/L). On days 8–22, the patients received ATRA, and on days
15–24, they received subcutaneous cytarabine (10 mg/m2 once daily). ATRA and cytarabine treatment
were repeated at 12-week intervals. Patients with later increasing peripheral blood blasts (>50 × 109/L)
received hydroxyurea or 5-mercaptopurine instead of cytarabine.
There is no general agreement with regard to which response criteria should be used for patients
receiving low-toxicity AML stabilizing treatment [20], and our patients were therefore evaluated both
with regard to the conventional AML criteria for remission induction [51] and the MDS response
criteria [52]. Two responders in the second study achieved complete hematological remission; the other
responders fulfilled the criteria for hematological improvement according to the MDS criteria and
lasting for at least eight weeks before progression.
2.3. Preparation and Analysis of Serum Samples
Venous peripheral blood was collected onto sterile serum-clot activator tubes with gel separator
(Greiner Bio-One GmbH, Kremsmünster, Austria or BD Vacutainer SST, Becton-Dickenson; Franklin
Lakes, NJ, USA). Samples were left upright for 30–120 min at room temperature before being centrifuged
(1300× g, 10 min). The serum supernatants were immediately allocated in plastic cryotubes (NuncTM,
Roskilde, Denmark) and stored at –80 ◦C. The patients had no dietary restrictions, and all samples
were collected from fasting patients, between 7:30 and 8:30 in the morning before breakfast.
The untargeted metabolomic profile analyses were performed in collaboration with Metabolon Inc
(Durham, NC, USA) as described previously [53]. Samples were prepared using the automated
MicroLab STAR®® system (Hamilton Company, Bonaduz, Switzerland) and extracted using
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Metabolon‘s standard solvent extraction method [53]. Four recovery standards were added
prior to the first extraction step, DL-2-fluorophenylglycine, tridecanoic acid, d6-cholesterol and
4-chlorophenylalanine [53]. To remove proteins, dissociate small molecules bound to proteins or
trapped in the protein matrix, and to recover chemically diverse metabolites, proteins were precipitated
with methanol under vigorous shaking for two minutes (Glen Mills GenoGrinder 2000) followed by
centrifugation. The resulting extract was divided into two fractions for analysis by two separate reverse
phase (RP)/ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS,
Waters ACQUITY, Milford, MA, USA) methods with positive ion mode electrospray ionization (ESI,
Thermo Scientific, Waltham, MA, USA) RP/UPLC-MS/MS with negative ion mode ESI, and hydrophilic
interaction liquid chromatography (HILIC)/UPLC-MS with negative ion mode ESI. A last sample
was stored for backup. Samples were placed briefly on a Zymark TurboVap®® (McKinley Scientific,
Sparta, NJ, USA) to remove the organic solvent; they were thereafter stored overnight under nitrogen
before further preparation. Extracted water samples served as process blanks and solvents used
during the extraction process served as solvent blanks. A pooled matrix sample generated by taking
a small volume of each experimental sample, and also a large pool of human plasma extensively
characterized and prepared by Metabolon, served as technical replicates throughout the data set.
Furthermore, a combination of quality control standards that were carefully chosen not to interfere with
the analyzes, were spiked into every analyzed sample to allow monitoring of instrument performance
and chromatographic alignment as described previously [53].
Instrument variability was determined for each sample by calculating the median relative standard
deviation (RSD) prior to injection into the mass spectrometers. The overall process variability was
determined by calculating the median RSD for all endogenous metabolites (i.e., non-instrument
standards) present in 100% of the pooled matrix samples (serum samples). The experimental samples
were randomly spaced across the platform and the control samples were evenly spread.
Metabolon Inc maintains a library based on authentical standards that contains the retention
time/index (RI), mass to charge ratio (m/z), and chromatographic data (including MS/MS spectral
data); the metabolites were identified by comparison to this library. Peaks were quantified using
area-under the-curve.
2.4. Statistical Analyses
Welch′s two sample t-test was used to identify metabolites that differed significantly between different
groups, the paired t-test was used comparison of paired samples, and ANOVA contrasts used to analyze
pharmacological effects for responders and non-responders separately. Random Forest analysis was used
to provide an unbiased estimate of how well individuals can be classified into each group based on the
metabolomic data. Metabolite pathway enrichment analysis was used for biological interpretation of
metabolite data at a system level using the MetaboLync analysis tool (MetaboLync®® Portal). Differences
were regarded as statistically significant when p-values were < 0.05. Statistical analyses were performed
with the programs ArrayStudio, R (http://cran.r-project.org/) and the data analyze software program
JMP (JMP®®, Statistical DiscoveryTM from©SAS Institute Inc., Lane Cove, NSW, Australia).
3. Results
3.1. The Pretherapy Serum Metabolomic Profiles Could Not Predict Responsiveness to Antileukemic Treatment
Based on ATRA, Valproic Acid, and Low-Dose Chemotherapy
The serum metabolomic profiles were analyzed in pretreatment serum samples derived from
44 patients (18 responders and 26 non-responders). Untargeted metabolomic profiling identified 886
metabolites, of which approximately 45 significant changes would be expected to occur by chance
alone when using p < 0.05 as significance level; however, only 36 metabolites showed a significant
difference (p < 0.05, Welch two-sample t-test) when comparing pretreatment levels of responders
and non-responders, and all of these metabolites had high q-values (q > 0.4). These results suggest
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that some of the statistically significant changes represent false discoveries (Figure S2). First, 10 of
the 36 significantly altered metabolites are classified as peptides (gamma-glutamyltyrosine), amino
acids (tyrosine, methionine, histidine, lysine, threonine, homoarginine), or amino acid metabolites
(indolepropionate, 2-methylbutyrylcarnitine, 5-hydroxylysinepropionyl) (Figure S2). Second, 11 of
the 36 significantly altered metabolites were classified as lipid metabolites (Figure S2). Thirdly, there
were also significantly altered levels of five metabolites classified as xenobiotics between responders
and non-responders (i.e., metabolites not naturally produced by the organism) and two of these
were vitamin A metabolites. Finally, only two metabolites from the subclass carbohydrate/energy
metabolism (mannose, citrate) differed significantly when comparing responders and non-responders,
and both showed only borderline significance (0.04 > p > 0.05).
As stated above, the significantly altered metabolites between responders and non-responders
showed high q-values in our analysis (Figure S2). Although both fatty acid and amino acid metabolism
seem important for the growth and chemosensitivity in human AML [48], and a distinct pretherapy
systemic glucose metabolism signature is associated with prognosis (i.e., survival) of younger
patients receiving intensive and potentially curative AML therapy [28], we could not identify any
highly significant differences in pretreatment systemic metabolite profiles between responder and
non-responder patients receiving low-intensity AML-stabilizing treatment. Finally, a random forest
analysis based on the overall metabolite profiles showed a predictive accuracy of only 48% for
responders versus nonresponders (data not shown).
We also did a metabolite pathway enrichment analysis based on the 36 metabolites with p < 0.05
(Figure S3). This analysis showed enriched pathways associated with amino acid and lipid metabolism,
although vitamin A metabolism also had a high ranking (two metabolites differed between groups).
Taken together, these analyses suggest that, in contrast to patients receiving intensive and potentially
curative antileukemic treatment, there is no (or only a minor) prognostic impact of the pretherapy
metabolomic profiles in our study for patients receiving leukemia-stabilizing treatment. Although
vitamin A metabolism was enriched in the pathway analysis this should be interpreted with great care
because only two of the five identified metabolites had borderline significance between responder and
non-responder groups (see Figure S2).
3.2. Pretherapy Differences in Fatty Acid Metabolism Are Found between Non-Responders with Rapidly
Progressive AML Compared with Other Non-Responders with Less Aggressive Disease
Six non-responders had rapidly progressive disease with increasing peripheral blood blast counts
and survival ≤12 days (Table S1, patients 39–44). We compared the metabolomic profile of these
six patients with the 20 other non-responders because, in clinical practice, it will be important to
identify such patients and start early with alternative therapy. This early cutoff was chosen because a
clinically relevant response is usually seen after 2–3 weeks of treatment with ATRA/valproic acid [19,27].
Eighty of the 886 metabolites differed significantly between these two groups (Figure 1, Table S2).
Most of the metabolites had a relatively high q-value, but when considering the relatively high
number of significantly altered metabolites (80 out of 886 metabolites) and the overall metabolomic
profiles/pathways (instead of individual metabolites), the most striking difference between these two
groups was the high number of lipid metabolites (45 out of 80 metabolites) of which patients with
rapidly progressive disease showed increased levels for 42 out of these 45 lipid metabolites (a more
detailed classification of metabolites is presented in Table S2). Thus, the six non-responders with
rapidly progressive disease seem to differ from the 20 other non-responders especially with regard to
lipid and fatty acid metabolites. Finally, a random forest analysis showed a predictive accuracy of 77%
(Figure 2), suggesting that it might be possible to use metabolite profiles to segregate these groups;
however, the group size of aggressive non-responders is very small, and the results therefore need to be
confirmed in a larger study. The 30 top-ranked metabolites from the random forest analysis included
26 metabolites with a p-value < 0.05 (six amino acid metabolites, 16 lipid metabolites, and four other
metabolites; see Figures 1 and 2).
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Figure 1. Significantly altered metabolites when comparing the pretreatment levels of non-responders
with rapidly progressive disease versus non-responders with less aggressive disease to antileukemic
treatment based on all-trans retinoic acid (ATRA) and valproic acid. The p-values, q-values and mean
fold change values for each metabolite are listed to the right in the figure (ranked by p-value), and a
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fold change >1 indicates that the levels were increased in non-responder patients with very aggressive
disease compared to non-responder patients with less aggressive disease. Levels of serum metabolites in
non-responders with less aggressive disease are shown in grey, increased levels found in non-responders
with aggressive disease are shown in green, while decreased levels in non-responders with aggressive
disease are shown in yellow. Color codes for classification of metabolites are explained at the bottom of
the figure. Error bars show Standard deviation (SD). * Nicotidamine SD 6.761, ** Spermidine SD 9.051.
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Figure 2. Random forest analysis based on pretreatment serum metabolites when comparing
non-responders with rapidly progressive disease versus non-responders with less aggressive disease
to antileukemic treatment based on ATRA and valproic acid. The figure shows the 30 top-ranked
metabolites from this analysis, which can segregate the two patient groups with a predictive accuracy
of 77%. Amino acid and lipid metabolites constituted the majority of t e top-ranked metabolites.
Color codes for classification of metabolites are shown to the lower right. This analysi included
26 metab lit s wi h a p-value < 0.05 (see Figure 1; six amino acid metabolites, 16 lipid metabolites,
and four other metabolites). Abbreviations; NR-Agg, non-responders aggressive disease (i.e., rapidly
progressive); NR-NAgg, non-responders non-aggressive disease.
We did a pathway enrichment analysis (Figure 3) based on metabolites with p-value below 0.05,
and mostly fatty acid pathways were enriched between non-responders with rapidly progressive AML
and non-responders with less aggressive disease. The metabolites important for the tricarboxylic
acid cycle (five metabolites, see Figure 1) all reflect transition of fatty acid metabolites to the energy
metabolism/mitochondria. Thus, our results suggest that rapidly progressive AML is associated with
alterations especially in lipid (i.e., fatty acid) metabolism.
Cells 2019, 8, 1229 8 of 22
Cells 2019, 8, x FOR PEER REVIEW 8 of 23 
 
 
Figure 3. Pathway enrichment analysis based on altered metabolites between non-responder patients 
with rapidly progressive disease (i.e., aggressive disease) versus non-responders with less aggressive 
disease. This analysis was based on significantly altered metabolites p < 0.05 (see Figure 1). Only 
pathways with an enrichment value greater than two and at least two metabolites within each 
pathway are shown in the figure. 
3.3. Effects of ATRA Monotherapy on Serum Metabolite Profiles 
We compared the serum metabolite profiles before and after two days of ATRA monotherapy 
for ten patients from the first clinical study (Table S1, the first five responders and five non-
responders) [27]. A total of 54 metabolites were then significantly altered after ATRA monotherapy 
(paired t-test, p < 0.05, Figure 4), though all metabolites had high q-values (q > 0.1, Figure 4). However, 
of the 54 altered metabolites, a large majority of 50 metabolites were increased after ATRA treatment. 
A large fraction of these 54 metabolites were amino acid metabolites (24/54), including 
isoleucine/leucine and tryptophan together with several of their metabolites as well as histidine, 
lysine, methionine/cysteine/taurine arginine, lysine, and valine metabolites (Figure 4). Nineteen lipid 
metabolites were also altered by ATRA; especially sphingolipid/sphingomyelin but also plasmalogen 
metabolites were increased. The largest subgroup of altered lipid metabolites was sphingolipids that 
are largely synthesized from serine and palmitoyl-CoA and are important as cell membrane 
components and regulators of cell proliferation and survival [54–56]. Although several 
sphingomyelins were increased, their second messenger ceramide was not altered. Finally, several 
one-carbon/methylated metabolites were increased after ATRA therapy together with the 
methylation reaction product S-adenosylhomocysteine. 
We performed a pathway enrichment analysis (Figure S4) based on the significantly altered 
metabolites observed after ATRA treatment. This analysis also showed that especially lipid 
metabolites but also amino acid metabolites before and during ATRA therapy. In addition, we finally 
also investigated the effects of ATRA monotherapy for the five responders and the five non-
responders separately. A similar profile was then observed where significantly altered metabolites (p 
< 0.05, but q > 0.05) consisted mainly of amino acid and lipid metabolites in both groups (data not 
shown). 
To conclude, our present metabolomic results suggest that ATRA mainly increases levels of 











0 1 2 3 4 5 6 7 8 9
Phosphatidylethanolamine (PE)
TCA Cycle
Purine Metabolism, Adenine containing
Diacylglycerol
Phosphatidylinositol (PI)





Non-responders, with rapidly progressive versus less aggressive 
disease 
Figure 3. Pathway enrichment analysis based on altered metabolites between non-responder patients
with rapidly progressive disease (i.e., aggressive disease) versus non-responders with less aggressive
disease. This analysis was based on significantly altered metabolites p < 0.05 (see Figure 1). Only
pathways with an enrichment value greater than two and at least two metabolites within each pathway
are shown in the figure.
3.3. Effects of ATRA Monotherapy on Serum Metabolite Profiles
We compared the serum metabolite profiles before and after two days of ATRA monotherapy for
ten patients from the first clinical study (Table S1, the first five responders nd five non-responders) [27].
A total of 54 m tabolites were then signific ntly ltered after ATRA monotherapy (paired t-test, p < 0.05,
Figure 4), though all metabolites had high q-values (q > 0.1, Figure 4). However, of the 54 altered
metabolites, a large majority of 50 metabolites were increased after ATRA treatment.
A large fraction of these 54 metabolites were amino acid metabolites (24/54), including
isoleucine/leucine and tryptophan together with several of their metabolites as well as histidine,
lysine, methionine/cysteine/taurine arginine, lysine, and valine metabolites (Figure 4). Nineteen
lipid metabolites were also altered by ATRA; especially sphingolipid/sphingomyelin but also
plasmalogen metabolites were increased. The largest subgroup of altered lipid metabolites was
sphingolipids that are largely synthesized from seri e and palmitoyl-C A and are important as cell
membrane c mponents and regulators of cell p oliferation and survival [54–56]. Although s veral
sphingomyelins were increased, their second messenger ceramide was not altered. Finally, several
one-carbon/methylated metabolites were increased after ATRA therapy together with the methylation
reaction product S-adenosylhomocysteine.
We performed a pathway enrichment analysis (Figure S4) based on the significantly altered
metabolites observed after ATRA treatment. This analysis also showed that especially lipid metabolites
but also amino acid metabolites before and during ATRA therapy. In addition, we finally also
investigated the effects of ATRA monotherapy for the five responders and the five non-responders
separately. A similar p ofil was then observ d where significantly altered metabolit s (p < 0.05,
but q > 0.05) consisted mainly of mino acid and lipid etabolites in both groups (data not shown).
To conclude, our present metabolomic results suggest that ATRA mainly increases levels of
metabolites involved in amino acid and lipid metabolism, but these observations must be interpreted
with great care because the effects were relatively weak and showed high q-values. However, previous
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animal studies have also shown that ATRA can alter the systemic levels of amino acid and fatty acid
metabolites [37]; these results are thus consistent with our present observations in AML patients.
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Figure 4. The effect of ATRA monotherapy on the serum metabolomic profiles of patients after two 
days of treatment. Fifty-four metabolites were significantly altered after ATRA treatment (p < 0.05). 
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Figure 4. The effect of ATRA monotherapy on the serum metabolomic profiles of patients after two
days of treatment. Fifty-four metabolites were significantly altered after ATRA treatment (p < 0.05).
The p-values, q-values, and mean fold change values for each metabolite are listed to the right in the
figure (ranked by p-value), and a fold change >1 indicates that the levels were increased in responders
compared with non-responders. Pretherapy levels of serum metabolites for the ten patients are
presented in grey, increased levels during ATRA treatment are presented in green and decreased levels
presented in yellow. Color codes for classification of metabolites are explained at the bottom of the
figure. Error bars show Standard deviation (SD). * Androstenediol (3 beta, 17 beta) pre-ATRA SD 3.862,
** Androstenediol (3 beta,17 beta) post-ATRA SD 2.542.
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3.4. Valproic Acid Monotherapy Alters the Systemic Amino Acid and Lipid Metabolite Profiles in Both
Responders and Non-Responders to the Antileukemic Treatment
We compared the systemic metabolomic profiles before and after seven days of valproic acid
monotherapy for ten patients included in the second clinical study, including the first five responders
and non-responders (Table S1) [19]. A total of 109 metabolites were significantly altered in patients
treated with valproic acid compared to pretreatment levels; 55 metabolites were increased, and 54
were decreased (p < 0.05; see Figure S5). Among these, 36 metabolites had both a p-value < 0.05 and a
q-value < 0.1 (Figure 5), and 23 of these metabolites also had a q-value below 0.05. Four of these 36
metabolites were valproic acid metabolites, whereas the rest included 13 amino acid metabolites and
12 lipid metabolites. Only one of these metabolites reflected energy/carbohydrate metabolism.
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Figure 5. Identification and classification of serum metabolites that differed significantly when
comparing samples taken prior to treatment and after seven days of valproic acid (VPA) therapy.
Thirty-six metabolites differed significantly between untreated and VPA-treated samples (p < 0.05,
Welch′s two sample t-test), with q-value < 0.1 (the upper 23 metabolites with q < 0.05). The p-values,
q-values, and mean fold change for each metabolite are listed to the right in the figure (ranked by
p and q-value), and a fold change >1 indicates that the levels were increased after valproic acid
therapy. Metabolite levels found in pretreatm nt samples r shown in grey, while increased levels
during treatment ar shown in green (22/36 increased) and decrea ed l ve s during trea ment are
shown in orange (14/36 decreased). Color codes for classification of metabolites are explained at the
bottom of the figure. Error bars show Standard deviation (SD). *Adipoylcranitine (C6-DC) SD 6.928
**Suberoylcarnitine (C8-DC) SD 8.50.
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A random forest analysis was performed after excluding the four valproic acid metabolites, and
then 14 lipid and seven amino acid metabolites were among the 30 top-ranked metabolites of this
analysis, with a predictive accuracy of 90% (Figure 6). Twenty-two of these 30 metabolites were
significantly altered by the valproic acid treatment (p < 0.05, see Figure S5), including six of the
highly significant carnitine metabolites (Figure 6). In addition, another random forest analysis was
performed including all identified metabolites (not excluding valproic acid metabolites) and the results
showed that the four top-ranked metabolites were all valproic acid metabolites as expected (Figure S6;
predictive accuracy of 100%). Hence, responsiveness to the combination of ATRA and valproic acid is
probably not determined by a difference in valproic acid metabolism.
Cells 2019, 8, x FOR PEER REVIEW 12 of 23 
 
 
Figure 6. The effect of 7-day valproic acid (VPA) monotherapy on the serum metabolomic profiles for 
ten patients (five responders and five non-responders). The random forest analysis was based on the 
identification of 886 metabolites in pretherapy samples and samples collected after seven days of 
valproic acid monotherapy. The analysis showed a predictive accuracy of 90% (see the insert table) 
after exclusion of the four valproic acid metabolites. The top-30 most important metabolites for 
separation of the two groups are shown in ranking order. Color codes indicate the classification of 
individual metabolites at the lower right part of the figure. 
Figure 6. The effect of 7-day valproic acid (VPA) monotherapy on the serum metabolomic profiles
for ten patients (five responders and five non-responders). The random forest analysis was based on
the identification of 886 metabolites in pretherapy samples and samples collected after seven days of
valproic acid monotherapy. The analysis showed a predictive accuracy of 90% (see the insert table) after
exclusion of the four valproic acid metabolites. The top-30 most important metabolites for separation
of the two groups are shown in ranking order. Color codes indicate the classification of individual
metabolites at the lower right part of the figure.
A pathway enrichment analysis for differential metabolites after valproic acid treatment revealed
enrichment of pathways relating especially to lipid metabolism as well as amino acid metabolism
(Figure 7). As discussed above, several lipid and fatty acid metabolites were altered after valproic
acid therapy, including increased levels of several fatty acid-carnitines (Figure 5, Figure S5). This is
consistent with impaired β-oxidation, and the increased levels of five out of nine significantly altered
dicarboxyl fatty acids suggests that ω-oxidation is used as an alternative mechanism in the liver to
compensate for impaired β oxidation [57]. Furthermore, a total of 33 amino acid metabolites were
significantly altered by valproic acid, in particular metabolites reflecting tryptophan (six metabolites)
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and valine/leucine/isoleucine metabolism (eight metabolites). Seven amino acid metabolites were also
included among the top-ranked metabolites in the random forest analysis (Figure 6). In our analysis,
the 109 metabolites with significant p-values < 0.05 (but high q-value) had a similar overall profile
as that found for metabolites with p < 0.05 and q < 0.05 (Figure 5), mainly consisting of metabolites
belonging to amino acid (see Figure S7) and lipid pathways (see Figure S8), whereas metabolites
reflecting the carbohydrate and energy metabolism were scarce.
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*5-hydroxyvalproate Valproic acid metabolite 0.0000 0.0000 13.83 
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Figure 7. Pathway enrichment analysis based on metabolites altered after seven days of valproic acid
treatment compared to pretherapy levels. This analysis was based on significant altered metabolites
p < 0.05 (see Figure S5), and only pathways with an enrichment value greater than two and at least two
metabolites within each pathway are shown. The most significant pathway is shown in red and less
significant pathways in light yellow.
We finally analyze and compared the effects of valproic acid monotherapy for the five patients
classified as responders and five non-responders separately (Table 1). Then, 78 metabolites were
significantly altered after valproic acid treatment for he respond rs, including divergent effects for 17
amino acid and 32 lipid metabolites, while 105 metabolites were significantly altered after valproic
acid treatment for the non-responders, including divergent effects for 21 amino acid and 49 lipid
metabolites (Table 1, Tables S3 and S4). Thus, a similar pattern was observed for both responders
and non-responders as described above; valproic acid mainly alters amino acid and lipid metabolism.
The metabolites showing both p- and q-value < 0.05 are listed in Table 1. These metabolites included
the valproic acid metabolites and also several carnitines, which also reflect differences in lipid and
amino acid m tabolism.
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p-Value q-Value Fold Change
RESPONDERS
*Valproate Drug concentration 0.0000 0.0000
*2-propyl-2-pentenoate (2-ene-valproate) Valproic acid metabolite 0.0000 0.0000 55.81
*5-hydroxyvalproate Valproic acid metabolite 0.0000 0.0000 13.83
*3-hydroxyvalproate Valproic acid metabolite 0.0000 0.0000 25.77
*Glucuronide of C8H16O2 (1)* Partially characterized 0.0000 0.0000 28.34
*Suberoylcarnitine (C8-DC) Fatty acid metabolism, acylcarnitine 0.0000 0.0000 30.82
Phenylacetylcarnitine Acetylated peptide 0.0000 0.0000 17.30
*Adipoylcarnitine (C6-DC) Fatty acid metabolism 0.0000 0.0000 17.06
*3-methylglutarylcarnitine (2) Leucine/isoleucin/valinemetabolism 0.0000 0.0000 0.18
*Adipate (C6-DC) Fatty acid, dicarboxylate 0.0000 0.0027 3.41
10-undecenoate (11:1n1) Medium chain fatty acid 0.0001 0.0043 0.49
*Isobutyrylca′rnitine (C4) Leucine/isoleucin/valinemetabolism 0.0001 0.0093 3.06
Glucuronide of C14H22O4 (2) Partially characterized 0.0003 0.0182 0.22
4-hydroxycinnamate sulfate Tyrosine metabolism 0.0004 0.0259 3.00
Isoeugenol sulfate Food component, plant 0.0005 0.0264 0.04
NON-RESPONDERS
*Valproate Drug concentration 0.0000 0.0000
*2-propyl-2-pentenoate (2-ene-valproate) Valproic acic metabolite 0.0000 0.0000 48.32
*5-hydroxyvalproate Valproic acic metabolite 0.0000 0.0000 31.58
*3-hydroxyvalproate Valproic acic metabolite 0.0000 0.0000 93.38
*Glucuronide of C8H16O2 (1) Partially characterized 0.0000 0.0000 16.16
*Suberoylcarnitine (C8-DC) Fatty acid, dicarboxylate 0.0000 0.0000 12.96
*Adipoylcarnitine (C6-DC) Fatty acid metabolism 0.0000 0.0000 7.34
*Adipate (C6-DC) Fatty acid, dicarboxylate 0.0000 0.0001 4.33
*3-methylglutarylcarnitine (2) Leucine/isoleucin/valinemetabolism 0.0000 0.0001 0.25




dicarboxylate 0.0001 0.0054 0.44
Hexanoylglycine Fatty acid metabolism, acyl glycine 0.0001 0.0077 3.03
3-hydroxyhexanoate Fatty acid metabolism,monohydroxy 0.0001 0.0100 2.03
Androstenediol (3beta,17beta) disulfate (1) Androgenic steroid 0.0003 0.0197 1.45
*Isobutyrylcarnitine (C4) Leucine/isoleucin/valinemetabolism 0.0004 0.0208 3.15
Gamma-CEHC Cofactors/vitamins 0.0004 0.0234 1.56
Isoursodeoxycholate Secondary bile acid metabolism 0.0005 0.0278 0.06
Indoleacetylglutamine Tryptophane metabolism 0.0006 0.0298 0.09
4-hydroxyphenylacetylglutamine Acetylated peptide 0.0008 0.0352 0.28
1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) Phosphatidylinositole 0.0008 0.0352 1.51
5-bromotryptophan Tryptophane metabolism 0.0010 0.0387 0.49
4-allylphenol sulfate Food component, plant 0.0010 0.0387 0.29
N-acetyltyrosine Tyrosine metabolism 0.0011 0.0413 2.42
Trans-4-hydroxyproline Urea cycle. Proline metabolism 0.0011 0.0411 1.73
Galactonate Carbohydrate metabolism 0.0012 0.0430 0.38
3-aminoisobutyrate Pyrimidine metabolism, thymine 0.0013 0.0433 1.86
The metabolites are ranked according to their p- and q-values, and the metabolites that were altered in responders
and non-responders to the antileukemic AML-stabilizing therapy are listed separately. Overlapping metabolites
between these two groups are marked with *. VPA, valproic acid.
4. Discussion
Epigenetic targeting based on combination therapy with ATRA and valproic acid can stabilize
the disease for a subset of AML patients. Furthermore, both drugs can also modulate the cellular
and/or systemic metabolism [32–37]. Such pharmacological effects may influence the metabolic
regulation of the leukemia cells through altered levels of nutrients in their microenvironment [48,49],
and these effects may even contribute to the epigenetic effects of the drugs [58,59]. We have therefore
performed metabolomic profiling of serum samples collected from AML patients before receiving
disease-stabilizing treatment to compare responders and non-responders to treatment, and we also
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compared systemic metabolite profiles before and after drug monotherapy. Our study suggests
that differences in pretreatment amino acid and lipid metabolite profiles are associated with disease
aggressiveness, and both ATRA and valproic acid cause further modulation of the systemic metabolic
signature (i.e., amino acid and lipid metabolism). This is different from patients receiving intensive
and potentially curative chemotherapy where a glucose metabolism signature has been shown to be
associated with chemoresistance and survival after chemotherapy [28].
Untargeted metabolomics generates large amounts of data that can be complex and challenging
to analyze. A p-value of 0.05 is the false positive rate when one test is performed, but for a large
number of tests on the data one has to account for false positives. There are different methods to correct
for multiple testing. One strategy is to use the family-wise error rate adjustment (e.g., Bonferroni
correction), but this is regarded as very conservative when one has a large number of tests; the use of
false discovery rates (i.e., the q-values) is therefore more common although it allows for a small number
of false discoveries [60]. A relatively high q-value (e.g., q > 0.10) indicates diminished confidence but
it does not necessarily rule out the biological significance of a result. In our opinion other evidence
should also be considered, for example (i) significance in another dimension of the study, (ii) inclusion
in a common pathway together with highly significant compounds, and (iii) residing in a similar
metabolic family with other statistically significant metabolites. Throughout the present study we have
therefore for each biological comparison listed all metabolites with the corresponding p-value < 0.05,
we have presented p-values together with the corresponding q-values and fold change values for all
these metabolites, and when we discuss the importance of single metabolites we focus on the q-values
(i.e., the studies of the valproic acid effects). We also performed pathway enrichment analysis based
on significantly altered metabolites (p < 0.05) which revealed enriched pathways instead of focusing
on single metabolites. In our opinion such an identification of a metabolic pathway can be justified
because it is based on several metabolites and not a single metabolite. However, we would like to
emphasize that all background information (p- and q-values and fold change values) are provided in
the text or in figures/tables for all metabolites included in our analyses, so the level of confidence in the
results can be further evaluated by the reader.
Our pretreatment profiles were probably determined by the metabolic characteristics of a large
leukemia cell burden together with the effects of this burden on systemic metabolic regulation. The lipid
and amino acid profiles were further modulated by metabolic effects of ATRA but especially of valproic
acid. The drugs have direct (i.e., epigenetic) effects on the AML cells, and metabolic modulation may
then represent an additional indirect effect on the leukemia cells by modulation of metabolite/nutrient
levels in their bone marrow microenvironment. Thus, altered metabolomic profiles may contribute for
the prognostic evaluation for such patients, but they may also influence AML cell chemosensitivity
and/or contribute to the antileukemic effects of the treatment.
The clinically relevant responses to this AML-stabilizing treatment are usually seen after 14–20
days of treatment [19,27]. Thus, in this study, the effects of ATRA and valproic acid on metabolomic
profiles were evaluated early before improvement of peripheral blood cell counts could be expected.
Despite the late clinical responsiveness, alterations in metabolomic signatures were found during the
first days of treatment and these effects differed between patients whom about two weeks later became
responders or non-responders to treatment.
There is no general agreement on how responses to AML-stabilizing treatment should be classified.
We used the generally accepted definition of complete hematological remission for AML patients [51]
and the MDS criteria for stable disease that require improvement/stabilization of normal peripheral
blood cell counts for at least two months [61]. However, the median survival for elderly patients not
receiving AML-directed therapy is only two-three months [7,62,63] and we therefore regarded such
disease stabilization as unexpected and classified this as a response.
Amino acid profiles in healthy individuals and cancer patients have been compared in several
previous studies [64]. The plasma amino acid profiles for patients with non-small-cell lung cancer
or colorectal cancer is considerably different from healthy controls, and altered amino acid profiles
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have been detected also in early stage breast cancer [64]. Our present study found altered amino
acid profiles in AML after both ATRA and valproic acid treatment, and we observed a considerable
heterogeneity in pretherapy metabolite levels among AML patients when comparing (i) responders
versus non-responders and (ii) non-responders with rapidly progressive disease versus other
non-responders. The mechanisms behind altered amino acid profiles in cancer patients may be
related to the risk of cancer [65] or reflect nutritional or microbiotic alterations, progression of the
disease, cachexia or weight loss [66–68]. In our opinion, it is most likely that the mechanism behind
the differences in amino acid metabolism between various AML patient groups is also multifactorial.
To the best of our knowledge, the present study is the first to investigate metabolomic profiles
in patients receiving AML-stabilizing treatment. We investigated elderly and unfit patients that
were included in two previous clinical studies; in both clinical studies the patients received the
same doses of ATRA, guidelines for adjustment of valproic acid treatment were similar, and we
used low-dose (i.e., low-toxicity) cytarabine/mercaptopurin/hydroxyurea. Our results showed that
responders and non-responders showed relatively small differences in pretherapy metabolic profiles,
but non-responders with rapidly progressive disease seemed to have more extensive differences
compared with the other non-responders. Fatty acid oxidation may be important for AML growth [69],
and increased levels of lipids/fatty acids in non-responders could then be a strategy to provide energy
substrates for the growing leukemia cells. In addition, the long chain fatty acid oleoyl ethanolamid
is suggested to contribute to drug resistance in other patients with hematological malignancies [70].
The increased oleoyl ethanolamid levels may also reflect cachexia that is associated with poor
prognosis in other malignancies [68]. Our responders and non-responders differed in their pretherapy
levels of the three endocannabinoids oleoyl ethanolamide, linoleoyl ethanolamide (both increased in
non-responders) and N-palmitoylserine (decreased in non-responders). Oleoyl ethanolamide activates
the nuclear peroxisome proliferator-activated receptor alpha (PPAR-alpha) that induces lipolysis and fat
utilization [71]. Consistent with increased lipolysis and energy utilization, non-responders also showed
significantly altered serum levels of four free fatty acids and one fatty acid metabolite, suggesting
release of fatty acids. Oleoyl ethanolamide may therefore represent a link between endocannabinoid
and fatty acid metabolism in different patient groups. In addition, responders and non-responders
also differed in xenobiotic metabolites including gut-bacteria derived metabolites. Taken together,
these observations suggest that differences in nutritional status or gut microbiome contribute to the
metabolomic heterogeneity of elderly patients with newly diagnosed AML.
Our analyses showed that the non-responders are not only heterogeneous with regard to survival
but also with regard to pretherapy metabolomic profiles. Patients with rapidly progressive disease
differed considerably from other non-responders especially in lipid metabolism but also amino acid
metabolism. AML is a very aggressive disease and if the first treatment fails the patients may become
unfit for further treatment. Our present observations have to be interpreted with great care because
few patients with very aggressive disease were studied and further studies are needed. Still, they
suggest that pretreatment metabolomic profiling may be helpful to select patients that should not
receive treatment based on ATRA plus valproic acid, especially patients that have rapidly progressive
disease because it takes 15–20 days before clinical responses can be detected.
Neither our comparisons of pretherapy metabolomic profiles of responders and non-responders nor
our studies of metabolite profiles during monotherapy detected any major differences in carbohydrate
or energy metabolism (glycolysis, citric acid cycle), even though such differences have a prognostic
impact for AML patients receiving intensive therapy [28]. However, clinically relevant responses
to our disease-stabilizing therapy can be seen even for patients with high-risk AML (e.g., high-risk
karyotype, relapse; Table S1). Thus, the conventional high-risk criteria, and also glucose metabolism,
seem less important for patients receiving treatment based on ATRA and valproic acid. Instead,
differences in or altered lipid and amino acid metabolism seem to be important for patients receiving
this disease-stabilizing treatment, and effects on systemic levels of metabolites induced by valproic acid
generally seem to be stronger than the ATRA-induced effects. Previous studies have also described an
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effect of ATRA on one-carbon metabolism [72], and similar effects were also seen in our AML patients
although they seemed to be relatively weak.
We also examined the effects of ATRA and valproic acid on metabolomic profiles for ten patients,
i.e., five responders and five non-responders analyzed together, after relatively short duration of
treatment (two and seven days, respectively); whereas clinically relevant responses are usually detected
after two-three weeks [19,27]. Thus, the observed alteration of metabolite profiles should be regarded
as early pharmacological effects that are common for responders and non-responders.
The most striking effects by the two drugs in our studies were altered lipid and amino acid
metabolism. ATRA increased serum levels of sphingolipids and sphingomyelins in non-responders;
a hypothesis is therefore that ATRA contributes to chemoresistance in the non-responders
through a growth-enhancing and antiapoptotic effect of these metabolites as described for other
malignancies [54–56]. Several sphingomyelins were altered by ATRA, but their second messenger
ceramide derived from hydrolysis of sphingomyelin was not altered. Altered ceramide synthesis has
been observed in other malignancies [73], and a subset of AML patients may even have mutations
in the sphingomyelin/ceramide pathway [74]. Taken together, these observations suggest that ATRA
also has complex effects on this pathway. Moreover, the levels of several plasmalogens were also
altered by ATRA. These glycerophospholipid derivatives are thought to be protective against reactive
oxygen species [75], their levels are high in inflammatory cells [76], and their levels increase during
differentiation-induction in the HL60 human AML cell line [77]. Thus, increased plasmalogens may
reflect ATRA-induced effects on AML cells that contribute to chemoresistance at least for certain patients.
Furthermore, several methylated metabolites were increased after ATRA treatment, including
3-methylhistidine, N6,N6,N6-trimethylhistidine, S-methycysteine, 2′-O-methylcytidine, N1-methyl-
4-pyridone-3-carboxamide, as well as the methylation reaction product S-adenosylhomocysteine. ATRA
has been shown to increase both glycine N-methyltransferase that regulates the methyl group supply
for S-adenosylmethionine-dependent transmethylation reactions [77] as well as the activation of histone
methyltransferase SUV39H2 that is important for epigenetic regulation of gene transcription [78].
ATRA-induced alteration of DNA methylation has also been described in the HL60 AML cell line [79].
Thus, these observations suggest that ATRA influences the general methylation potential in AML cells.
Lipid and amino acid metabolism were both altered during valproic acid therapy, and especially
altered levels of fatty acid metabolites were observed. There seem to be several links between epigenetic
regulation and fatty acid metabolism in AML [58], including expression of fatty acid binding protein
4 (FABP4) in AML cells that is important both for fatty acid uptake and epigenetic regulation [80].
Epigenetic regulation is also important for the expression of acetyl-CoA carboxylase 2, a key driver of
fatty acid β-oxidation in AML cells [81] and a regulator of the general lipid metabolism [82]. Repression
of this gene by histone deacetylation allows for simultaneous β-oxidation and fatty acid synthesis
to take place [81]. Finally, valproic acid has been shown to alter lipid metabolism and fatty acid
oxidation [33,35]. Our overall results thereby support the hypothesis that valproic acid alters epigenetic
regulation both through direct effects on histone acetylation and indirectly through modulation of fatty
acid metabolism.
We compared the effects of ATRA and valproic acid for five responders and five non-responders;
these results have to be interpreted with great care due to the low number of samples. However,
non-responders showed more extensive effects on amino acid and lipid metabolism after two days
of ATRA monotherapy but especially after seven days of valproic acid monotherapy. In our opinion,
these more extensive effects in non-responders may partly reflect pharmacological effects, but may also
be influenced by disease progression [30–36].
5. Conclusions
Both ATRA and valproic acid have been used in the treatment of AML, and this is the first study
to investigate systemic metabolomic profiles in AML patients receiving leukemia-stabilizing treatment
based on ATRA plus valproic acid. Our study shows that especially amino acid and lipid metabolism
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varies between patients and during treatment. The effect of valproic acid on the regulation of lipid and
amino acid metabolism is particularly strong and may contribute to the antileukemic and/or epigenetic
effects of this drug, whereas the effects of ATRA and the differences between patient subsets are
weaker. Metabolites related to carbohydrate or energy metabolism showed only minor variations in our
study. Systemic metabolomics should be further investigated to identify biomarkers for pretreatment
evaluation of susceptibility to AML stabilizing treatment, though larger studies are needed. Finally,
changes in metabolomic profiles may influence the bone marrow microenvironment and thereby
modulate AML cell metabolism as well as epigenetic regulation and contribute to therapy resistance.
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7 
 
Table S3. Significantly altered metabolites after seven days of valproic acid monotherapy; a comparison of 
pretreatment samples versus samples collected during treatment for patients classified as responders to 
antileukemic therapy. The comparison is based on the results for 5 responders from the study by Fredly et al. 
(PMID 23915396) [2]. Seventy-eight metabolites were significantly altered after valproic acid therapy; 48 were 
significantly increased and 30 decreased. The arrows (↑↓) indicate whether the metabolite was increased or 
decreased by the treatment. Metabolites with q<0.05 are marked with yellow. 
 
Main class / Subclassifications  Metabolite 
Amino Acid (n=17) 








Phenylalanine Metabolism ↑ Phenylacetate 
Tyrosine Metabolism ↑ 4-hydroxycinnamate sulfate 








Leucine, Isoleucine and Valine Metabolism 
 
↑ Isovalerylcarnitine (C5) 
↑ Beta-hydroxyisovalerate 
↓ 3-methylglutarylcarnitine (2) 
↑ Isobutyrylcarnitine (C4) 
Methionine, Cysteine, SAM and Taurine 
Metabolism 
↑ Cysteine sulfinic acid 
Urea cycle; Arginine and Proline 
Metabolism 
↑ Homocitrulline 
Peptide (n=3)   
 Dipeptide ↑ Glycylvaline 
Acetylated Peptides ↑ Phenylacetylcarnitine 
↓ 4-hydroxyphenylacetylglutamine 
Carbohydrate (n=3)   
 Disaccharides and Oligosaccharides ↑ Lactose 
Fructose, Mannose and Galactose 
Metabolism 
↓ Mannose 
Aminosugar Metabolism ↓ N-acetylneuraminate 
Lipid (n=32)   
 Medium Chain Fatty Acid ↓ 10-undecenoate (11:1n1) 
↓ 5-dodecenoate (12:1n7) 
Polyunsaturated Fatty Acid (n3 and n6) ↓ Adrenate (22:4n6) 
Fatty Acid, Dicarboxylate ↑ Adipate (C6-DC) 
↑ Suberate (C8-DC) 
↑ Sebacate (C10-DC) 
↓ 3-carboxy-4-methyl-5-pentyl-2-furanpropionate (3-
Cmpfp) 
Fatty Acid, Amino ↓ 2-aminooctanoate 
Fatty Acid Metabolism (also BCAA 
Metabolism) 
↑ Propionylcarnitine (C3) 
Fatty Acid Metabolism(Acyl Glycine) ↑ Hexanoylglycine 
Fatty Acid Metabolism(Acyl Carnitine) ↑ 3-hydroxybutyrylcarnitine (2) 
↑ Suberoylcarnitine (C8-DC) 
↑ Adipoylcarnitine (C6-DC) 










↑ 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) 
↑ 1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) 
Phosphatidylinositol (PI) ↑ 1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) 
Diacylglycerol 
↑ Diacylglycerol (14:0/18:1, 16:0/16:1) [1] 
↑ Diacylglycerol (14:0/18:1, 16:0/16:1) [2] 
↑ Palmitoyl-palmitoyl-glycerol (16:0/16:0) [2] 
↑ Oleoyl-oleoyl-glycerol (18:1/18:1) [2] 
↓ Linoleoyl-linolenoyl-glycerol (18:2/18:3) [1] 
Sterol ↑ Beta-sitosterol 
Androgenic Steroids 
↓ Dehydroisoandrosterone sulfate (DHEA-S) 
↓ Androsterone glucuronide 
Primary Bile Acid Metabolism ↑ Tauro-beta-muricholate 
Nucleotide (n=2)   
 
Pyrimidine Metabolism, Uracil containing ↓ 2'-deoxyuridine 
Pyrimidine Metabolism, Thymine 
containing 
↑ 3-aminoisobutyrate 
Cofactors and Vitamins (n=3)   
 Ascorbate and Aldarate Metabolism ↓ Oxalate (ethanedioate) 
Tocopherol Metabolism ↑ Gamma-CEHC 
Hemoglobin and Porphyrin Metabolism ↓ Bilirubin (E,E) 
Xenobiotics (n=16)   
 Benzoate Metabolism ↑ 3-(3-hydroxyphenyl)propionate sulfate 
↑ 3-(3-hydroxyphenyl)propionate 
Food Component/Plant ↑ Cinnamoylglycine 
↑ Dihydroferulic acid 
↑ Ferulic acid 4-sulfate 
↑ Glycyrrhetinate 
↓ Naringenin 7-glucuronide 
↓ Isoeugenol sulfate 
Drug - Cardiovascular ↓ 4-hydroxycoumarin 
↓ Candesartan 
Drug - Neurological ↑ 3-hydroxyvalproate 
↑ 2-propyl-2-pentenoate (2-ene-valproate) 
Chemical ↑ 3-acetylphenol sulfate 
↑ HEPES 
↑ 1,2,3-benzenetriol sulfate (2) 
↑ 2-methoxyresorcinol sulfate 
Partially Characterized Molecules (n=2)   
 Partially Characterized Molecules ↑ Glucuronide of C8H16O2 (1) 















Table S4. Significantly altered metabolites after seven days of valproic acid therapy; a comparison of 
pretreatment samples versus samples collected during treatment for patients classified as non-responders to 
antileukemic treatment. The comparison is based on the results for 5 non-responders from the study by Fredly et 
al. (23915396). A total of 105 metabolites were significantly altered after valproic acid therapy; 52 were significantly 
increased and 53 were decreased. The arrows (↑↓) indicate whether the metabolite was increased or decreased by 
the treatment. Metabolites with q<0.05 are marked with yellow. 
 
Main class / Subclassifications  Metabolite 
Amino Acid (n=21)   
 Glycine, Serine and Threonine Metabolism ↑ Dimethylglycine 





Histidine Metabolism ↑ N-acetylhistidine 
Lysine Metabolism ↑ 6-oxopiperidine-2-carboxylate 
Phenylalanine Metabolism ↑ N-acetylphenylalanine 









Leucine, Isoleucine and Valine Metabolism ↑ Beta-hydroxyisovalerate 
↓ 3-methylglutarylcarnitine (2) 
↑ Ethylmalonate 
↑ Isobutyrylcarnitine (C4) 
↑ 2,3-dihydroxy-2-methylbutyrate 
Methionine, Cysteine, SAM and Taurine 
Metabolism 
↑ N-acetylmethionine 
Urea cycle; Arginine and Proline Metabolism ↑ Trans-4-hydroxyproline 
Peptide (n=2) 
 Acetylated Peptides ↓ 4-hydroxyphenylacetylglutamine 
↓ Phenylacetylglycine 
Carbohydrate (n=4) 
 Pentose Metabolism ↑ Ribitol 
↑ Xylose 
↑ Arabitol/xylitol 
Fructose, Mannose and Galactose Metabolism ↓ Galactonate 
Energy (n=1) 
 TCA Cycle ↓ Succinylcarnitine (C4-DC) 
Lipid (n=49) 
 Medium Chain Fatty Acid ↓ Caprate (10:0) 
↓ 10-undecenoate (11:1n1) 
Fatty Acid, Dicarboxylate 
 
↑ Adipate (C6-DC) 
↑ Pimelate (C7-DC) 
↑ Suberate (C8-DC) 
↓ Dodecanedioate (C12-DC) 
10 
 
↓ Tetradecanedioate (C14-DC) 
↓ Hexadecenedioate (C16:1-DC) 
↓ Octadecanedioate (C18-DC) 
↓ Octadecenedioate (C18:1-DC) 
↓ Eicosanodioate (C20-DC) 
↓ 3-carboxy-4-methyl-5-pentyl-2-furanpropionate (3-
Cmpfp) 
Fatty Acid Metabolism(Acyl Glycine) ↑ Hexanoylglycine 
Fatty Acid Metabolism(Acyl Carnitine) ↑ Hexanoylcarnitine (C6) 
↑ 5-dodecenoylcarnitine (C12:1) 
↑ Cis-4-decenoylcarnitine (C10:1) 
↑ Laurylcarnitine (C12) 
↑ Myristoylcarnitine (C14) 
↑ Myristoleoylcarnitine (C14:1) 
↑ Suberoylcarnitine (C8-DC) 
↑ Adipoylcarnitine (C6-DC) 
↑ Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) 





Endocannabinoid ↓ N-stearoylserine 
Phosphatidylcholine (PC) ↓ 1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6) 
Phosphatidylinositol (PI) 
 
↑ 1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) 
↑ 1-stearoyl-2-linoleoyl-GPI (18:0/18:2) 
Lysophospholipid ↓ 1-palmitoyl-GPC (16:0) 
↓ 1-palmitoleoyl-GPC (16:1) 
↓ 1-stearoyl-GPC (18:0) 
Diacylglycerol ↓ Diacylglycerol (14:0/18:1, 16:0/16:1) [1] 
↓ Diacylglycerol (14:0/18:1, 16:0/16:1) [2] 
↓ Palmitoyl-oleoyl-glycerol (16:0/18:1) [2] 
↓ Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2] 
Sphingolipid Metabolism ↓ Sphinganine-1-phosphate 
Progestin Steroids ↓ 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) 
↓ Pregnanediol-3-glucuronide 
Corticosteroids ↑ Cortisone 
Androgenic Steroids ↑ Androstenediol (3beta,17beta) disulfate (1) 
↑ Androstenediol (3beta,17beta) disulfate (2) 
↑ Andro steroid monosulfate C19H28O6S (1) 
Primary Bile Acid Metabolism ↓ Glycochenodeoxycholate glucuronide (1) 
Secondary Bile Acid Metabolism ↓  Isoursodeoxycholate 
↓ 7-ketolithocholate 
↓ 3b-hydroxy-5-cholenoic acid 
Nucleotide (n=6) 
 
Purine Metabolism, (Hypo)Xanthine/Inosine 
containing 
↑ N1-methylinosine 
Purine Metabolism, Adenine containing ↑ N6-carbamoylthreonyladenosine 
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Purine Metabolism, Guanine containing ↑ 7-methylguanine 
Pyrimidine Metabolism, Uracil containing ↑ 3-ureidopropionate 
Pyrimidine Metabolism, Cytidine containing ↑ Cytidine 
Pyrimidine Metabolism, Thymine containing ↑ 3-aminoisobutyrate 
Cofactors and Vitamins (n=4) 
 Nicotinate and Nicotinamide Metabolism ↑ N1-Methyl-2-pyridone-5-carboxamide 
Pantothenate and CoA Metabolism ↓ Pantothenate 
Tocopherol Metabolism ↑ Gamma-CEHC 
Hemoglobin and Porphyrin Metabolism ↓ Bilirubin (E,E) 
Xenobiotics (n=15) 
 Benzoate Metabolism ↓ 4-hydroxyhippurate 
↓ Catechol sulfate 
↓ Guaiacol sulfate 
↓ 4-ethylphenylsulfate 
Xanthine Metabolism ↑ 3-methylxanthine 
Food Component/Plant ↓ Ferulylglycine (1) 
↓ Ferulylglycine (2) 
↓ Acesulfame 
↓ Thymol sulfate 
↓ 4-allylphenol sulfate 
Drug - Analgesics, Anesthetics ↓ Lidocaine 
Drug - Cardiovascular ↓ 4-hydroxycoumarin 
Drug - Neurological ↑ 3-hydroxyvalproate 
↑ 2-propyl-2-pentenoate (2-ene-valproate) 
Chemical ↑ O-sulfo-L-tyrosine 
Partially Characterized Molecules (n=3) 
 Partially Characterized Molecules ↑ Glucuronide of C8H16O2 (1) 
↓ Glucuronide of C10H18O2 (7) 






Figure S1. Timeline of treatment schedule for patients included in two clinical studies. In the first 
study shown at the top (Ryningen et al.), patients were give ATRA alone for two days before theophylline 
and valproic acid were given on day 3. Samples were collected pretherapy (day 1) and after 2-days of 
ATRA treatment. In the second study shown at the bottom (Fredly et al.), patients received valproic acid 
alone for 7 days before ATRA and then subsequently cytarabine were given. Samples were collected 














Figure S2. Identification and classification of metabolites in pretherapy serum samples that differed 
significantly between responders and non-responders to the antileukemic treatment of ATRA plus 
valproic acid. Thirty-six metabolites differed significantly between responders and non-responders (p<0.05, 
Welch´s two sample t-test). The p-values, q-values and mean fold change values for each metabolite are listed 
to the right in the figure (ranked by p-value), and a fold change >1 indicates that the levels were increased in 
responders compared with non-responders. Metabolite levels for non-responders are shown in grey, while 
increased levels in responders are shown in green (25/36 increased), and decreased levels in responders are 
shown in orange (11/36 decreased). Color codes for classification of metabolites are explained at the bottom 





Figure S3. Pathway enrichment analysis based on pretreatment levels of metabolites that differed between 
responders and non-responders to antileukemic treatment based on ATRA and valproic acid. The analysis is 
used for visualization and biological interpretation of the metabolomics data and was based on significantly altered 
metabolites (p<0.05). Only signaling pathways with an enrichment value greater than two and at least two 
metabolites within each pathway are shown. The most significant pathway is shown in red and less significant 
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Figure S4. Pathway enrichment analysis based on metabolite levels that differed in patients pretherapy 
compared to during ATRA treatment for responders and non-responders to antileukemic treatment. The analysis 
was based on significantly altered metabolites (p<0.05), and only signaling pathways with an enrichment value 
greater than two and at least two metabolites within each pathway are shown in the figure. The most significant 
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Supplementary Figure 5. The effect of 7-day valproic acid (VPA) monotherapy on the serum metabolomic 
profiles of AML patients. A total of 109 metabolites were significantly altered after VPA treatment (p < 0.05). The 
p-values for each individual metabolite are listed to the right, ranked according to p-values. Pretherapy systemic 
levels of metabolites are presented in light grey, increased levels during VPA treatment are presented in green and 
decreased levels in yellow. Color codes for classification of individual metabolites are explained at the bottom of 





Supplementary Figure 6. The effect of valproic acid monotherapy for seven days on the serum metabolomics 
profiles for 10 patients (5 responders and 5 non-responders; patients included in the study described in PMID 
23915396, valproic acid metabolites included in the study). The random forest analysis was based on the 
identification of all 886 metabolites in pretherapy samples and samples collected after seven days of treatment. The 
analysis showed a predictive accuracy of 100% (insert table). The importance plot shows the metabolites listed after 
their importance for separation of the two sets of samples. The figure shows the top-30 ranked metabolites. Color 






Supplementary Figure 7. The effect of 7-day valproic acid monotherapy on serum metabolomic profiles; 
significantly altered amino acid and peptide metabolites when comparing samples derived from 10 patients (5 
responders and 5 non-responders; all patients included in the study by Fredly et al. PMID 23915396). The 
pretreatment samples are presented in grey; metabolites increased during valproic acid therapy are presented in 






Supplementary Figure 8. The effect of 7-day valproic acid monotherapy on serum metabolomic profiles; 
significantly altered lipid metabolites when comparing samples derived from 10 patients (5 responders and 5 
non-responders; all patients included in the study by Fredly et al. PMID 23915396). The pretreatment samples are 
presented in grey; metabolites increased during valproic acid therapy are presented in green and decreased levels 
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Patients with Treatment-requiring 
chronic graft versus host Disease 
after allogeneic stem cell 
Transplantation have altered 
Metabolic Profiles due to the Disease 
and immunosuppressive Therapy: 
Potential implication for Biomarkers
Håkon Reikvam1,2*, Ida-Sofie Grønningsæter1,2, Knut Anders Mosevoll1,2, Roald Lindås1, 
Kimberley Hatfield2 and Øystein Bruserud1,2
1 Section Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway, 2 Department of Clinical 
Science, University of Bergen, Bergen, Norway
Chronic graft versus host disease (cGVHD) is a common long-term complication 
after allogeneic hematopoietic stem cell transplantation. The objective of our study 
was to compare the metabolic profiles for allotransplant recipients and thereby iden-
tify metabolic characteristics of patients with treatment-requiring cGVHD. The study 
included 51 consecutive patients (29 men and 22 women; median age: 44  years, 
range: 15–66 years) transplanted with peripheral blood stem cells derived from human 
leukocyte antigen-matched family donors. All serum samples investigated by global 
metabolomic profiling were collected approximately 1  year posttransplant (median 
358 days). Thirty-one of the 51 patients (61%) had cGVHD 1 year posttransplant. The 
affected organs were (number of patients) liver/bile duct (23), eyes (15), gastrointesti-
nal tract (14), skin (13), mouth (10), lungs (3), and urogenital tract (1). We compared 
the metabolic profile for patients with and without cGVHD, and a Random Forrest 
Classification Analysis then resulted in 75% accuracy in differentiating the two groups. 
The 30 top-ranked metabolites from this comparison included increased levels of 
bile acids, several metabolites from the cytokine-responsive kynurenine pathway for 
tryptophan degradation, pro-inflammatory lipid metabolites, phenylalanine and tyrosine 
metabolites derived from the gut microbial flora, and metabolites reflecting increased 
oxidative stress. However, nine of these 30 top-ranked metabolites were probably 
altered due to cyclosporine or steroid treatment, and we therefore did a hierarchical 
clustering analysis including all 51 patients but only based on the other 21 cGVHD- 
specific metabolites. This analysis identified three patient subsets: one cluster included 
mainly patients without cGVHD and had generally low metabolite levels; another cluster 
included mainly patients with cGVHD (most patients with at least three affected organs) 
and high metabolite levels, and the last intermediate group including cGVHD patients 
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with limited organ involvement. We conclude that allotransplant recipients with cGVHD 
have an altered metabolic profile caused both by the disease and its immunosuppres-
sive treatment.
Keywords: metabolomics, chronic graft versus host disease, stem cell transplantation, biochemical profiling, 
biomarkers
inTrODUcTiOn
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) 
is used in the treatment of severe bone marrow failure and 
aggressive hematological malignancies, including acute leuke-
mia (1, 2). The treatment approach depends on the ability of the 
engrafting immune system to remove residual leukemia cells via  
a graft-versus-leukemia effect (1). Allo-HSCT is then a poten-
tially curative treatment, although at the same time the treatment 
is associated with a relatively high risk of morbidity and mortality 
due to severe transplant-related complications (3). Chronic graft 
versus host disease (cGVHD) is then the most common cause 
of late non-relapse mortality (4–6). Guidelines for the diagnosis 
and treatment of this complication have recently been published 
(7). However, the complex immunopathology of cGVHD is still 
poorly understood (8), and preclinical models have weakness 
and limitations in the study of the disease (9). An increasing 
interest for biomarkers, to confirm diagnosis and prognosis 
in cGVHD, has evolved the last decade (10–13), although still 
no biomarkers are established in routine clinical practice (10, 
13). Among the risk factors for cGVHD are older patient age, 
previous acute GVHD (aGVHD), reduced intensity condition-
ing, female donor to male recipient, peripheral blood stem cell 
(PBSC) grafts and human leukocyte antigen (HLA) mismatched 
donors (14–19).
Graft versus host disease can be considered an exaggerated 
manifestation of normal inflammatory mechanisms in which 
donor lymphocytes encounter foreign antigens in a pro-
inflammatory milieu, and this inflammation involves several 
donor immunocompetent cell subsets (8, 9, 20–22). Metabolic 
regulation is important for immunoregulation, and we have pre-
viously demonstrated that pretransplant cytokine profiles as well 
as the pretransplant metabolic status of allotransplant recipients 
is associated with a risk of later aGVHD (23–25).
Our present study was initiated to compare patients with 
and without cGVHD 1 year posttransplant and thereby identify 
possible associations between the serum metabolic profile, the 
diagnosis and severity (i.e., organ involvement) of cGVHD 
requiring systemic immunosuppression, and the effects of this 
immunosuppressive (i.e., cyclosporine, steroids) on the metabolic 
profiles in cGVHD patients.
Abbreviations: aGVHD, acute graft versus host disease; allo-HSCT, allogeneic 
hematopoietic stem cell transplantation; cGVHD, chronic graft versus host disease; 
GC, gas chromatography; G-CSF, granulocyte-colony stimulating factor; GVL, 
graft-versus-leukemia; HLA, human leukocyte antigen; LC, liquid chromatogra-
phy; MS, mass spectrometry; PBSC, peripheral blood stem cell; PCA, principal 




The study was approved by the local Ethics Committee (Regional 
Ethics Committee III, University of Bergen, Norway; REK), and 
the samples were collected after obtaining written informed 
consent from the patients. The study included 51 consecutive 
allotransplant recipients (29 men and 22 women; median 
age: 44  years with range: 15–66  years) with HLA-matched 
family donors; these patients were transplanted during the 
period March 2006–December 2014. Ninety-five patients were 
transplanted in our institution during this period; 25 of them 
died from treatment-related causes, 6 patients relapsed, and 
13 were lost to follow-up. The decision to perform an allo-
HSCT was taken by the Norwegian Advisory Board for Stem 
Cell Transplantation and based on national guidelines. Thus, 
our study is population-based and includes an unselected and 
consecutive group of well-characterized patients with family 
donors. All samples were collected approximately 1 year post-
transplant (median 358  days). The patient characteristics are 
given in Table 1 and Figure 1. Patients were transplanted with 
granulocyte colony-stimulating factor mobilized PBSC. Most 
patients received GVHD prophylaxis with cyclosporine A plus 
methotrexate (n = 50), only one patient received cyclosporine 
A alone.
Detailed information about individual patients is given 
in Figure  1, including previous aGVHD, the presence of 
treatment-requiring cGVHD and when this was diagnosed, 
the type of cGVHD. All these patients were able to travel with 
public communication to come to the hospital for controls and 
blood sampling. All except two patients had active cGVHD 
requiring continued immunosuppression, but only four patients 
(patients 37, 38, 42, and 43) had platelet counts observed below 
100 × 109/L at the time of sampling (this was also true for the 
time of diagnosis).
Diagnosis of cgVhD
Chronic graft versus host disease was diagnosed according to 
generally accepted criteria based on careful clinical evaluation 
and additional biopsies for histological confirmation (7, 26).
Preparation of serum samples
All venous blood samples were collected into sterile plastic 
tubes (BD Vacutainer® SST™ Serum Separation Tubes; Becton-
Dickenson, Franklin Lakes, NJ, USA) and allowed to coagulate 
for 120  min at room temperature (18°C) before centrifugation 
(300 ×  g for 10  min) and serum collection. All samples were 
immediately frozen and stored at −70°C until analyzed.
TaBle 1 | Demographical, clinical, and laboratory data for the 51 patients included in the study.
Patient characteristics Observation +cgVhD −cgVhD
Demographic data and disease history
Gender (numbers) Male/female 29/22 19/12 10/10
Age (years, median and range) 44 (15–66) 44 (18–62) 43 (15–66)
Height (cm, median and range) 172 (149–193) 169 (158–190) 172 (149–193)
Weight (kg, median and range) 69 (42–133) 72 (47–133) 66 (42–98)
BMI (kg/m2, median and range) 23.4 (16.9–39.7) 23.7 (17.9–39.7) 22.2 (16.9–28.5)
Diagnosis (numbers) AML/MDS 31 22 9
ALL 13 8 5
CLL 2 0 2
MF 4 1 3
AA 1 0 1
Conditioning regimen (numbers) BU + CY 39 25 14
ATG + CY 1 0 1
TBI + CY 1 1 0
BEAM 1 1 0
TBI + ETO 1 0 1
FLU + BU 5 3 2
FLU + CY 2 0 2
FLU + BU + ATG 1 1 0
cGVHD organ involvement Liver (23 patients), eyes (15), gastrointestinal tract 
(14), skin (13), mouth (10), lungs (3) and urogenital 
tract (1).
Unless otherwise stated the values are presented as median with range given in parenthesis. Height and weight were registered at the start of conditioning therapy.
BMI, body mass index; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MF, 
myelofibrosis; AA, aplastic anemia; BU, busulfan; CY, cyclophosphamide; ATG, anti-thymoglobulin; TBI, total body irradiation; ETO, etoposide; FLU, fludarabine; cGVHD, chronic 
graft versus host disease.
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analysis of Metabolite serum levels
Metabolomic analysis was done in collaboration with 
Metabolon® (27). Briefly, samples were prepared using the auto-
mated MicroLab STAR® system (Hamilton Company, Bonaduz, 
Switzerland). A recovery standard was added prior to the first 
step in the extraction process for quality control. To remove 
protein, dissociate small molecules bound to protein or trapped 
in the precipitated protein matrix, and recover chemically 
diverse metabolites, proteins were precipitated with methanol 
under vigorous shaking for 2 min followed by centrifugation. 
The resulting extract was divided into four fractions: one for 
analysis by ultra-performance liquid chromatography-mass 
spectrometry (UPLC-MS)/MS with positive ion mode elec-
trospray ionization, the second for analysis by UPLC-MS/MS 
with negative ion mode electrospray ionization, the third for 
analysis by gas chromatography-mass spectrometry, and the 
last sample was reserved as a backup. Samples were placed 
briefly on a Zymark TurboVap® (McKinley Scientific, Sparta, 
NJ, USA) to remove the organic solvent. The samples for liquid 
chromatography (LC) were stored overnight under nitrogen 
before preparation for analysis. For GC, each sample was dried 
under vacuum overnight before preparation for analysis. A 
total of 755 metabolites of known identities (named biochemi-
cals) were analyzed in all samples (Table S1 in Supplementary 
Material).
Bioinformatical and statistical analyses
Bioinformatical analyses were performed using the J-Express 
(MolMine AS, Bergen, Norway) (28). For hierarchical clustering, 
all values were median variance standardized and log(2) trans-
formed. The complete linkage was used as the linkage method, 
and for distance measured the Pearson correlation was used. 
Statistical analyses were performed using the Statistical Package 
for the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, 
IL, USA). The Mann–Whitney U-test was used to identify 
biochemicals that differed significantly between groups. The 
Chi-Square test was used for analysis of categorized data. Unless 
otherwise stated p-values <  0.05 were regarded as statistically 
significant.
resUlTs
allotransplant recipients are 
heterogeneous with regard to Their serum 
Metabolic Profile When Tested 1 Year 
Posttransplant
31 of the 51 patients included in the study (61%) had signs of 
cGVHD 1  year posttransplant; 29 of the 31 cGVHD patients 
required systemic immunosuppressive treatment either as pro-
longed or increased treatment with cyclosporine A (27 patients). 
Eleven of these 27 cyclosporine-treated patients (22% of the 
whole cohort) received combination treatment also including 
systemic steroid therapy, and two additional patients received 
mycophenolate mofetil monotherapy. The two last patients were 
diagnosed with cGVHD of the skin and received only topical 
steroid treatment. Thus, the large majority of the 31 cGVHD 
patients (29/31) received systemic treatment either as prolonged 
FigUre 1 | Continued
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FigUre 2 | Random forest analysis of the systemic metabolite profiles including all 51 patients; a comparison of patients with and without chronic graft versus 
host disease (cGVHD) and identification of the 30 top-ranked metabolites showing increased levels in patients with posttransplant cGVHD. Random forest 
analysis could distinguish between the metabolic signatures of patients with and without acute GVHD with a predictive accuracy of 75.0%. The figure presents 
the 30 top-ranked metabolites and their classification (indicated in the figure, lower right) based on their importance for the identification of the two patient 
subsets.
FigUre 1 | Clinical data of the 51 patients included in the study. The figure presents the clinical and demographical characteristics of the patients, including (from 
left to right) the presence of chronic graft versus host disease (cGVHD) and acute GVHD, the form of GVHD and the time when developing treatment-requiring 
cGVHD, organ involvement, ongoing immunosuppressive treatment at the time of sampling, and the clinical characteristics of the patients (hematological diagnosis, 
conditioning treatment, gender, female to male transplantation, and age). Abbreviations: AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, 
acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MF, myelofibrosis; AA, aplastic anemia; BU, busulfan; CY, cyclophosphamide; ATG, 
antithymoglobulin; TBI, total body irradiation; ETO, etoposide; FLU, fludarabine.
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or increased cyclosporine A therapy, or they received additional 
immunosuppression with oral prednisolone (daily doses 
2.5–40  mg) to maintain disease control. The most commonly 
affected organ was the liver/bile duct (23 patients; for additional 
details on organ involvement see Figure 1 and Table 1).
Seven of the 20 patients without signs of cGVHD received pro-
longed cGVHD prophylaxis at 1 year posttransplant due to either 
previous severe aGVHD and/or the presence of other risk factors 
for the development of cGVHD. Thus, a total of 34 patients (67%) 
received cyclosporine A 1 year posttransplant.
We first used principal component analysis (PCA) and hier-
archical clustering to analyze the overall metabolic profiles of the 
patients. However, these analyses could not distinguish between 
the 31 patients with and the 20 patients without cGVHD (data 
not shown); this is probably due to the metabolic heterogeneity 
for both patient subsets.
Patients with and without cgVhD Differ in 
Fatty acid and Bile acid Metabolism
In contrast to PCA and unsupervised hierarchical clustering, 
random forest analysis is an unbiased and supervised classi-
fication technique based on an ensemble of a large number of 
decision trees. In addition to producing a metric of predictive 
accuracy (Figure 2), this analysis also gives a list of the metabo-
lites ranked according to their importance for the classification 
scheme, i.e., their degree of difference between the two compared 
groups. Random forest analysis of serum metabolic profiles dif-
ferentiated patients with and without cGVHD with a predictive 
accuracy of 75%. Eighteen of the 30 top-ranked metabolites 
from this comparison reflected differences in lipid/fatty acid/
bile acid metabolism (Figure  2), most of them belonging to 
the annotations sphingolipids, plasmalogens/lysoplasmalogens, 
lysolipids, and phospholipids. We therefore compared the levels 
FigUre 3 | Hierarchical clustering analysis including all 51 patients and based only on 10 primary bile acid metabolites, identification of patient subsets with high 
frequency of chronic graft versus host disease (cGVHD) patients. We performed a hierarchical clustering analysis (Euclidian Correlation, complete linkage) based 
on the bile acid metabolites indicated to the right in the figure. The heat map and the corresponding dendrograms are shown in the figure. As indicated to the 
lower left in the figure red indicates high metabolite levels and green low levels. The clinical characteristics of each individual patient are presented in the upper part 
of the figure; for the lower horizontal bars the presence of a factor is indicated by red and the absence by green, whereas the color codes for the upper horizontal 
bars are explained in the figure. We identified two main clusters; the left included a major part of patients with cGVHD, whereas the right cluster included mainly 
patients without cGVHD. 28 of the 31 cGVHD patients clustered in the group with high bile acid metabolite levels, two patients clustered in the group with low 
levels, and the last cGVHD patient was an outlier. The frequency of cGVHD patients differed significantly between the two main clusters (Chi-square test, 
p < 0.0001).
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of all metabolites from these classes for patients with and with-
out cGVHD. These subclasses include a total of 122 metabolites 
(Table S1 Supplementary Material), and 46 of them were signifi-
cantly increased in patients with cGVHD.
Four of the 30 top-ranked metabolites (i.e., the secondary 
bile acid hyocholate and the primary bile acids glycochenode-
oxycholate sulfate, taurocholate, and glycocholate) reflect dif-
ferences in bile acid metabolism and were increased in patients 
with cGVHD (Figure  2). The subclass primary bile acids 
include 10 metabolites, and eight of them were significantly 
increased in patients with cGVHD. We therefore performed a 
hierarchical cluster analysis based on the serum levels of the 10 
primary bile acid metabolites (Figure 3). This analysis identi-
fied a minor subset of 14 patients with generally low levels of 
these metabolites and including 12 of the 20 patients without 
cGVHD; only two patients with cGVHD were included and 
both patients required systemic immunosuppression with only 
cyclosporine A alone. The remaining patients (a major subset 
of 36 patients together with one outlier) showed relatively high 
levels of most primary bile acid metabolites and thus included 
28 of the 31 patients with cGVHD, i.e., all patients requiring 
systemic steroids were included among these 37 patients. The 
difference in frequency of patients with cGVHD between 
these two groups was statistically significant (Chi-square test, 
p  <  0.0001). Finally, neither the cGVHD patients receiving 
cyclosporine alone, receiving additional systemic steroids nor 
having cGVHD with liver involvement clustered together in this 
analysis.
0 1 2 3 4 5 6 7 8 9
Fay Acid, Amino
Sterol
Primary Bile Acid Metabolism








Pyramidine Metabolism, Uracil containing
Secondary Bile Acid Metabolism
FigUre 4 | Metabolic pathway analysis based on the analysis of all 51 patients; a comparison of patients with and without chronic graft versus host disease 
(cGVHD). The figure presents the metabolic pathways with an enrichment score > 2 when comparing patients with and patients without cGVHD.
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a comparison of Patients with and 
without cgVhD by Metabolic Pathway 
analysis—increased levels of Metabolic 
Markers of inflammation, Protein 
Degradation and Oxidative stress in cgVhD
We next performed a metabolic pathway analysis to compare 
patients with and without cGVHD (Figure 4). The nine highest 
ranked metabolic classes included (1) amino fatty acid metabolism 
(a small class only including two metabolites in our analysis); (2) 
sphingolipid, plasmalogen, and lysoplasmalogen metabolites; (3) 
sterol and primary bile acid metabolites; (4) amino acid metabo-
lites (alanine and aspartate, glycine, serine, and threonine); and 
(5) amino sugar metabolism. Thus, this alternative analysis, 
which is based on the overall results and not only the highest 
ranked metabolites, shows that fatty acid/triglyceride/bile acid 
metabolism differs between patients with and without cGVHD 
not only when comparing the highest ranked metabolites but also 
when comparing the overall results.
The presence of cGVHD was associated with a metabolic 
signature consistent with ongoing inflammation and significantly 
increased levels of (1) the three lysolipid metabolites 1-linoleoyl-
GPC (18:2), 1-oleoyl-GPC (18:1), 1-palmitoleoyl-GPC (16:1), (2) 
the eicosanoid 12-HETE; and (3) the sphingolipid sphingosine 
(Figure  2) (29, 30). These signs of inflammation could still be 
detected despite the systemic immunosuppressive treatment for 
the large majority of the cGVHD patients. Furthermore, patients 
with cGVHD showed a significant increase in phennylacetat, 
3-(4-hydroxyphenyl) lactate, phenylalanine, and tyramine 
o-sulfate compared with patients without cGVHD; a possible 
explanation for these differences is altered gastrointestinal func-
tion (31), probably caused by gastrointestinal disturbances 
and altered microbial flora (Figure  5). Furthermore, increased 
levels of several markers for proteolysis and accelerated protein 
catabolism were also detected in the cGVHD patients (32), 
including N-acetylserine, N-acetylaspartate, N-acetylasparagine, 
N-acetylglutamate, and 1-methylhistidine (Figure 5).
Increased oxidative stress seems to be important in the 
pathophysiology of GVHD (33). The significantly increased 
levels in cGVHD patients of gamma-glutamyl amino acids 
(e.g., gamma-glutamylglutamate, gamma-glutamyltryptophan, 
gamma-glutamylphenylalanine, and gamma-glutamylthreonine) 
are consistent with an oxidative stress phenotype and increased 
activity of the gamma-glutamyl cycle that is important for recycling 
and regeneration of the antioxidant glutathione (34). Similarly, a 
significant increase in other oxidative stress markers, including 
alpha-tocopherol, cysteine sulfonic acid, and methionine sulfox-
ide (35), was also observed in cGVHD patients (Figure 5). Taken 
together, these observations suggest altered protein metabolism 
with disturbed redox homeostasis in cGVHD patients, and we 
therefore performed a hierarchical clustering analyses based on 
the 10 metabolites included in the term “oxidative stress” (Table 
S1 in Supplementary Material) (Figure  6). Two main clusters 
were then identified, and the frequency of cGVHD patients was 
significantly higher for the subset showing generally high levels 
of these metabolites (p = 0.0010, Chi-square test).
steroid Treatment of cgVhD is associated 
with increased levels of Phospholipids, 
lysolipids, Plasmalogen, 
Monoacylglycerol, and Diacylglycerol 
Metabolites
We first compared the metabolic profiles for the 11 patients 
receiving systemic steroid therapy versus all the other 40 patients. 
The 30 top-ranked metabolites are presented in Figure 7. 26 of 
the 30 top-ranked metabolites altered by systemic steroids were 
classified as lipid metabolites, and 20 of these lipid metabolites 
FigUre 5 | Altered phenylalanine/tyrosine metabolism (a) and altered proteolysis (B); a comparison of single metabolites including all patients with and without 
chronic graft versus host disease (cGVHD). [(a), upper part] The serum levels of the four metabolites phennylacetat, 3-(4-hydroxyphenyl) lactate, phenylalanine, and 
tyramine o-sulfate were significantly increased in cGVHD patients compared to patients without cGVHD. [(B), lower part] The serum levels of the proteolysis markers 
N-acetylserine, N-acetylaspartate, N-acetylasparagine, N-acetylglutamate, and 1-methylhistidine were significantly increased in cGVHD patients (marked with red) 
compared with patients without cGVHD (marked with green). All results are presented as the median, the 25%/75% percentiles and the variation range; results for 
cGVHD patients are presented as red boxes whereas patients without cGVHD are marked with green. The metabolites and the corresponding p-values  
(Mann–Whitney U-test) are shown at the top of each individual figure.
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belonged to the subclasses phospholipid (5 metabolites), lysolipid 
(7), plasmalogen (4), monoacylglycerol (3), and diacylglycerol 
(1). Thus, a major effect of systemic steroid treatment seems to be 
altered triglyceride/fatty acid metabolism.
We then did an alternative analysis and compared the meta-
bolic profiles for the nine cGVHD patients receiving systemic 
steroids together with cyclosporine versus the cGVHD patients 
only treated with cyclosporine, i.e., comparing two patient subset 
with similar cGVHD/cyclosporine status but differing with 
regard to steroid treatment (see Figure 1 for identification of the 
patients in these two subsets). The top-ranked metabolites from 
this comparison also included a large number of lipid metabolites 
(20 metabolites), and most of these metabolites were classified as 
phospholipid (three metabolites), lysolipid (8), plasmalogen (2), 
monoacylglycerol (2), and diacylglycerol (1). Thus, this compari-
son also suggests that a major effect of systemic steroid treatment 
of patients with cGVHD is an altered fatty acid/triglyceride 
metabolism.
Finally, the steroid-associated pattern presented in Figure 7 
was also reflected in our overall comparison of patients with 
and without cGVHD (Figure 2), although the phospholipid (2 
metabolites), lysolipid (1), plasmalogen (2), monoacylglycerol 
(none), and diacylglycerol (none) metabolites only constituted a 
minor subset (5 metabolites) among the 30 top-ranked metabo-
lites from this cGVHD comparison. These metabolites may 
reflect the systemic steroid treatment, but several of them are also 
increased during inflammation (29, 30), and alternatively reflect 
the more severe manifestation of cGVHD for patients requiring 
systemic steroids.
cyclosporine has Diverse effects on the 
systemic Metabolic Profile of 
allotransplant recipients and These 
effects are similar for Patients with and 
without cgVhD
We first compared the profile of all patients receiving cyclosporine 
(34 patients, including nine patients receiving combination treat-
ment with systemic steroids) versus all the other allotransplant 
recipients (17 patients); the 30 top-ranked metabolites are shown 
in Figure 8. It can be seen that cyclosporine treatment had diverse 
effects and was associated with altered levels of many different 
FigUre 6 | Altered serum levels of oxidative stress markers in patients with chronic graft versus host disease (cGVHD); a comparison of patients with and without 
cGVHD and including all 51 patients. [(a), upper part] We observed increased levels of seven metabolites classified as oxidative stress markers in cGVHD patients 
(red boxes) compared with patients without cGVHD (green boxes). All results are presented as the median, the 25%/75% percentiles and the variation range. The 
metabolites and the corresponding p-values (Mann–Whitney U-test) are shown at the top of each individual figure. [(B), lower part] We performed a hierarchical 
clustering analysis based on the 10 metabolites belonging to the group oxidative stress. The clinical characteristics of each individual patient are presented in the 
upper part of the figure; for the lower horizontal bars the presence of a factor is indicated by red and the absence by green, whereas the color codes for the upper 
horizontal bars are explained in the figure. Two main clusters could then be identified; one with generally high metabolite levels and another with generally low levels. 
The cluster characterized by generally high levels had a significantly higher frequency of patients with cGVHD (25 out of 32 cGVHD patients; p = 0.0010,  
Chi-square test).
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metabolites/metabolite subsets. Firstly, eight of these 30 metabo-
lites belonged to the subset amino acid metabolites, and none 
of them overlapped with the top-ranked metabolites for those 
patients receiving systemic steroids. However, 12 lipid metabo-
lites were also included among the top-ranked metabolites; 5 of 
these lipid metabolites belonged to the subclasses phospholipid/
lysolipid/plasmalogen and may therefore reflect alterations in the 
11 cGVHD patients receiving systemic steroid, although it should 
be emphasized that only 3 of the 12 lipid metabolites overlapped 
with the 30 top-ranked metabolites identified in the comparison 
of patients with and without steroid treatment (Figure 7).
We then compared the metabolic profiles for a subset of 
patients without cGVHD and receiving no immunosuppressive 
treatment with the subset of seven patients characterized by 
without cGVHD but still receiving prophylactic cyclosporine 
treatment 1 year posttransplant. These subsets can be identified 
from Figure  1; in this subset analysis we thus could compare 
two groups of patients with a similar cGVHD status (i.e., no 
cGVHD) but differing with regard to cyclosporine treatment. 
Even though the ranking of individual metabolites differed, one 
should emphasize that 27 of the 30 top-ranked metabolites from 
this comparison overlapped with the 30 top-ranked metabolites 
identified in the previous comparison of all patients receiving 
cyclosporine versus all the other patients (Figure 8).
Finally we compared (1) the 30 top-ranked metabolites previ-
ously identified by the comparison of all patients with versus all 
without cGVHD (Figure 2) versus the (2) 30 top-ranked metabo-
lites identified when we compared all patients with and without 
cyclosporine treatment (Figure  8). There was only a minor 
overlap including 5 heterogeneous metabolites between the 30 
top-ranked metabolites identified in each of these 2 analyses, and 
the 5 metabolites included N-acetylneuraminate (amino sugar 
metabolism), 2-aminooctanate (fatty acid, amino), 2-hydroxy-
octanoate (fatty acid, monohydroxy), lactosyl-N-nervonoyl-
sphingosine (d18:1/24:1) (sphingolipid), and sulfamethoxazole 
(drug). Thus, even though cyclosporine seems to have distinct 
5 10 15 20 25 30
2-acetamidophenol sulfate



































FigUre 7 | Random forest analysis based on the overall metabolomics profile for all 51 patients included in the study; a comparison of patients receiving and not 
receiving treatment with systemic steroids. Random forest analysis could distinguish between these two patient subsets with a predictive accuracy of 73.0%. The 
figure presents the 30 top-ranked metabolites and their classification (indicated in the figure, lower right) based on their importance for the identification of the two 
patient subsets.
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effects on the systemic metabolic profile in allotransplant recipi-
ents, the effects of cGVHD by itself seem to be stronger than the 
cyclosporine effects.
clustering analysis Based Only on 
Metabolites identified as cgVhD-
associated in random Forest analyses 
identifies Three Patient subsets with 
Different Frequencies of cgVhD
We compared the 30 top-ranked metabolites for the random for-
est analysis of all patients with and without cGVHD (Figure 2) 
and the 30 top-ranked metabolites from the analysis of all 
patients with and without cyclosporine treatment (Figure 8), and 
we then found 4 overlapping metabolites [lactosyl-N-nervonoyl-
sphingosine (d18:1/24:1), sulfamethoxazole, 2-hydroxyoc-
tanoate, and 2-aminooctanoate]. Similarly, when comparing the 
top-ranked metabolites for the cGVHD analysis (Figure 2) with 
the 30 top-ranked metabolites from the comparison of all patients 
with and without additional steroid treatment (Figure  7), we 
identified the five overlapping metabolites 1,2-dipalmitoyl-GPC 
(16:0/16:0), 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2), 
1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1), hyocholate, 
and 1-palmitoyl-2-oleoyl-GPC (16:0/18:1). Thus, the 30 top-
ranked metabolites from the comparison of all patients with 
and without cGVHD included 21 metabolites that only were 
associated with cGVHD but not with cyclosporine or steroid 
therapy.
We then did a clustering analysis of all 51 patients based on 
the 21 non-overlapping metabolites from the cGVHD random 
forest analysis (Figure  9). First, the middle cluster showed a 
low frequency of patients with cGVHD (3 out of 16), and this 
is significantly different from the other 35 patients (28/35; 
Chi-Square test, p <  0.0001). Second, patients with cGVHD 
were mainly included in the two other clusters (11 out of 13 in 
the left and 17 out of 22 in the right cluster). The frequencies 
of patients with cGVHD did not differ significantly between 
these two clusters, but the frequency of patients with extensive 
cGVHD affecting at least three organs was significantly higher 
in the right cluster (10 out of 22 patients) than in the left cluster 
(2 out of 13 patients; Chi-Square test, p =  0.027). Third, the 
frequencies of patients receiving cyclosporine treatment and 
additional steroid treatment did not differ between the right 
and left clusters, i.e., the two clusters including the majority 
of cGVHD patients. Thus, differences in immunosuppressive 
therapy cannot explain the localization of severely affected 
cGVHD patients mainly into one cluster. Finally, the two 
cGVHD patients without immunosuppressive therapy also 
clustered within the intermediate (left) cluster together with 
several other cGVHD patients.
Seven exceptional patients without cGVHD clustered together 
with the majority of cGVHD (Figure  9, left and right patient 








































FigUre 8 | Random forest analysis based on the overall metabolomics profile for all 51 patients included in the study, a comparison of patients receiving and not 
receiving treatment with cyclosporine. Random forest analysis could distinguish between these two patient subsets with a predictive accuracy of 60%. The figure 
presents the 30 top-ranked metabolites and their classification (indicated in the figure, lower right) based on their importance for the identification of the two patient 
subsets.
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clusters). Five of these exceptional patients (patients 2, 4, 24, 32, 
and 41) had a minor increase in liver enzymes at the time of blood 
sampling without other signs of cGVHD, but additional diagnos-
tic procedures were not indicated. Thus, they were classified as 
not having treatment-requiring GVHD in our study; the two last 
exceptional patients had no signs of cGVHD.
The three patient clusters were separated mainly due to the 
variation of 11 metabolites that clustered together in the lower 
metabolite cluster and included 5 amino acid metabolites 
(beta-citrylglutamate, alpha-ketoglutarate, glutamate, aspartate, 
and glycylvaline) and 4 bile acid metabolites (glycochenode-
oxycholate, glycocholate, glycohyocholate, and taurocholate) 
together with the 2 additional lipid metabolites sphingosine and 
1-arachidonoyl-GPA (20:4).
DiscUssiOn
Graft versus host disease is characterized by immune dysregula-
tion/deficiency, organ damage, and decreased survival (8, 9). 
Alloreactive T-cells have been implicated in its pathogenesis, but 
the precise role of specific T-cell subsets, autoantigens, alloanti-
gens, and B-cells as well as the contribution from immunoregula-
tory soluble mediators is not known (8, 9, 20–22). Thus, GVHD 
reflects an exaggerated response of inflammatory mechanisms 
that involve donor T cells as well as multiple innate and adap-
tive cells and various mediators. Moreover, the involvement of 
inflammatory and profibrotic cytokines, such as transforming 
growth factor beta or platelet-derived growth factor receptors, 
are also important for GVHD-targeted organ injury (8, 9, 36).
We decided to investigate the patients 1 year posttransplant. 
This time point was selected because the impact of pretransplant 
and early posttransplant factors on the metabolic profile was then 
expected to be low, the early hematological and immunological 
defects in reconstitution would be less important, a substantial 
number of patients would have developed cGVHD but the 
impact on the metabolic profiles from more severe organ failures 
was expected to be limited.
The present metabolomic profiling study was conducted to 
identify serum metabolic changes associated with cGVHD. To 
the best of our knowledge, this is the first study to investigate the 
metabolic profile of patients with cGVHD. Our results have to be 
interpreted with care because we investigated a relatively small 
group of patients, but the patients are relatively homogenous 
because all patients received grafts from matched family donors, 
most of them received the same GVHD prophylaxis and a limited 
number of conditioning treatments were used. Our study should 
also be regarded as population-based because our patient cohort 
represents all allotransplanted patients with a family donor from 
a defined geographic area and during a defined time period. 
Additional studies are therefore needed to investigate whether 
our results are representative also for other subsets of allotrans-
plant recipients (e.g., other donors).
We first compared all patients with and all patients without 
cGVHD, and this comparison suggests that cGVHD patients 
FigUre 9 | Hierarchical clustering analysis including all 51 patients and based on 21 selected metabolites. The analysis was based on the 30 top-ranked 
metabolites identified by the random forest analysis of the overall metabolic profile of all 51 patients and comparing patients with and without chronic graft versus 
host disease (cGVHD) (see Figure 2), but 9 of these 30 metabolites were excluded from this analysis because they overlapped with the 30 top-ranked metabolites 
identified by the comparison of patients with/without cyclosporine treatment (Figure 8) or with/without systemic steroid treatment (Figure 7). Based on the 21 
remaining metabolites we performed a hierarchical clustering analysis (Euclidian Correlation, complete linkage). The heat map and corresponding dendrograms are 
shown in the figure together with the clinical characteristics of individual patients (see horizontal bars in the upper part). The metabolites are listed to the right in the 
figure; red color means high metabolite levels and green color low levels as indicated to the lower left in the figure. The clinical characteristics of each individual 
patient are presented in the upper part of the figure; for the lower horizontal bars the presence of a factor is indicated by red and the absence by green, whereas the 
color codes for the upper horizontal bars are explained in the figure.
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have a unique metabolic signature (Figure  2). We examined 
the patients at a defined time point and the metabolic profile of 
our patients may therefore be influenced both by differences in 
immunosuppressive treatment, different duration of cGVHD 
and thereby also differences in cumulative effects by the ongoing 
pathological process. Despite this heterogeneity our random for-
est analysis could distinguish between patients with and without 
cGVHD with a predictive accuracy of 75%. The identification 
and validation of biomarkers in cGVHD remain very challeng-
ing (10–12), but our study suggests that metabolic markers may 
become useful in these patients.
As stated above, the altered metabolic profile in our cGVHD 
patients can be caused either by the disease itself or its treat-
ment, i.e., cyclosporine and/or systemic steroids. Several obser-
vations suggest that cyclosporine can affect systemic metabolic 
profiles. First, we analyzed all the 51 patients in our patient 
cohort and compared all patients with and all patients without 
cyclosporine treatment (Figure 8); the 30 top-ranked metabo-
lites from this comparison showed a minimal overlap (only four 
metabolites) with the 30 top-ranked metabolites from the com-
parison of all patients with versus all patients without cGVHD 
(Figure 2). Second, to further identify metabolic effects prob-
ably caused by cyclosporine treatment we compared our patient 
subset without cGVHD and still receiving cyclosporine with 
another subset  also being without cGVHD but not receiving 
cyclosporine, i.e., these two subsets had similar cGVHD status 
and differed only with regard to cyclosporine treatment. The 30 
top-ranked metabolites from these two comparisons of patients 
with and without cyclosporine treatment showed a large degree 
of overlap (27 metabolites). Thus, both these comparisons sug-
gest that cyclosporine has diverse effects on systemic metabolic 
profiles, and our present observations are consistent with 
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previous observations in kidney transplant recipients (37). 
We conclude that cyclosporine treatment can alter systemic 
metabolic profiles in allotransplant recipients, but our observed 
differences between patients with and without cGVHD cannot 
be explained by cyclosporine alone because the 30 top-ranked 
cGVHD-associated metabolites (Figure 2) included only four 
of the cyclosporine-associated metabolites (Figure 8).
We used the same strategy as for cyclosporine when we 
investigated the contribution from steroid treatment. First, we 
examined the whole patient cohort and compared all patients 
with and all patients without steroid treatment. When compar-
ing the results from this analysis (Figure 7) with the results from 
the with/without cGVHD comparison (Figure 2), we identified 
five overlapping metabolites, i.e., lipid metabolites associated 
both with cGVHD and systemic steroid therapy. Taken together 
these observations suggest that the increased levels of these 
overlapping metabolites in cGVHD patients are mainly due to 
the steroid treatment rather than the cGVHD. Our present results 
are consistent with previous studies of steroid-treated myasthenia 
gravis patients showing that steroids alter triglyceride/fatty acid 
metabolism (38). However, one cannot exclude the possibility 
that even these steroid-associated effects may be at least partly 
due to the more severe and thereby steroid-requiring cGVHD 
of these patients. This last possibility is actually supported by 
previous observations suggesting that increased levels of these 
lipid metabolites are also associated with inflammation (29, 30).
The altered levels of bile acid as well as tyrosine and phenyla-
lanine metabolites in cGVHD patients may reflect at least partly 
an altered microbiome composition. Previous studies have dem-
onstrated the complex and multidirectional interactions between 
inflammation, microbiota, and immune reconstitution in 
allotransplant recipients (39–43). Allo-HSCT can alter the intes-
tinal flora and this may then be more pronounced in individuals 
with cGVHD (39–41). The human gut microbiome is involved 
in vital biological functions, such as maintenance of immune 
homeostasis, modulation of intestinal function and metabolic 
regulation; disturbances of the intestinal microbiota can thereby 
be associated with development and progression of inflamma-
tion, including GVHD (44). The microbial intestinal flora is 
responsible for the generation of several metabolites derived from 
amino acids, bile acids, heme, and dietary sources; several of these 
metabolites are absorbed and can bind specific receptors on host 
cells. The metabolism of aromatic amino acids, phenylalanine, and 
tyrosine is partly due to enzymes encoded within the microbiome 
(44). Thus, a change in microbiome-derived metabolites might be 
due to a shift in the flora with translocation of pro-inflammatory 
metabolites or bacterial components into the systemic circulation 
and thereby further acceleration of GVHD through the release 
of pro-inflammatory cytokines such as tumor necrosis factor-
alpha and IL-1 (45, 46). Thus, our present observation supports 
the hypothesis that effects of altered microbiota on the systemic 
metabolic profile contribute to the biological and clinical impact 
of microbiota in allotransplant recipients (39–43).
Chronic graft versus host disease was associated with increased 
levels of primary bile acid metabolites. Bile acids are derived from 
cholesterol in the liver and released into the small intestine to 
facilitate dietary lipid absorption. Differences in serum bile acid 
levels may be caused by altered synthesis, release, or reabsorption. 
Bile acid malabsorption has previously been reported in GVHD 
(47), but an altered gut microbiome is an alternative explanation 
as discussed earlier. The increased levels of bile metabolites may 
then induce hepatic cell dysfunction and induction of pro-
inflammatory mediators (48).
Serum levels of multiple markers of inflammation and oxida-
tive stress were increased in our cGVHD patients (36), possibly 
reflecting an increased risk of inflammatory complications after 
allo-HSCT. Uremic toxicity, metabolic acidosis, and pro- 
inflammatory soluble mediators may activate protein degradation 
in cGVHD (25, 32, 49), and cGVHD may thereby be associated 
with altered metabolic and endocrine functions of several organs 
(8, 31, 36). An altered balance between protein synthesis and 
catabolism may then be the final result.
The altered lipid profiles in cGVHD may be due to differences 
in membrane lipid turnover. Immunocompetent cells switch 
from resting to activated state after stimulation, and this requires 
increased energy metabolism to fuel cell proliferation and acquire 
effector functions (50, 51). Disruption of lipid synthesis can 
reduce GVHD in murine models (52), indicating an important 
role of lipid metabolism in the pathogenesis of GVHD. Our find-
ings are in concordance with these observations.
Based on our overall results we did a final clustering analysis 
of our entire patient cohort to distinguish between cGVHD-
associated and treatment-associated metabolic effects in our 
patient cohort. Because we analyzed a relatively small number of 
patients, this analysis was based on the 30 top-ranked metabo-
lites from the initial with/without cGVHD analysis (Figure 2). 
We then excluded from these 30 metabolites the 9 overlapping 
metabolites identified by the comparisons of patients with/with-
out cyclosporine (Figure 8, four metabolites) and patients with/
without steroid (Figure 7, five metabolites). Thus, this analysis 
was based on 21 cGVHD-associated metabolites and included 
all patients in our cohort. We did not leave out from the analysis 
those metabolites that may be associated with an altered gastro-
intestinal microbiome because we regard the microbiome as a 
part of the overall clinical status of allotransplant recipients. The 
results from this last clustering analysis (Figure 9) showed that 
the patients were distributed in three main clusters; one cluster 
included mainly patients without cGVHD, a second cluster 
included mainly patients with cGVHD, but the disease involved 
only one or two organs for the large majority of these patients; 
and a third cluster including a majority of patients with cGVHD 
and many of them having involvement of at least three organs. 
This identification of three patient subsets could not be explained 
by pharmacological differences, and it was mainly caused by dif-
ferences in the systemic levels of five amino acid and six lipid 
metabolites (most of them being bile acids) that clustered together 
in Figure 9 (lower metabolite cluster). Finally, our two cGVHD 
patients not receiving immunosuppressive therapy clustered 
within the intermediate (left) cluster together with several other 
cGVHD patients; this observation further supports our view that 
this clustering analysis reflects differences in cGVHD-induced 
metabolic alterations.
To the best of our knowledge, this is the first study of systemic 
metabolic profiles in allotransplant recipients. We describe altered 
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metabolic profiles for patients with treatment-requiring cGVHD, 
and the overall profile includes effect due to both cGVHD itself 
and the immunosuppressive treatment. However, our study 
identified a subset of 11 metabolites that seem to reflect both the 
diagnosis and the severity of cGVHD.
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